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Matrix metalloproteinases (MMPs) are required for tissue remodelling processes, including 
angiogenesis. MMP activity is generally proangiogenic but MMP-12 is suggested to be 
antiangiogenic and its precise role is still unclear. The work in this thesis describes the 
synthesis of an MMP-12 inhibitor and activity probe to address the hypothesis that MMP-12 
inhibits angiogenesis.   
An inhibitor, synthesised in-house, selectively inhibited MMP-12 in in vitro recombinant 
enzyme assays. An activity probe, also synthesised in-house, was selective for MMP-12 in in 
vitro recombinant enzyme assays. 
The function of MMP-12 during angiogenesis was assessed using murine models of 
angiogenesis; the in vivo sponge implantation, and the ex vivo aortic ring assays. Angiogenesis 
and MMP activity were imaged in vivo in sponges in C57Bl6/J mice over 7 − 21 days (D) 
using commercial probes (MMPSense™ and AngioSense™). MMP-12 protein concentration 
and activity were higher in sponges during early angiogenesis (D 3 − 7) when gene expression 
of vascular endothelial growth factor (a proangiogenic marker) was also high. Gene expression 
for MMP-12 and platelet-derived growth factor receptor (a marker of vascular maturation) 
were both higher on D 21 as angiogenesis started to stabilise. The MMP-12 activity probe was 
unsuccessful in selectively detecting MMP-12 activity in sponge lysate mixtures from D 7 − 
21. 
Administration of an MMP-12 inhibitor did not increase angiogenesis in the sponges in vivo. 
Additionally, sponges implanted in MMP-12-/- mice did not exhibit significant changes in 
angiogenesis or MMP activity when imaged in vivo using commercial probes (MMPSense™ 
and AngioSense™) on D 7. Supporting this, histological analysis of the sponges (removed on 










Furthermore, in the ex vivo aortic ring assay, the inhibition or deletion or MMP-12 did not 
increase the number or length of microvessel outgrowths.  
To summarise, MMP activity and angiogenesis can be imaged in vivo with commercial probes. 
The inhibition or deletion of MMP-12 did not inhibit angiogenesis in the in vivo sponge 
implantation, or the ex vivo aortic ring assays. These results suggest that MMP-12 does not 














The cardiovascular system consists of the heart, blood and vessels. It is required for delivering 
nutrients and removing harmful by-products from around the body. New vessels are formed 
as part of normal day-to-day body maintenance or in response to an increased oxygen demand 
of a tissue. Angiogenesis is the formation of new blood vessels from existing blood vessels. 
Angiogenesis requires the temporary dismantling of the existing vessel structure to allow the 
cells to move and multiply to form a new vessel structure. 
Matrix metalloproteinases (MMPs) are a large family of enzymes (26+) which are required for 
the breakdown of the network of structural fibres found between cells. The disassembly of this 
fibrous network creates new space for cells to move and multiply. It is generally accepted that 
MMPs encourage new vessel formation. MMP-12 is an exception: whilst its precise role is 
unclear, there is some evidence that MMP-12 creates molecules that inhibit angiogenesis. 
This thesis explores the influence of MMP-12 on angiogenesis. This was achieved by making 
molecules that would inhibit or detect MMP-12, and applying them to two models of 
angiogenesis in which MMP-12 was thought to be involved. In the first model new vessel 
growth (over a 21day period) is stimulated by insertion of small sponges under the skin of 
adult mice. Using this model, new methods of visualising angiogenesis and MMPs within live 
animals were tested. For the first time commercially-available agents were used to image 
angiogenesis and MMP activity in mice (over a period of 2 weeks) within sponges implanted 
under the skin. The second model of angiogenesis involved stimulating new vessel growth in 
the lab using vessels taken from mice. It was proposed that blocking MMP-12 activity would 
increase the number of new vessels formed in both models but it was shown that blocking 











This study showed that angiogenesis and MMPs can be imaged in sponges during vascular 
remodelling in live mice. However, MMP-12 is not required for angiogenesis in the models 
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 Chapter 1: Introduction  
1.1 Overview 
Blood vessels have evolved to supply oxygen and nutrients to tissues and dispose of carbon 
dioxide and other waste products. A healthy network of blood vessels supports tissue 
maintenance, growth and repair but structural and functional abnormalities in the network can 
contribute to disease. Poor blood supply can cause ischemia in tissues, leading to myocardial 
infarction or stroke; whilst abnormal vessel remodelling and excessive blood supply is 
implicated in poor cancer prognosis and inflammatory diseases. The ability to image this 
network and blood flow could contribute towards the assessment of disease states. 
The activity of matrix metalloproteinases (MMPs) is associated with increased vessel growth 
and the progression of several cardiovascular diseases. Interestingly, MMP-12 is suggested to 
inhibit vessel growth but its precise role is still unclear (Li et al., 2012). The ability to 
selectively image and/or manipulate MMP-12 activity in vivo could contribute to a better 
understanding of its role during vessel formation and diseases where MMP-12 is suggested to 
have an active role.  
This introduction will first discuss the MMP family, with emphasis on MMP-12, and its role 
in angiogenesis and disease. Next, tools for molecular imaging of MMPs and angiogenesis 
will be considered, followed by a discussion on MMP-12 inhibitors, with a focus on the choice 






1.2 Matrix metalloproteinases 
MMPs constitute a large family of zinc dependent endopeptidases which are required for the 
breakdown of the extra cellular matrix (ECM) and regulation of cell behaviour. MMPs 
contribute to tissue remodelling by cleaving the ECM, basement membrane and cell-cell 
junctions (Page-McCaw et al., 2007). This connective tissue is found between cells and 
comprises structural material such as collagens, elastin, proteoglycans, and laminins (Visse & 
Nagase, 2003). MMPs create space to enable cell migration and tissue remodelling (Figure 
1.1). Furthermore, MMPs can manipulate cell behaviour by processing (activating or 
disabling) signalling molecules or creating substrate cleavage fragments which have 
independent biological activity (Figure 1.2); the role of MMPs and cell behaviour has been 
reviewed comprehensively by Sternlicht & Werb (2001) and Newby (2006). 
MMP activity is under tight endogenous regulation and is essential for many physiological 
processes, including: embryo development (Shi et al., 2008), bone formation (Paiva & 
Granjeiro, 2014), ovulation (Goldman & Shalev, 2004), and wound healing (Gill & Parks, 
2008). However, unregulated and excessive MMP activity is associated with the progression 
of disease pathology. Rheumatoid arthritis (Burrage et al., 2006), tumour angiogenesis 
(Kerkelä et al., 2002) and atherosclerosis (Liang et al., 2006) are all conditions in which MMP 
activity contributes to disease pathology. Consequently, the pharmaceutical industry now 
targets, or has targeted, MMPs to treat diseases including COPD (Dahl et al., 2012), arthritis 








Figure 1.1 Matrix metalloproteinases (MMP) can cleave components of the extracellular matrix 
(ECM), basement membrane and intercellular junctions, resulting in space for cell movement. a) 
MMPs cleave components of the ECM which creates space for cell migration through tissue. b) MMPs 
can also directly regulate epithelial tissue architecture through cleavage of intercellular junctions or (c) 
the basement membrane which facilitates cell migration. Figure reproduced with permission from Page-







Figure 1.2 Matrix metalloproteinases (MMPs) proteolysis of extracellular matrix (ECM) 
components or signal molecules can generate specific cleavage products that then signal in an 
autocrine or paracrine manner. a) MMP proteolysis of the ECM matrix can generate biologically 
active cleavage products (for example, MMP -9, -3, -12 and -13 can generate an antiangiogenic peptide, 
endostatin, from collagen XIII (Ferreras et al., 2000; Halfter et al., 1998)). b) MMPs can activate or 
modify the action of latent signalling molecules (for example vascular endothelial growth factor (Lee 
et al., 2005). c) MMPs can also deactivate or modify the action of active signalling molecules, the 
resulting molecules can affect cell proliferation, death, differentiation or motility. Reproduced with 





1.2.1 MMP Evolution and structure 
Members of the MMP family, which comprises at least 26 members, share a similar gene 
arrangement, suggesting that they arose through duplication of a single ancestor gene (Shapiro 
et al., 1998). The MMP family can be split approximately into two distinct groups; those that 
are secreted and those that are membrane associated (membrane-type; Table 1.1). Membrane-
type MMPs include MMP-14, -15, -16, -17, -23, -24 and -25; these are anchored to the cell 
membrane. The secreted MMPs fall into several categories, including the: gelatinases (MMP-
2, -9); collagenases (MMP-1, -8, -13), and stromelysins (MMP-3, -10, -11). Other secreted 
MMPs which are not in these categories are MMP-7 and 12. MMP-7 lacks an anchor domain 
like membrane type MMPs but instead is membrane associated through binding to cholesterol 
sulfate in cell membranes (Yamamoto et al., 2006). MMP-12 also lacks an anchor domain but 
the catalytic domain is suggested to have favourable electrostatic attraction to cell membranes 
(Koppisetti et al., 2014). MMPs have a wide variety of ECM substrates (Table 1.1). 
 
Table 1.1 MMP family classifications and substrates.  MMPs have multiple substrates and can be 
sub-classified into collagenases, gelatinases, stromelysins, matrilysins and membrane-type. MMP-4, -
5, -6 and -22 are missing from the table since they were shown to be identical to other members. MMP-
18 (collangense-4) has only been identified in Xenopus. Table is adapted from MMP review paper 






Table 1.1 MMP family classifications and substrates 
  
  









Collagens (type I, II, and III), gelatin, aggrecan.
MMP-13 Collagenase-3
Collagens (type I, II, III, IV3, VI, IX, X, and XIV), 
gelatin, fibronectin.
MMP-2 Gelatinase-A
Gelatin, collagens (type I, II5, III, IV, V, VII, X, and 
XI), elastin, fibronectin.
MMP-9 Gelatinases-B
Collagens (type IV, V, XI, and XIV), gelatin, elastin, 
vitronectin, laminin.
MMP-3 Stromelysin-1
Collagens (type III, IV, V, VII, IX, X, and XI), gelatin, 
elastin, fibronectin.
MMP-10 Stromelysin-2
Collagens (type III, IV, and V), gelatin, elastin, 
fibronectin.
MMP-11 Stromelysin-3 gelatin, fibronectin, collagen type IV, laminin.
MMP-27




Collagens (type I, and IV), gelatin, elastin, 
fibronectin, laminin, entactin.
MMP-26 Matrilysin-2 Collagen type IV, gelatin, fibronectin, vitronectin.
MMP-14 MT-MMP
Collagens (type I, II, and III), gelatin, fibronectin, 
laminin, entactin, aggrecan.
MMP-15 MT2-MMP fibronectin, tenascin, entactin, laminin.
MMP-16 MT3-MMP




Fibronectin, Gelatin, chondroitin sulphate 
proteoglycan.




Collagens (type I, V, and IV), gelatin, elastin, 
fibronectin, vitronectin, laminin.
MMP-19 RASI 1
Collagen type IV, gelatin, laminin, entactin, 
fibronectin.












MMPs are multi-domain proteases but all have a signal peptide domain, pro-domain and 
catalytic domain (Figure 1.3). Most MMPs also have a hemopexin domain for recognition of 
substrates and tissue inhibitors of metalloproteinases (TIMPs) (Nagase et al., 2006). 
Membrane bound MMPs have additional anchor domains which binds the MMP to the 
membrane. They generally also have a furin cleavage site in the pro-peptide for activation. 
MMP-2 and -9 uniquely also have a fibronectin recognition construct. 
The 3D structures of some MMP catalytic domains have been resolved using X-ray 
crystallography and NMR techniques (Lang et al., 2001; Iyer et al., 2006; Rush & Powers 
2004). The catalytic domains are almost superimposable within the MMP family; they consist 
of a 5-stranded β-pleated sheet, three α-helices and a selectivity loop. The site contains two 
zinc ions, one catalytic (bound by three histamines) and one which provides a structural 
support (Lang et al., 2001). MMPs also have 3 calcium counter ions to stabilise the structure 






Figure 1.3 The structure of sub-groups in the MMP family. MMPs are multi-domain proteases that 
are initially inactive due to the pro-domain which binds to the catalytic zinc blocking its activity. Each 
MMP also has a signal peptide which directs it towards the secretory pathway. The hemopexin-like 
domain contributes to substrate and/or ligand specificity, subcellular localisation and 
activation/inhibition; MMP-2 and -9 also have a gelatin-binding domain (fibronectin type II repeat). 
MMPs located on the cell membrane normally have a transmembrane domain with a cytoplasmic tail. 
However, MMP-17 and -25 are glycosylphosphatidylinositol anchored. Linkers are short peptide 
sequences connecting the domains. Reproduced with permission from Page-McCaw and colleagues 





1.2.2 Regulation of MMP activity 
Generally, regulation of MMP activity can occur at several stages within the life of an MMP 
protein: transcription, post-translational modifications, secretion, activation of latent MMP, 
endogenous inhibition and, finally, degradation. MMP transcription can be promoted by 
transcription factors (including activator protein-1 (AP-1) and nuclear factor kappaB (NF-kB)), 
inflammatory cytokines (such as TNFα), growth factors, hormones and by cell–cell and cell–
matrix interactions (Vincenti & Brinckerhoff 2002; Yabluchanskiy et al., 2013; Nagase & 
Woessner 1999; Sternlicht & Werb 2001).  
MMPs are released as zymogens (proMMPs) and so require activation to become functional 
(Figure 1.4). A thiol group (cysteine) from the pro-domain inactivates the enzyme by binding 
to the catalytic zinc within the active site, this is known as the “cysteine switch”. Membrane 
bound MMPs are activated in the Golgi apparatus before delivery to the cell membrane. 
Secreted proMMPs are generally activated by serine proteases (such as plasmin) or by other 
active MMPs already in the extracellular space. When the pro-domain is cleaved it breaks the 
interaction of cysteine–zinc, opening the active site to substrates for hydrolysis (Figure 1.5).  
Active MMPs can be endogenously inhibited by α2-macroglobulin and TIMPs (Baker et al., 
2002). Four  TIMPs (TIMP-1, 2, 3, 4) have been described; each are 184–194 amino acids 
long and folded into 2 domains to form a ‘‘wedge-like’’ molecule (Gomis-Rüth et al., 1997). 
TIMPs inhibit MMPs in a 1:1 stoichiometry; the N-terminal domain of a TIMP blocks the 
active site of a MMP (Murphy et al., 1991). α2-Macroglobulin, a 725 KDa plasma 
glycoprotein, can engulf extracellular MMPs (and other proteinases), irreversibly blocking 







Figure 1.4 The cysteine switch activation of MMPs. MMPs are secreted in the inactive form. This is 
due to the integration of the catalytic zinc molecule with a thiol group from a cysteine residue in the 
pro-domain. Proteases can cleave the pro-domain, breaking this interaction and activating the MMP. 
Reproduced with permission from Page-McCaw and colleagues (2007) and modified. 
 
 
Figure 1.5 Mechanism of proteolysis of a peptide by an MMP.  During proteolysis, the carbonyl of 
the peptide bond to be cleaved coordinates with the catalytic zinc (sphere); the peptide bond is 
hydrolysed by nucleophilic attack of water (polarised by the carboxylate group of the glutamate (Glu) 
residue in the active site) on the carbonyl carbon of the peptide bond. After rearrangement, the resulting 






MMP-12 (macrophage elastase, MME) was first found in lung alveolae of cigarette smokers 
(Shapiro et al., 1993). MMP-12 activity has since been recognised in other diseased tissues 
(Liu et al., 2004; Scholtes et al., 2012; Houghton et al., 2006) but its expression is rarely found 
in normal tissue (Belaaouaj et al., 1995). It is predominantly secreted by pro-inflammatory 
macrophages and is required for their migration across the basement membrane (Shipley et 
al., 1996). MMP-12 can degrade ECM components (elastin, IV collagen, laminin and 
fibronectin, (Gronski et al., 1997)) and other proteins including plasminogen (Xu et al., 2008).  
 
1.3.1 Structure 
The domain structure of MMP-12 is similar to most other MMPs (Figure 1.3) and consists of 
a five-stranded β-sheet and three α-helices constructed into 4 domains: catalytic, propetide and 
a helmopexin and signal peptide (cleaved off early in the life of MMP-12) (Figure 1.6). The 
zymogen (54 KDa) is activated by proteinases; initially the pro-domain is lost to produce an 
active 45 KDa metalloproteinase, then the C-terminal hemopexin domain can also be lost to 
produce the 22 KDa mature MMP-12 (Nar et al., 2001). The full human and mouse MMP-12 
enzymes have amino acid sequences that are 64% identical (Shapiro et al., 1993). 







Figure 1.6 A 3D image of the active site of MMP-12 bound to a MMP inhibitor (batimastat).  Here 
the binding sites of the 2 zinc ions (black dots) and 3 calcium ions (green dots) are shown on the tertiary 
structure of MMP-12 (yellow ribbon). The inhibitor batimastat (circled) is a broad spectrum MMP 
inhibitor; it binds to the catalytic zinc ion (which itself is coordinated to 3 histidine residues). The 
selectivity loop is highly influential for the selectivity of substrates and inhibitors for all MMPs. Image 
is modified from Gossas & Danielson (2006). 
 
1.3.2 MMP-12 contributes to protection against infection 
Interestingly, MMP-12 has antiviral and antibacterial properties, which are not necessarily a 
direct result of its proteinase action. MMP-12 is secreted by macrophages in response to 
bacterial lung infection (Houghton et al., 2006); however, MMP-12-/- mice with this infection 
exhibit impaired bacterial clearance and increased mortality (Houghton et al., 2009). 
Interestingly, proteolysis is not responsible for this antimicrobial activity. Rather a unique four 
amino acid sequence on an exposed beta loop of the C-terminal is responsible, although the 
exact mechanism remains unknown. MMP-12 is also antiviral, Marchant and colleagues 
(2014) found that MMP-12 promotes the secretion of interferon alfa (IFN-α) from the host cell 
which enhances its antiviral protection. Briefly, in vitro studies showed that macrophage-





the promotor of the IKBα gene and enhances its transcription. IKBα protein then promotes the 
export of IFN-α from cells (extracellular IFN-α stimulates an antiviral immune response 
(Taniguchi & Takaoka, 2002)). In MMP-12-/- mice, infected cells do not express IKBα and do 
not export INF-α. MMP-12, therefore, promotes the secretion of antiviral IFN-α which 
enhances the host cell protection. However, MMP-12 was also found to inactivate extracellular 
INF-α which prevented an unchecked immune response and contributed towards resolving 
inflammation. This evidence was supported by an MMP-12 inhibitor study (Marchant et al., 
2014); selective inhibition of only extracellular MMP-12 resulted in an increase of IFN-α 
secretion and a reduction of viral replication. Although these properties of MMP-12 are 
beneficial for health, MMP-12 activity is also associated with disease. 
 
1.3.3 MMP-12 and disease 
Unregulated MMP-12 activity generally inflicts the greatest damage in tissues with a high 
elastin content. Elastin is a highly crosslinked hydrophobic ECM protein found in tissues 
which require elasticity, such as: skin, ligaments, arterial vessel walls and lungs. In 
inflammatory lung disease, breakdown of elastin can lead to permanently compromised lung 
function and ongoing degenerative disease (Shifren & Mecham 2006). Chronic obstructive 
pulmonary disease (COPD) is an umbrella term for a collection of inflammatory lung diseases 
including chronic bronchitis, emphysema and chronic obstructive airways disease. Patients 
with COPD often have high levels of MMP-12 and MMP-9 in their lungs (Demedts et al., 
2006; Molet et al., 2005). In preclinical models MMP-12 activity was found to be necessary 
for the development of COPD (Hautamaki et al., 1997; Valença et al., 2004). Inhibitors 
targeting MMP-12 are suggested to be a good potential treatment option for COPD (Lagente 






The skin has multiple layers of ectodermal tissue which are joined together with connective 
tissues. The disappearance of normal elastic fibres is a typical feature of skin damage; MMP-
12 expression is increased in granulomatous skin diseases (Vaalamo et al., 1999) and in areas 
of sun-damaged skin (Saarialho-Kere et al., 1999). Therefore, MMP-12 activity is suggested 
to play a detrimental role in these conditions. 
The vascularisation and subsequent dissemination of tumours are key stages in the 
development of cancer. MMPs generally play important roles in facilitating these processes 
(Kessenbrock et al., 2010), but the role of MMP-12 is unclear. MMP-12 is expressed in human 
skin and liver cancers; indeed increased MMP-12 expression is correlated with tumour 
invasiveness or a negative long term prognosis (Kerkelä et al., 2000; Kerkelä et al., 2002; 
Yang et al., 2007; Ng et al., 2011). Conversely, other in vivo preclinical cancer studies have 
found the presence of MMP-12 to be protective. In a model of lung cancer (Lewis lung 
metastases) MMP-12-/- mice had increased tumour growth and metastasis (Houghton et al., 
2006). In models of breast cancer and colon cancer MMP-12 reduced tumour growth 
(Margheri et al., 2009; Shi et al., 2006; Xu et al., 2008; Gorrin-Rivas et al., 2001). This 
discrepancy between the roles of MMP-12 in cancer pathology and prognosis in pre-clinical 
models may be due to the cancer type and/or the cellular source of MMP-12. Kerkelä and 
colleagues (2002) found that MMP-12 expression in human squamous cell carcinoma 
promoted tumour invasiveness whereas expression of MMP-12 in macrophages was protective 
against cancer. 
In the clinic, MMP-12 activity is protective against gastric cancer; patients with increased 
MMP-12 expression within their tumours, had reduced metastasis size and had a higher “two-
year survival rate” (Zhang et al., 2007). Furthermore in human samples of colorectal cancer, 
increased mRNA expression of MMP-1, -2, -3, -7, -9, -13 correlated negatively with disease 





patient survival (Zucker & Vacirca 2004; Yang et al., 2001). Interestingly, most studies which 
report a protective effect of increased MMP-12 expression in cancer, also tended to report 
reduced vascular growth within the tumours (Margheri et al., 2009; Yang et al., 2001; Gorrin-
Rivas et al., 2001; Shi et al., 2006). 
MMPs, including MMP-12, are required for remodelling of the cardiovascular system. MMP-
12 has been suggested to be antiangiogenic (Li et al., 2012), it has also been identified as 
playing an active role in the progression of vascular disease involving remodelling, such as 
atherosclerosis (Johnson et al., 2011; Yamada et al., 2008) and aortic aneurysms (Curci et 





1.4 MMP activity during vascular remodelling and 
disease. 
1.4.1 The cardiovascular system and disease  
The cardiovascular (CV) system consists of the heart, blood vessels and blood, and is the first 
operational organ system in vertebrate embryos. Blood is pumped through vessels by the heart, 
from large arteries down to the fine capillary beds where chemical exchange takes place before 
blood is returned to the heart by the veins. The primary role of the CV system is to meet the 
metabolic demands of tissues by transporting nutrients, gases and waste products; it also 
transports immune cells, endocrines and some cytokines around the body.  
Cardiovascular disease (CVD) includes coronary artery disease (angina and myocardial 
infarction), stroke, cardiomyopathy, aortic aneurysms, peripheral artery disease, hypertensive 
heart disease and venous thrombosis. CVD is the primary cause of death globally. 
Approximately 17.5 million people died from CVDs in 2012 accounting for 31% of all global 
deaths (World Health Organisation, cardiovascular disease fact sheet N°317). The underlying 
biological mechanisms of disease development vary depending on the disease in question.  
 
1.4.2 Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease; it can remain asymptomatic for decades but 
can also quickly deteriorate with deadly consequences. Atherosclerotic plaques are a build-up 
of fatty material and inflammatory cells within the walls of arteries. These cause the affected 
vessel to become narrowed which can result in ischemia of downstream tissues (Figure 1.7). 
Most plaques are generally considered stable but those with a thin fibrous cap, high 
macrophage content and increased vascularity are vulnerable to rupture (Ross, 1999). Plaque 
erosion and rupture can lead to thrombus formation and often occlusion of the vessel. Tissue 





location, this can induce a myocardial infarction (heart attack) or stroke (in the brain); both 
can cause sudden death. Highly aerobic tissues (such as the heart) can suffer irreversible 
damage in just a few minutes post occlusion. If the patient survives such an event, there is 
gradual scarring of the damaged tissue post injury which normally leaves it unable to perform 
its function efficiently. Therapies to regenerate damaged tissue would be highly beneficial; 
this process may be aided by promoting healthy angiogenesis into the scared tissue.  
 
MMP activity worsens atherosclerosis pathology 
The degradation of extracellular matrix (ECM) proteins in the vessel walls is critical for the 
development, increased vulnerability and eventual rupture of atherosclerotic plaques (Newby 
2005). MMPs can facilitate macrophage invasion (Shipley et al., 1996) and promote 
angiogenesis (Pepper 2001; Li et al., 2012) in plaques; both of which contribute towards 
increased plaque vulnerability. In preclinical models, MMP-9 activity increased lesion size 
(Johnson et al., 2005). Furthermore, MMPs can weaken the fibrous cap: MMP-1, -3, -9, -13, 
-12 and -14 have all been found in plaque regions with a thinning fibrous cap (Galis et al., 
1994; Formato et al., 2004; Deguchi et al., 2005; Newby, 2006). Generally, MMP activity, 






Figure 1.7 Mechanism of atherosclerosis. a) Atherosclerosis is initiated by endothelial cell 
dysfunction, characterised by increased permeability to lipoproteins (yellow) and increased adhesion 
and migration of inflammatory cells (lymphocytes) into the arterial wall. b) A fatty steak forms: 
inflammatory cells phagocytose the free lipids, forming foam cells. Smooth muscle cells migrate from 
the vessel wall into the plaque which begins to stabilise the lesion. c) An advanced lesion: a necrotic 
core forms as a result of lipid accumulation and cell apoptosis/ necrosis; a fibrous cap made of smooth 
muscle cells (SMC) and connective tissue stabilises it. d) Plaques are generally stable in this state; 
however, those with thin caps and/or under high shear stress and/or highly vascularised are prone to 
rupture. A ruptured plaque results in the necrotic core contents entering the lumen and thrombosis 
formation which often results in occlusion of the artery. Figure reproduced with permission from Ross 





MMP-12 activity accelerates atherosclerosis 
MMP-12 has been shown to be pro-atherosclerotic in two murine models. Mice do not 
naturally develop extensive lesions on a high fat diet so genetically modified animals are used. 
Murine models of atherosclerosis are based on deletion of either the low density lipoprotein 
(LDL) receptor (LDLr-/-) or apolipoprotein E (ApoE-/-). ApoE is a circulatory fat transporter 
protein whereas the LDLr recognises the ApoE protein and removes it and free LDL from the 
circulation. Mice lacking either of these proteins develop hyperlipidaemia and spontaneously 
develop atherosclerotic plaques throughout the arterial tree when fed a high fat diet (Ishibashi 
et al., 1993; Nakashima et al., 1994).   
LDLr-/- mice fed a high fat diet for 16 weeks have a 22 fold higher expression of MMP-12 
mRNA in their aortic lesions (compared to aorta from LDLr-/- mice on a normal diet which did 
not develop lesions), double that of other MMPs investigated (Prescott et al., 1999). The 
administration of a broad spectrum MMP inhibitor did not inhibit lesion development in this 
model but did decrease elastin destruction in the vessel wall.  Double knockout ApoE-/- : MMP-
12-/- mice have smaller brachiocephalic artery lesions (with increased smooth muscle cell 
content and reduced macrophage content) compared to single ApoE-/- knockouts (Johnson et 
al., 2005). In a subsequent study, ApoE-/- mice treated with a selective MMP-12 inhibitor had 
lesions with a significantly reduced (50 %) cross sectional area (Johnson et al., 2011). Both 
murine models support the hypothesis that MMP-12 promotes atherosclerosis.  
Non-genetically altered rabbits fed a high cholesterol diet (1%, 16 weeks) developed aortic 
plaques which contained foam cells and MMP-12 (mRNA and protein); this was compared to 
aortae from rabbits on normal chow which have no MMP-12 expression and do not develop 
lesions (Matsumoto et al., 1998). Another study utilised transgenic (Tg) rabbits modified to 
overexpress human (h) MMP-12 in the macrophages (hMMP-12 Tg). These hMMP-12 Tg 





weeks) to 2.3 times (9 weeks) larger than those in their WT counterparts (Yamada et al., 2008). 
The lesions from the hMMP-12 Tg rabbits exhibited increased elastolysis and macrophage 
content (which had a negative impact on the appearance of plaque stability) and a small 
increase in smooth muscle cell content (which is considered to improve plaque stability). In a 
longer study, rabbits were fed a high cholesterol diet (0.8%) for 28 weeks; hMMP-12 Tg 
rabbits had a greater total number of lesions (up to 50% more) and twice as many advanced 
lesions compared with their non-transgenic counterparts (Liang et al., 2006). The lesions also 
contained an increased number of macrophages and more disruption of the elastic lamina. This 
data further supports the role of MMP-12 in the progression of atherosclerosis in animal 
models. 
The pro-atherosclerotic role of MMP-12 has also been indicated in human disease.  Unstable 
human carotid plaques (obtained from endarterectomy) have higher levels of MMP-12 
expression compared to stable plaques and healthy vessel controls (Müller et al., 2014). 
Moreover, MMP-12 mRNA expression is higher in ruptured plaques than in those without cap 
disruption; again highlighting the role of MMP-12 in elastin degradation and disease 
pathogenesis (Morgan et al., 2004). Studies on human carotid endarterectomy samples found 
that those with a high ratio of MMP-12/CD68 (a marker for monocytes/macrophages, both 
detected by immunohistochemistry) had a high lipid and macrophage content and a reduced 
number of vascular smooth muscle cells, all characteristics of vulnerable plaques (Scholtes et 
al., 2012). Furthermore, those patient samples possessing the highest MMP-12/ CD68 ratio 
(highest quartile) had a 3 − 4 fold higher risk of subsequent stroke compared to the lowest 
quartile. However, endarterectomies are an invasive surgical procedure and are of little use for 
diagnosis and prognosis. Jguirim-Souissi and colleagues (2007) found that the circulating level 
of MMP-12 in the patients plasma could predict the presence of a carotid stenosis but not the 





protein concentrations compared to those without treatment, suggesting that statin therapy, as 
well as reducing CVD risk, also reduces MMP-12 protein expression in carotid stenosis. 
The evidence presented here supports that MMP-12 has an important role in the initiation, 
progression and prognosis of atherosclerosis in preclinical and clinical studies. Lesions with 
MMP-12 expression have high inflammatory cell infiltration and thinner caps, while advanced 
lesions exhibit accelerated ECM breakdown in the protective cap, leading to increased 
vulnerability to rupture. This supports the need for a simple way to measure MMP-12 in 
plaques as a marker of plaque vulnerability.  
 
1.4.3 Neointimal hyperplasia  
Neointimal hyperplasia refers to proliferation and migration of vascular SMC, primarily in the 
tunica intima, resulting in the thickening of arterial walls, a decrease in the luminal diameter 
and arterial stiffening. Restenosis after angioplasty can occur as a result of neointimal 
hyperplasia (Johnson et al., 1990). Mice subject to the fine-wire femoral artery injury model 
(FAI; in which a wire is briefly inserted into the femoral artery which denudes and stretches 
the arterial wall, and is followed by neointimal hyperplasia) have increased vessel 
permeability, leukocyte adhesion, and smooth muscle proliferation, all contributing towards 
neointimal hyperplasia (Sata et al., 2000; Roque et al., 2000). MMP-2 and -9 are expressed in 
the artery after FAI and contribute towards remodelling (Zou et al. 2009). MMP-12 mRNA 
expression and activity were increased in vessels post FAI which contributed towards an 
observed elastin breakdown; mice with a selective deletion of MMP-12-/- only in the SMC had 
a reduced proliferative response to FAI with reduced neointimal thickening (Liu et al., 2015). 







Aneurysms are a life-threatening condition and are associated with aging, atherosclerosis and 
family history (Kent et al., 2010). An aneurysm is an abnormal bulge in an artery formed when 
the vessel wall is weakened by progressive connective tissue destruction and distorted by 
blood pressure (Figure 1.8). True aneurysms may be classified by morphology and location; 
they can be saccular or fusiform (Figure 1.8). Saccular aneurysms are spherical shaped and 
tend to only affect one side of the vessel wall, while fusiform are “spindle shaped” and often 
involve a large portion of the aorta. Aneurysms can occur throughout the arterial vascular 
system and cause abnormal blood flow within the artery. Abdominal aortic aneurysm (AAA) 
generally remain clinically silent until rupture; the risk of rupture increases with increased 
expansion rate (diameter dilates > 0.5 cm in 6 months is at high risk of rupture) and size (an 
aneurysm with a diameter of 8 cm has a 30 to 50% risk of rupture) (Aggarwal et al., 2011). A 
ruptured AAA can result in sudden internal bleeding, hypovolemic shock, leading to death in 
> 55% of cases (Harris et al., 1991). Asymptomatic aneurysms are normally detected during 
screening or a routine physical examination or incidentally during imaging for other purposes. 
Patients with AAA are regularly monitored and those with an aneurysm greater than 5.5 cm 
are recommended to undergo surgery to stabilise the vessel. MMPs play a destructive role 









Figure 1.8 Example structures of aneurysms. a) Saccular aneurysm; these are typically found in 
smaller vessels and are more common in the brain (cerebral aneurysm). b) fusiform aneurysm; these are 
typically found in larger vessels, such as the aorta. They are at higher risk of rupture which can lead to 
hypovolemic shock and sudden death. Aneurysms rupture as a result of structural weakening and can 
cause massive internal bleeding and death. Figure reproduced with permission from (Withers et al., 
2013) and modified.  
 
MMP activity increases the size of aortic aneurysms  
MMP-9 levels in patient plasma can be used as a marker of AAA size (Lindholt et al., 2000). 
Pre-clinical models are needed to explore the mechanisms contributing towards AAA 
formation and the development of treatment. AAA can be induced by the application of a 
calcium chloride solution to the abdominal aorta; this disrupts the elastic network within the 
media and induces an inflammatory response (Chiou et al., 2001). Application of calcium 
chloride solution to the aorta of MMP-2-/-  mice results in a 52% increase in aortic diameter 
compared with controls, whereas MMP-9-/- mice show a 75% increase (Longo et al., 2002).  
Elastin is a major component of the aorta and is a principal substrate for MMP-12. MMP-12-/- 
mice treated with an aortic application of calcium chloride solution exhibited a reduced size 
of AAA, combined with lower macrophage cell numbers within the aortic wall compared to 
their WT counterparts (Longo et al., 2005). Studies on donated human AAA samples found 
that diseased tissues contained more macrophages and showed higher MMP-12 activity 





(1998) also found that the expression of MMP-12 was uniquely co-localised to residual elastin 
fibre fragments within the aneurysm tissue in a distinct pattern, unlike MMP- 2, -7 and -9 
which did not co-localise. Therefore, MMP-12 likely plays an important role in the 
pathogenesis of AAA. 
 
1.4.5  Angiogenesis 
Mechanisms of vascular growth 
New vessels grow as a result of either angiogenesis or vasculogenesis which are both multi-
step processes. Vasculogenesis requires de novo production of endothelial cells (EC) from 
angioblasts which assemble to form primitive vessels. Vasculogenesis has been observed in 
adults during tumour vascularisation and endometriosis but is primarily observed during 
embryonic development (Ribatti et al., 2001; Laschke et al., 2011). The cardiovascular system 
is the first functioning organ system in the developing embryo (Chung et al., 2010). In 
embryos, an organised network of vessels grows as a result of vasculogenesis. These 
eventually develop into arteries, capillaries and veins. Vessels mature and expand by the 
recruitment of vascular smooth muscle cells and pericytes which encompass the EC tubes to 
provide support and control perfusion (arteriogenesis) (Jain, 2003).  
 
In contrast, angiogenesis is the formation of new vessels from existing blood vessels 
(Figure1.9). Stimulation of angiogenesis can be by mechanical (activity induced) or chemical 
signals, with the former being poorly characterised and somewhat controversial (reviewed in 
depth by Egginton (2009)). Angiogenesis is controlled by a balance between a host’s pro- and 
anti-angiogenic factors. Angiogenesis most commonly occurs in response to the oxygen 
demands of the tissue and is triggered by the release of potent pro-angiogenic stimuli. Hypoxic 





HIF-1α is an important transcriptional regulator of a broad array of genes including the potent 
angiogenic stimulator vascular endothelial growth factor (VEGF) (Forsythe et al., 1996). 
VEGFs play a key role in activating EC (Ferrara et al., 2003); VEGF-A regulates EC 
chemotaxis and proliferation during angiogenesis. Sprouting angiogenesis is characterised by 
sprouts composed of ECs, which usually grow towards an angiogenic stimulus such as VEGF-
A. Briefly, sprouting angiogenesis can be divided into 4 key stages (Figure 1.9) which are well 
reviewed in the literature (Adams & Alitalo, 2007).  
Firstly, proangiogenic signals and growth factors (GFs) stimulate pericytes and SMC to detach 
from the vessel wall and proteases (including MMPs) break down the basement membrane 
and surrounding ECM. In the absence of potent endogenous inhibitors, such as angiostatin and 
endostatin (which inhibit EC migration and proliferation (Moser et al., 1999; Ferreras et al., 
2000)), ECs (tip cells) protrude filopodia, become motile and begin to move into the 
surrounding tissue. Next, the endothelial cell-cell adherins of the surrounding ECs break down; 
these ECs (stalk cells) then detach from the ECM and follow the tip cell. The stalk cells 
proliferate and migrate from the mother vessel, elongating the sprout along a chemotactic 
gradient. ECs form stable cell-cell connections and generate a lumen. Blood flow is established 
when neighbouring sprouts fuse to form a vascular loop. The third stage of angiogenesis is the 
maturation of the new vessels. This is stimulated by GFs such as platelet-derived growth factor 
(PDGF) which promotes the proliferation, migration and adhesion of smooth muscle cells 
(Hellström et al., 1999). The adhesion of pericytes and the deposition of a basement membrane 
is also key for the stability of the new vessel. The final stage is the pruning and remodelling 
of the new network to best fit the needs of the surrounding environment. Once the pro-











Figure 1.9 The four stages of sprouting angiogenesis. Stage 1) Hypoxic tissues release vascular 
growth factors (GF, such as vascular endothelial growth factor (VEGF)) and fibroblast growth factor 
(FGF)) which simulate vascular remodelling. Stage 2) Matrix metalloproteinases (MMPs) break down 
the basement membrane and weaken inter-endothelial contacts to facilitate their migration. Some 
endothelial cells (ECs) are polarised (tip cells) and migrate in the direction of the GF to form the body 
of a new vessel. The trailing EC (stalk cells) divide to form a solid core around which there is deposition 
of new matrix. EC in the core of the stalk form vacuoles which fuse to form the eventual lumen. This 
process continues until it is stopped by angiogenesis inhibitors (e.g. Notch-1). Stage 3) New vessels can 
fuse with neighbouring vessels and mature through the attachment of pericytes and smooth muscle cells, 
leading to vessel maturation. Stage 4) The new vascular network is remodelled to best suit the needs of 
the microenvironment. Figure taken from TOCRIS, 2015 and modified. 
 
MMPs, other than MMP-12, promote angiogenesis 
MMP activity generally promotes angiogenesis by degrading basement membrane and other 
ECM components, allowing vascular cells to detach and migrate, and also by releasing ECM-
bound pro-angiogenic factors (reviewed by Rundhaug et al., 2005). Interestingly, various 
cancer studies have shown that tumour samples with increased MMP-12 expression also had 
reduced vascular content (Margheri et al., 2009; Yang et al., 2001; Gorrin-Rivas et al., 2001; 
Shi et al., 2006). MMP-12 activity is not only suggested to be anti-angiogenic in cancer but 
also in a murine model of (hypoxia-induced) retinal damage. MMP-12-/- mice had a reduced 
inflammatory response and increased revascularisation 5 days post injury (Figure 1.10; Li et 
al., 2012). Subsequent studies treated WT mice with a selective MMP-12 inhibitor: these mice 
also exhibited increased angiogenesis in response to hypoxia-induced retinal damage (Li et 






Figure 1.10 MMP-12 deficiency increases angiogenesis in vivo during oxygen-induced 
retinopathy. New born post-natal mice were kept in a hyper-oxygen environment (75%) for 5 days 
(postnatal day (P) 7 to P 12), then returned to a normoxic environment for a further 5 days (P 17 to P 
21). The mice were then culled, retinas dissected and their vessels imaged by retinal fluorescein 
angiography (green). Images show retinas from (a) MMP-12+/+ (wild type, WT) and (b) MMP-12-/- 
(knockout, KO) mice. The red line indicates the area considered to be avascular. (c) Quantification of 
the avascular area showed that MMP-12 KO mice exhibit faster revascularisation post ischeamia, 
resulting in a reduced avascular area. Figure reproduced with permission from Li et al., (2012) and 
modified.  
 
MMP-12 has also been identified as an inhibitor of angiogenesis in peripheral vascular disease. 
Systemic sclerosis (SSc) is a disease of defective angiogenesis (mostly of small vessels) which 
can result in significant damage to the peripheral vasculature, tissue ischemia and damage to 
vital organs. D’Alesso and colleagues (2004) isolated microvascular EC (MVECS) from the 
skin from SSc patients. When cultured, these expressed more MMP-12 than MVECs from 
unaffected controls. Matrigel assays are used to assess EC behaviour and growth in vitro; on 
Matrigel covered surfaces, EC form a network (suggestive of the microvascular capillary 
systems) that is otherwise difficult to observe under normal EC culture conditions (Arnaoutova 
et al., 2009). Cultured, human MVECs, when treated with conditioned medium from patient-
derived cultured SSc-fibroblasts, developed impaired proliferation, invasion and capillary 
morphogenesis in Matrigel assays (Serrati et al., 2006). However, if conditioned medium from 





in the Matrigel assay (Serrati et al., 2006). These observations suggest that MMP-12 activity 
disrupts EC network formation. MMP-12 is suggested to be antiangiogenic; two potential 
mechanisms underlying this action have been proposed but their relative importance has not 
been established. 
 
Mechanisms of MMP-12-mediated inhibition of angiogenesis 
It has been suggested that MMP-12 inhibits angiogenesis in two ways: firstly, by the inhibition 
of pro-angiogenic protease activation and, secondly, by the production of inhibitors of 
angiogenesis. 
The pro-Urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor 
(uPAR) system has a complex role in regulating cell function, inflammation, cancer and cell 
signalling processes (Crippa 2007; Blasi & Carmeliet 2002; Smith & Marshall 2010). The EC 
uPAR is bound to the cell surface (Figure 1.11) and binds to extracellular pro-uPA, converting 
it to active uPA. The uPA can then catalyse the production of plasmin from plasminogen in 
the extracellular space. Plasmin is a broad-spectrum protease which can activate proteases, 
including pro-MMPs, and hydrolyse ECM proteins, notably fibrin (Pepper 2001). This 
generates a “leaky” matrix and, combined with the presence of angiogenic stimulants, this 
stimulates the migration of ECs required for angiogenesis (Blasi & Carmeliet, 2002). Mice 
lacking uPA have impaired revascularisation in infarcted murine hearts, this was suggested to 








Figure 1.11 The activation of plasmin by pro-Urokinase plasminogen activator (uPA) and 
urokinase plasminogen activator receptor (uPAR) on the surface of endothelial cells (ECs). The 
uPAR is present on the EC surface where it is able to bind extracellular pro-uPA, activating it to uPA. 
Active uPA can convert the zymogen plasminogen into active plasmin. Plasmin is a broad spectrum 
protease which can activate MMPs and hydrolyse many extracellular proteins. Its activity is considered 
proangiogenic. 
 
MMP-12 can cleave endothelial uPAR in vitro, generating a truncated form; this may render 
it unable to sustain its role in promoting angiogenesis via the activation of plasmin in vivo 
(Serrati et al., 2006; D’Alessio et al., 2004; Koolwijk et al., 2001). In this way MMP-12 is 
suggested to indirectly inhibit the activation of plasmin and, therefore, inhibit plasmin-
dependent angiogenesis. 
An alternative mechanism by which MMP-12 may inhibit angiogenesis is by the production 
of the anti-angiogenic substrate cleavage products angiostatin and endostatin. Angiostatin is 
an inhibitor of angiogenesis. The mechanism involved remains unclear but it can bind to many 
proteins, including angiomotin and EC surface adenosine triphosphate (ATP) synthase 
(Troyanovsky et al., 2001; Moser et al., 1999). This can inhibit EC migration and proliferation, 
and can induce EC apoptosis (O’Reilly et al., 1994; Moser et al., 1999). Preclinical in vivo 
studies of Lewis lung carcinoma found that both active MMP-12 (suggested to be from 





al., 1997). MMP-12 is the most efficient member of the MMP family at cleaving plasminogen 
to form angiostatin, which inhibits EC proliferation in vitro and in vivo (Cornelius et al., 1998; 
Serrati et al., 2006). Additionally, macrophages from MMP-12-/- mice cannot produce 
angiostatin from plasminogen (Cornelius et al., 1998). 
MMP -9, -3, -12 and -13 can also produce endostatin, a 20 kDa C-terminal fragment of 
collagen XVIII (found in the vascular basement membrane) which also acts as a potent 
inhibitor of angiogensis (Ferreras et al., 2000; Halfter et al., 1998). As with angiostatin, its 
mechanism of action is not clear but it can bind to pro-angiogenic growth factors, such as 
VEGF (Kim et al., 2002), or induce EC apoptosis (Dhanabal et al., 1999). Endostatin 
significantly inhibits microvessel formation in the ex vivo aortic ring assay (Kruger et al., 
2000; Li & Olsen 2004) and in tumours in vivo (O’Reilly et al., 1997).  
To summarise, MMP-12 is suggested to inhibit angiogenesis in two ways (Figure 1.12): firstly 
by the production of pro-angiogenic plasmin by inhibiting the uPA/ uPAR system. Secondly 








Figure 1.12. Suggested mechanisms for MMP-12-induced inhibition of angiogenesis. Two 
suggested mechanisms for the inhibition of MMP-12. Firstly, by the production of angiogenic inhibitors: 
direct cleavage of plasminogen/ plasmin by MMP-12 creates angiostatin fragments (potent inhibitors 
of angiogenesis) or MMP-12 can generate endostatin, a 20 kDa C-terminal fragment of collagen XVIII 
(also a potent inhibitor of angiogenesis). Secondly, by cleaving uPAR from the ECs, which subsequently 
inhibits the activation of pro-uPA to uPA. This limits the production of plasmin; plasmin is considered 
to be pro-angiogenic as it activates proMMPs and promotes the breakdown of the ECM and 
angiogenesis. 
 
1.4.6 Summary: MMP-12 and tissue remodelling 
CVD is the primary killer in the developed world and MMP-12 is implicated in the progressive 
pathogenesis of atherosclerosis, aneurysms, restenosis and arterial stiffening. MMP-12 is also 





growth or regression are highly sought after by the pharmaceutical industry. For example, 
angiogenesis is undesirable in advanced atherosclerotic plaques (as it is a risk factor for 
rupture) or in cancerous tissue (as it promotes growth and metastasis). The promotion of 
angiogenesis is, however, desirable in ischemic tissue and in biomedical implants which 
require tissue adhesion and integration. Therefore, there are continuing efforts to develop 
biomedical strategies to manipulate the process. The ability to image and inhibit MMP-12 
activity in vivo could allow for the development of new drugs and better understanding of the 






1.5 Molecular imaging  
Traditional clinical imaging modalities generally provide structural information of the scanned 
tissues, but there is increasing excitement and movement into the field of molecular imaging. 
Molecular imaging often utilises a labelled functional group to target a disease biomarker or 
pathway. Labels could be contrast agents such as gadolinium (magnetic resonance imaging 
(MRI)), radionuclides (positron emission tomography (PET)), single photon emission 
computed tomography (SPECT)), or microbubbles (ultrasound) (Figure 1.13) (Molecular 
imaging has been reviewed by James & Gambhir, 2012). Alternatively, selective fluorophores 
can be made optically “silent” until presented with certain environmental conditions (e.g. low 
pH or hypoxia). Preclinical tracers have already been designed to image enzyme activity (Lim 
et al., 2014), low pH in tissues (Urano et al., 2009) and bacterial infections (Akram et al., 
2015). In doing so, these probes can provide a real-time dynamic assessment of the molecular 
processes and micro-environment of diseased or infected tissues. This technology has the 
potential to provide vital lifesaving information to doctors who are currently unable to quickly 
assess these attributes. In the clinic, molecular imaging could also provide, in real-time, 
information about the effectiveness of treatments and, thus, contribute to the development and 
use of  personalised medicine for patients (Garland et al., 2016; Willmann et al., 2008). 
Clinical molecular imaging has mainly focused on the use of radionuclides such as 18F (PET) 
or 111In and 99mTc (both SPECT) (reviewed by James & Gambhir, 2012). However, these 
species are short lived, expensive, time intensive to prepare and expose patients to radiation. 
Optical molecular imaging, however, has the potential to be a safer and simpler method for 






1.5.1 Optical molecular imaging  
Optical detection methods are commonly used in in vitro assays (such as enzyme-linked 
immunosorbent assays (ELISA), reverse transcription polymerase chain reaction (RT-qPCR) 
or fluorescent immunohistochemistry). Until recently use of optical detection methods in vivo 
has been limited due to lack of user-friendly tools and equipment. Now, commercial optical 
molecular imaging probes and benchtop in vivo detection equipment (which is less bulky than 
MRI or PET) have become available for preclinical studies (Groves et al., 2010). Commercial 
optical probes have been designed to target a selection of molecular processes. New probes 
are also being synthesised and tested by small companies and research groups, which has led 
to an increase in vivo optical molecular imaging publications (Aslam et al., 2015; Akram et 







Figure 1.13 Summary of some modalities used for molecular imaging. Listed is the energy sources 
and the advantages/disadvantages of: ultrasound imaging, magnetic resonance imaging (MRI) optical 
imaging, computed tomography (CT) imaging, positron emission tomography (PET) and single positron 
emission computer tomography (SPECT). Figure reproduced with permission from Willmann and 





Regrettably there has been limited utilisation of optical molecular imaging techniques. This is 
because, unlike other molecular imaging methods, there are still considerable limitations that 
preclude clinical translation. Disadvantages of in vivo optical molecular imaging include: 1) 
short tissue penetration depth and high scattering of light (even with near infrared (NIR) dyes, 
it is only a few cm); 2) low signal-to-noise ratio and a lack of specificity and sensitivity of 
some optical molecular imaging probes; 3) limited equipment and probes commercially 
available for human imaging (reviewed by Keereweer et al., 2013). Despite this, optical 
molecular imaging has great potential for endoscopy and bornchoscopy (Akram et al., 2015), 
camera guided surgery (Figure 1.14, Mito et al., 2012) and intravascular imaging (Osborn & 
Jaffer 2013). 
Furthermore, unlike other molecular imaging modalities, optical molecular imaging is also not 
limited to imaging a single contrast agent per scan; multiple optically-tagged probes can be 
administered and imaged in one session. This is possible provided the excitation and emission 
profiles of the attached fluorophores do not interfere, and the imaging system is capable of 
discriminating one from the other (Troyan et al., 2009). Using this system, more information 
about a disease state could be gained in a single imaging session, improving disease 
understanding and diagnostic medicine.  
In vivo optical molecular imaging generally requires the injection of a fluorescent contrast 
agent into the vasculature which accumulates in a specific region. Accumulation can occur as 
a result of using a fluorescently-labelled inhibitor or an antibody which targets and collects in 
the location of the protein of interest (the excess is metabolised/excreted) (Waschkau et al., 
2013). Secondly probes can be designed to be silent until “switched on” by a target protease 
or environmental trigger. This results in an increase in fluorescence in a tissue region(s) (Lim 






Figure 1.14 Molecular imaging using optical probes. Possible future applications of optical molecular 
imaging tools, including: diagnostics, real-time drug engagement studies and surgical guidance (in vivo 
and ex vivo). In vivo fluorescent imaging with indocyanine green, methylene blue and 5-aminolevulinic 
acid has already been successful in small clinical trials for the detection of cancerous tissue during 
surgery (Mito et al., 2012). Figure reproduced with permission from Garland et al., 2016 and modified.  
 
1.5.2 Förster resonance energy transfer (FRET) probes 
Substrate-based Förster resonance energy transfer (FRET) probes, also known as activity 
FRET probes, are fluorescent molecules that are quenched until activated by one or more 
targeted proteases (Figure 1.15). Briefly, substrate-based FRET probes are constructed from 
two or more fluorophores (or a fluorophore and a dark quencher) tethered with a short peptide 
sequence. The distance between  fluorophores is typically in the range of 1 −10 nm (peptide 
and linkers) (Jares-Erijman & Jovin, 2003) for efficient FRET but rapidly drops if this distance 
between the fluorophores increases (Equation 1.1). When fluorophores with overlapping 
excitation and emission spectra are held close in space, the donor excitation energy is 
transferred to the acceptor (Figure 1.15a) resulting in quenched fluorescence or a shift in the 













Equation 1.1 FRET rapidly drops if the distance between the fluorophores increases. The Förster 
resonance energy transfer efficiency (E) is the fraction of energy transfer event occurring per donor 
excitation event (the quantum yield of the energy of transfer transition). E depends on the donor-to-
acceptor separation distance (r). R0 is the Förster distance, which is the distance at which the energy 
transfer efficiency is 50%, (Jares-Erijman & Jovin, 2003). 
Figure 1.15 Activity probes using Förster resonance energy transfer (FRET) systems. FRET 
requires a donor–acceptor spectral overlap, short distance and the relative orientation of the donor and 
acceptor transition dipole moments. a) In an intact probe the FRET pair is in close proximity (distance 
(r), up to 10 nm) and the donor excitation energy is transferred to the acceptor should the dipoles align 





wave number (λ) and/or by vibrations. b) Cleavage of the peptide sequence causes the FRET fluorophore 
system to break down as the distance between the fluorophores is too great (R > 100 Å). This results in 
an increase in the donor fluorophore emissions combined with a decrease in the observed emissions 
from the acceptor. Therefore, monitoring fluorophore emissions can provide information about the 
proximity of the fluorophores and, consequently, the state of the probe construct. 
 
The FRET system breaks down when the peptide sequence is cleaved and the fluorophores 
disperse, with the distance between them becoming too great to allow FRET (Figure 1.15b). 
Break down of FRET results in an increase in emissions from the donor fluorophore whereas 
the emission from the acceptor fluorophore decreases. Therefore, by monitoring these 
emissions from the fluorophores, information about their proximity can be gained. Thus they 
can be used as a tool to monitor biological activity and interactions. Another great advantage 
of FRET probes is that they generally have low toxicity; most peptides and selective 
fluorophores are not toxic (Choyke et al., 2009; Nolting et al., 2011). Furthermore, molecular 
imaging generally requires low quantities of probes. However, there are still regulatory and 
approval challenges associated with the design of clinical trials for these agents (Garland et al. 
2016). 
 
1.5.3 Commercial probes for optical molecular imaging. 
The advancement of optical molecular imaging has been, in part, due to the advances in 
preclinical technology. There are now many commercially-available probes which can be used 
in vitro and ex vivo in combination with confocal and multiphoton microscopy, or in vivo using 
fluorescence molecular tomography (FMT) which allows for 3D localization and 
quantification of fluorescent light in tissue (Zhang et al., 2014; Ntziachristos et al., 2003; 





FMT imaging with the FMT 2500, Perkin-Elmer™; further details on the FMT machine are 
available in Appendix 1. There is a wide range of optical imaging agents for different targets 
(Perkin-Elmer™) which take advantage of NIR dyes (700-900 nm) (Groves et al., 2010; 
Peterson 2011). This region is where the absorption coefficient of tissue is at its lowest, 
allowing for better tissue penetration (Frangioni et al., 2003).  
In this project AngioSense 680 and MMPSense 750 FAST were used to measure vascular 
leakiness and MMP activity in vivo, respectively. The AngioSense 680 is a blood pool imaging 
agent (and not a FRET probe). It is high-molecular-weight (250 kDa) pegylated 
macromolecule made of copolymers which are non-immunogenic (Peterson 2011); each 
macromolecule is conjugated to a fluorophore (Montet et al., 2007). After intra-venous 
injection, the initial high circulating level of the probe drives its extravasation from circulation. 
Depending on the time of imaging, two different measurements can be made about the 
vasculature. AngioSense probes can be used to measure vascular density 3-4 h post injection 
(as the macromolecule is still mostly in the vasculature) (Montet et al., 2007; Montet et al., 
2005; Zhang et al., 2014). Although AngioSense can be used to measure vascular density in a 
whole subject it has proved challenging due to a low signal to noise ratio; therefore this 
measurement is better suited to intravital window microscopy. Alternatively AngioSense can 
be used to measure vascular leakiness after 24 h (vascular leakiness increases in tissues 
undergoing angiogenesis), at this point the probe is accumulated in tissues with leaky 
vasculature and the circulating probe is mostly cleared from circulation (Zhang et al., 2011; 
Zhang et al., 2014). 
MMPSense 750 FAST (MMPSense) is a 43 kDa  FRET probe constructed of a peptide 
(PLGVR) labelled with NIR fluorophores and conjugated to a pharmacokinetic modifier 
(Figure 1.16 A) (Groves et al., 2010). MMP -2, 7, 9, 12 and 13 enzymatically cleave the 





intravascular injection (Groves et al., 2010). MMPSense has been used to image MMP activity 
in a number of inflammatory disease models, including: atherosclerosis (Hermus et al., 2010), 
deep vein thrombosis (Ripplinger et al., 2012), aneurysms (Kaijzel et al., 2010) and arthritis 
(Ibarra et al., 2011). MMPSense was also successfully used to detect MMP activity in ex vivo 
human carotid artery samples (Wallis de Vries et al., 2009).  
MMPSense 750 is not specific to a particular member of the MMP family member and, 
therefore, the data collected using this tool consequently lack important information on the 
specific roles of individual MMPs in the disease model. The ability to image these 
relationships selectively would be a fantastic tool to interrogate the dynamic nature of these 
proteases in vivo.  
Members of the Bradley and Dhaliwal group have synthesised and tested FRET probes for: 
the selective detection of neutrophil elastase in in vitro cell based assays (Avlonitis et al., 
2013); for the selective in vitro imaging of Caspase 3 activity (Mackay et al., 2016); tracking 
of intracellular labelled murine macrophages during pulmonary inflammation (Dhaliwal et al., 
2011), and imaging live bacterial infections in ex vivo human lungs (Akram et al., 2015). More 
recently, research has focused on the development of new imaging systems (data not shown 
or published) and of new selective FRET probes for new substrates including MMP-9 (data 







Figure 1.16 MMPSense 750 FAST: structure, activation and in vivo imaging. a) The structure of 
MMPSense 750FAST before and after activation by MMPs. The probe is a peptide (PLGVR) labelled 
with 2 NIR fluorophores and conjugated to a pharmacokinetic modifier (PKM) designed to effect rapid 
accumulation and activation in target tissues. The fluorophores are self-quenched by their close 
proximity imposed by the peptide link. When the peptide is cleaved by the MMPs the fluorophores are 
no longer self-quenched. b) MMPSense 750 FAST (0.5 µM final concentration in the assay) was 





optimal buffers, pH and temperature (Groves et al., 2010). c) Representative images of reflectance 
imaging of MMPSense in vivo in a mouse tumour xenograph (dashed circle) over 72 h. (d) The measured 
tumour-to-background-ratio over 72 h after injection of MMPSense. Figure reproduced with permission 
from Waschkau et al., 2013 and modified, or redrawn from Groves et al., 2010.  
 
1.5.4 MMP-12-targeting substrate FRET probes.  
Due to the strong links between MMP-12 activity and vascular remodelling, it was decided 
that an optical molecular imaging FRET probe for MMP-12 detection would be a very useful 
tool. MMP-12 selective FRET probes have already been synthesised. The peptide substrate 
sequence PLGLEEA is selective for MMP-12, but showed minor cross reactivity with MMP-
13 and -9 (Figure 1.17; Devel et al., 2006). This is likely to be the result of the high structural 
homology between the MMP family members. A similar FRET probe (PLGLEEA peptide 
sequence with a lipid tail and 2 fluorophores) was found to selectively label macrophages 
stimulated to express MMP-12 (Figure 1.18; Cobos-Correa et al., 2009). Lim and colleagues 
(2014) have more recently found that a NIR fluorophore-labelled FRET probe (with the 
PLGLEEA sequence) could be used to detect active MMP-12 in vivo in a murine model of 
arthritis (Figure 1.19). As of yet, there are no examples of a similar probe with the PLGLEEA 






Figure 1.17 The peptide sequence PLGLEEA is selective for MMP-12.  First order full-time reaction 
curves observed for the breakdown of the 7-methoxycoumarin-4-acetic acid (Mca) and 9,10-
diphenylanthracene (Dpa) Förster resonance energy transfer (FRET) pair; Mca-PLGLEEA-Dpa-NH2 
(0.5 nM) by MMPs (11 nM), 50 mM Tris, pH 6.8, 10 mM CaCl2, 25 °C. Nonlinear regression fitting of 
these curves with the integrated Michaelis-Menten Equation 1 was used to determine the kcat/Km 
values for MMP-12, -9, and -13. This probe is selective for MMP-12 but can also be cleaved by MMP-
9 and MMP-13 with slower Michaelis-Menten kinetics. Figure reproduced with permission from Devel 







Figure 1.18 An MMP-12-selective peptide sequence utilised by Cobos-Correa to create an MMP-
12 probe (Courmarin 343 and TAMRA adapted to integrate a lipid tail to allow binding to a lipid 
membrane. a) MMP-12 selective FRET probe was activated by inflammatory macrophages. The probe 
(1 µM) was incubated with LPS-stimulated macrophages (top, LPS simulates an inflammatory response 
and MMPs are released) and non-stimulated cells (centre) or those stimulated but also treated with an 
MMP inhibitor (bottom) (scale bar, 25µm). b) This probe showed an MMP-12 specific response. 
C57BL6/J (WT, left) and MMP-12-/- (right) mice which were challenged with particulate fraction PM10 
by intra-tracheal instillation (stimulated an inflammatory response)); bronchoalveolar lavage fluid was 
then incubated with the FRET probe (3 µM). Figure reproduced with permission from Cobos-Correa et 






Figure 1.19. FRET probe MMP12ap (QSY21-GPLGLEEAK[Cy5.5]G) is shown to be selective 
for MMP-12 in vitro and in vivo. a) Fluorescence images of 1 µM MMP12ap solutions spotted on 
glass slides after incubation with 50 nM of an MMP (MMP-1 (cat), MMP-2, MMP-3 (cat), MMP-12 
(cat) or MMP-13) for 30 min at 37°C. b) Representative fluorescence images of zymosan-induced 
inflammation and oedema over 16 h in a single animal showing specific activation of the MMP-12 
activity probe (MMP12ap) after intra-plantar injection with or without MMP inhibition (GM6001). c) 
Quantification of probe activation after intra-plantar injection of the probe alone or in combination with 
a broad-spectrum MMP inhibitor (GM6001) or selective MMP-12 inhibitor (MMP-12i) or a selective 
MMP-13 inhibitor (MMP-13i) (n = 3/group). These data strongly suggest that this probe is selectively 





1.6 MMP-12 inhibitors 
1.6.1 MMP inhibitors in clinical trials  
Unregulated MMP activity is closely associated with progressive disease pathology (Hu et al., 
2007; Johnson et al., 2005; Burrage et al., 2006). Consequently these zinc-dependent 
extracellular enzymes appeared to be promising targets in a range of diseases, including CVD 
(Hu et al., 2007) and cancer (Cathcart et al., 2015). The first clinically-tested, broad spectrum 
MMP inhibitors (batimastat (1) and the orally available marimastat (2); Figure 1.20) were 
developed to target cancers (Hidalgo & Eckhardt, 2001).  
 
 
Figure 1.20 Structures of batimastat (1) and the orally available marimastat (2). 
 
Studies in murine models of gastric (Kimata et al., 2002; Wada et al., 2003), lung (Wojtowicz-
Praga et al., 1998) and prostate (Somlyo et al., 2003) cancer showed improvements after 
treatment with marimastat, which generally resulted in reduced tumour size and vascularity. 
Unfortunately, these results were not easily reproduced in human clinical studies. Some trials 
observed no change compared to placebo (for example, in breast cancer; Sparano et al., 2004), 
but patients with gastric cancer did demonstrate a small improvement in overall survival 
(Bramhall et al., 2002). These MMP inhibitor drugs were also found to have muscoskeletal 
toxicity so they never became the breakthrough cancer treatments once hoped (Wojtowicz-





future generations of MMP inhibitors could have reduced toxicity if they are designed to target 
a single MMP (prominent in the pathology of the disease being targeted), or that the zinc 
binding could be weakened to limit the off target effects (Saghatelian et al., 2004).  
 
1.6.2 MMP imaging using selective inhibitors  
Therapeutic targeting of MMPs with broad spectrum inhibitors has proved challenging due to 
toxicity. However, some MMP inhibitors could still be used as molecular imaging probes by 
labelling with a reporter. This may have reduced toxic effects as only a single, low dose would 
be required for imaging.  
MMP-12 has been successfully covalently labelled in vitro with fluorescent or radiolabelled 
labelled MMP inhibitors (Figure 1.21), but these probes utilised reactive species such as a 
photo labile group (3) (Nury et al., 2013) or an electrophile (4) (Morell et al., 2013) which are 
prone to cross reactivity. The latter also required MMP-12 to be engineered to incorporate a 
cysteine near the active site. These are time consuming processes and quicker techniques 
would be beneficial. Furthermore, these attributes are not practical for in vivo studies. Covalent 
bonding of MMP-12 in vivo is unlikely to be possible. An alternative strategy is to use high 







Figure 1.21 Molecular tools for covalently and selectively labelling MMP-12 in vitro. a) Structures 
of MMP-12 targeting probes: Probe 3 utilises a phosphinic peptide (green) designed to selectively target 
the MMP-12 active site (Devel et al., 2006), this was conjugated to a photo-labile group (blue) and 
radionuclide (tritium) reporters (red) (Nury et al., 2013). Probe 4 utilises an MMP targeting, zinc-
binding (hydroxamic acid) group (green) conjugated to an α-chloroacetamide electrophile (blue) and a 
fluorophore (Cy5.5, red) (Morell et al., 2013). b) Imaging protein bound probe 3 in BALf separated by 
electrophoresis and imaged using radio imaging. Irradiated probe 3 (100 nM) labelled free MMP-12 
(arrow head) and MMP-12 bound α-macroglobulin (black filled arrow) in BALf collected from mice 





α macroglobulin (protease inhibitor) prior to irradiation blocked MMP-12 binding to probe 3. c) Probe 
4 was designed to, and did, selectively react with a mutant recombinant form of MMP-12 with a cysteine 
residue within the active site (T184C MMP-12, arrowhead, compared to wild type (WT) MMP-12) in 
spiked rat liver lysates (50 μg) with negligible background labelling (when used at low probe 
concentrations). This labelling could be blocked using a broad spectrum inhibitor (GM6001, 10 μM, 30 
min, 37 ̊C). Samples were analysed by electrophoresis gel and then imaged Cy5 fluorescence. Figure 
reproduced with permission from Nury et al., 2013 and Morell et al., 2013 and modified.  
 
Non-covalently bound MMP imaging probes have been developed for in vivo use (Figure 
1.22). Wagner and colleagues (2009) synthesised an 18F labelled MMP inhibitor (5) designed 
for PET imaging. Probe 5 displayed no accumulation in the heart and aorta of C57BL/6J mice 
and was predominatly found in the liver and bladder; it has yet to be used in a disease model. 
Schäfers and colleagues (2004) developed a very similar 123I labelled MMP inhibitor (6) which 
was successfully used to image carotid atherosclerotic lesions in ApoE-/- mice in vivo using 
planer scintigraphy.  Waschkau and colleagues (2013) optically labelled a related MMP 
inhibitor (Cy5.5-AF489, 7).  In vivo optical molecular imaging of probe 7 showed that it 
accumulated in tumour xenographs (Ewing's sarcoma) in minutes (with a higher signal to noise 
ratio) after tail vain injection (Figure 1.23). This was much faster than the commercial 
MMPSense™ 750 but after 6 h post injection, the MMPSense probe had a higher signal to 







Figure 1.22 Structures of imaging probes, based on MMP inhibitors, that are suitable for in vivo 
imaging. Probes have a zinc binding hydroxamic acid group (green) and a reporter (red). Probes 5 and 
6 are labelled with radionuclide and are suitable for radio imaging methods whereas 7 is conjugated to 







Figure 1.23 Optical imaging of MMP activity with an MMP inhibitor and FRET probe.  Top) 
Fluorescent in vivo images were captured of mice with tumour xerographs over a 72 h period post 
administration of probe 7 or commercial MMPSense™ 750 (MMP activity FRET probe). Images 
clearly demonstrate the accumulation of the probes within the tumours; this could be blocked by co-
administering a broad spectrum MMP inhibitor (data not shown). Bottom) The signal intensity of the 
two probes was quantified within the xenograph over the 4 day period. Probe 7 (which targeted MMP-
2, -8, -9, -13) accumulated within the tumour xerographs within minutes but started to be cleared after 
6 h; whereas MMPSense took longer to accumulate and was best imaged 24 h post administration. 





Overall this demonstrates the capacity of labelled MMP inhibitors as optical molecular 
imaging contrast agents. They can quickly accumulate in target tissues in vivo in the target 
tissue allowing for quick imaging (compared to FRET probes). Furthermore, structural 
changes to the inhibitor moiety could tune the probe to target specific MMPs. To date labelled 
MMP-12 selective inhibitors have not been used to image MMP activity in CVD tissues. 
 
1.6.3 MMP-12-targeting inhibitors  
MMPs have very similar structures (for example, all have a zinc atom chelated to three 
histamines in the active site, Figure 1.3). Therefore to obtain selectivity attempts have mostly 
concentrated in the S1′ pocket where some differences between the MMPs are present 
(Morales et al., 2004). The S1′ pocket is surrounded by a “selectivity loop” which varies in 
length, flexibility and chemical properties between MMPs. MMP-12 also has a large, 
predominantly hydrophobic, S1ʹ pocket which is part of a channel running through the protein 
(Morales et al., 2004). 
Selective inhibitors for MMP-12 have been predominantly developed for the treatment of 
chronic obstructive pulmonary disease (COPD) (Lagente et al., 2009). Compound AZD1236 
(8) is an MMP-9 and -12 selective inhibitor; it was in Phase II clinical trials for the treatment 
of COPD but failed to meet its biomarker endpoints to progress (Magnussen et al., 2011; Dahl 
et al., 2012). Compound RXP470.1 (9) is a phosphinic peptide inhibitor of MMP-12, which 
has been successful in preclinical trials for reducing atherosclerotic plaque development 
(Devel et al., 2006; Czarny et al., 2013; Johnson et al., 2011). Compound MMP408 (10) is a 
potent MMP-12 inhibitor which significantly reduced (>70%, p<0.001) the number of 








Figure 1.24 MMP-12 selective inhibitors. The suggested structure of AZD1236 (8) which is still under 
patent by AstraZeneca (Barnwell et al., 2007). The exact mechanism of action has not been published. 
Compound RXP470.1 (9) binds to zinc within the active site of MMP-12 via the phosphoryl group. The 
peptide backbone interacts with the MMP-12 selectivity loop and the long muti-ring (P1′) group sits 
deep in the activity site (S1) pocket (Czarny et al., 2013). Compound MMP408, (10) is a highly potent 
MMP-12 inhibitor (IC50 = 2 nM). The affinity of 10 for MMP-12 is primarily due to the presence of the 
carboxylic acid which binds to Zn2+ within the active site of MMP-12, rendering it inactive. 
 
1.6.4 MMP-12 inhibitor selection 
It was hoped that in future studies a selective MMP-12 inhibitor could be labelled for optical 
molecular imaging of CV remodelling. Compound MMP408 was selected as a starting 
compound for this study on the basis of its high potency and selectivity towards MMP-12. The 
binding of MMP408 to MMP-12 is primarily due to the presence of the carboxylic acid which 






Figure 1.25 MMP408 and analogue inhibitors. The co-crystal structure of MMP408 docking in the 
active site (S1ʹ pocket) of MMP-12. The carboxylic acid of MMP408 forms ionic bonds to the zinc 
atom, blocking its proteolytic activity. Selectivity of MMP408 for MMP-12 over other MMPs was due 
to various factors. The dibenzofuran ring provides rigidity and stability to the compound. It also formed 
pi-stacking bonds with histamine and tyrosine residues (HIS218 and TYR240) in the MMP-12 S1ʹ 
pocket (Shamsara et al., 2014). The addition of substituents to the ring was also limited to the C2, C3, 
C7 and C8 positions of dibenzofuran ring as others were blocked by the limited size of the S1ʹ channel 
(Shamsara et al., 2014). The sulphonamide moiety also had favourable hydrogen bond interactions (red 
dotted lines) with the protein backbone in the S1′ pocket. Figure reproduced with permission from Li et 
al., 2009 and modified. 
 
Following consideration of analogues of MMP408, compound LiMMPI-12 (11, Table 1.3) 
was selected for this study as it was very potent for MMP-12 and had a relatively simple 
synthesis (Li et al., 2009). Encouragingly, it showed potential to also carry large functional 
groups and still have acceptable potency towards MMP-12 (Table 1.; Li et al., 2008). This 
could allow for future MMP inhibitor labelling and imaging studies should LiMMPI-12 elicit 






Table 1.2 Structural differences of between MMP408 (10) and analogue LiMMPI-12 (11). Table 
was adapted from Li et al., 2009. 
 
 
Table 1.3 MMP-12 selective inhibitors. The structure activity relationships of LiMMPI-12  and its 







1.7 Hypothesis and aims 
1.7.1 Hypothesis 
The work described in this thesis uses commercial and in-house synthesised MMP inhibitors 
and FRET probes to address the hypothesis that MMP-12 activity is anti-angiogenic. 
 
1.7.2 Aims 
1. To synthesise and characterise an MMP-12 selective inhibitor and to use it in in vitro, 
ex vivo and in vivo models of angiogenesis. 
2. To synthesise and characterise a small library of MMP-12 selective FRET probes and 
to test them in vitro using recombinant enzymes and tissue extracts. 
3. To characterise a preclinical model of angiogenesis with MMP-12 activity. 


































 Chapter 2: Materials and Methods 
2.1 Materials and reagents 
All reagents and solvents were from Sigma Aldrich or Fisher Scientific unless otherwise stated 
and were used without further purification. 
2.1.1 Buffers  
MMP buffer: 50 mM Tris, 10 mM CaCl2, 0.15 M NaCl, 0.05% polyethylene glycol dodecyl 
ether (Brij® 35), pH 7.5, 0.2 µm filtered. 
Sample buffer: 3X solution; 6 mL 20% sodium dodecyl sulfate (SDS), 6 mL 0.5M Tris pH 
6.8, 6 mL glycerol, 1.2 mL 0.5% bromophenol blue (BoB) (in EtOH), 240 µL 0.5M 
ethylenediaminetetraacetic acid (EDTA) made up to 20 mL using H2O. 
Phosphate buffered saline (PBS): 0.01 M phosphate buffer, 2.7 mM potassium chloride and 
0.137 M sodium chloride, pH 7.4, at 25 °C.  
Citrate buffer: 10 mM citric acid, 0.05% Tween 20, pH 6. 
PBlec: 0.1 mL MnCl2 (1M) in PBS (1 L) with 1% (v/v) Tween 20. 
2.1.2 Reagents and solutions 
MTT solubilising solution: 10% Triton-X 100 in acidic isopropanol (0.1 M HCl) 
Sinapic acid matrix solution: 15 mg/mL of sinapic acid dissolved in a 30% solution of 
acetonitrile (ACN) in H2O (70%) with trifluoroacetic acid (TFA) (0.1%). 
Picro-sirius red staining solution: Pico-sirius red solution was prepared: 1% direct red, 1% 
fast green FCF in water; immediately before use, this was diluted 1:9 in picric acid saturated 





Dde deprotection stock solution: NH2OH·HCl (1.25 g, 1.8 mmol) and imidazole (0.918 g, 
0.35 mmol) in 5 mL of N-Methyl-2-pyrrolidone (NMP) (stable for 2 weeks at −20 °C). 
Kaiser test reagents: Reagent A Solution 1: Reagent grade phenol (40 g, 0.43 mol) was 
dissolved in absolute ethanol (10 mL). Aberlite mixed bead resin MB3 (4 g) was added, stirred 
for 45 min and then filtered. Solution 2: KCN (65 mg, 1 mmol) was dissolved in water (100 
mL). The KCN solution (2 mL) was diluted to 100 mL with pyridine (freshly distilled). 
Aberlite mixed bead resin MB3 (4 g) was added, stirred for 45 min, filtered and mixed with 
solution 1 to give Regent A. Regent B: ninhydrin (2.5 g, 14 mmol) was dissolved in absolute 
ethanol (50 mL). 
Chloronil test reagents: Reagent A: 2% acetaldehyde in dimethylformamide (DMF); Reagent 







All animal experiments were carried out according to the Home Office Animals (scientific 
procedures) Act of 1986 (PPL: 60/4523 19b1/19b2 and PILs (Stott) 13818 / I16D1B9E2, 
Hadoke 60/7976/ I93FA603D) and approved by the University of Edinburgh ethics 
committees. C57BL6/J mice were purchased from Harlan or Charles River, MMP-12-/- mice 
(B6.129X-Mmp12tm1Sds/J) were purchased from The Jackson Laboratories (USA) via 
Charles River (UK). Animals were housed in groups, where appropriate, and maintained under 
controlled conditions of light (lights on 08:00 – 20:00) and temperature (21 – 22 ˚C). All 
surgical procedures were performed by myself, or under the direct supervision of Dr Hadoke 







2.3 Data analysis and statistics. 
Data groups were checked for outliers using a Grubb’s test. Prism (GraphPad version 5) 
software was used to plot the data and check for normality within groups (Kolmogorov–
Smirnov test). Differences between groups were then tested for significance using an 
appropriate assay: 
 Student’s t-test (2 data groups, two-sided, normally distributed) 
 A one–way ANOVA (3 or more normally distributed groups with a single variable) 
 A two–way ANOVA (2 or more normally distributed groups with > one variable) 
 Kruskal–Wallis-test (3 or more not normally distributed data sets) 
These tests were followed by an appropriate Post-Hoc test: a Bonferroni multiple comparisons 
test; Dunnett’s multiple comparison test vs the control or samples collected on day (D) 3; 
Dunn’s multiple comparison test vs the control or samples collected on D 3. A comparison 
was considered statistically significant when P < 0.05. When a trend was reported, P < 0.01 
but > 0.05. In general results are presented as mean ± standard error of the mean (SEM). See 






2.4 General equipment, software and analytical 
procedures. 
2.4.1 Equipment and software 
Microsoft Office: Microsoft Corporation, version 2013; with NormFinder Excel Add-In, 
version 0.953 (MOMA - Department of Molecular Medicine, Aarhus University Hospital, 
Denmark, http://moma.dk/normfinder-software) 
ImageJ: Wayne Rasband, National institute for health, USA, version 1.48. 
Plate reader: Synergy HT machine with GEN 5 software version1.1 (Bio-Tek). 
Fluorescence molecular tomography (FMT) machine: FMT 2500 with TrueQuant software 
version 3.1 (VisEn medical, Perkin Elmer). 
Slide Scanner: Zeiss AxioScan.z1 with Zen lite Software (blue version 6.1.7 and black 8.1.0 
editions) 2012 (Carl Zeiss Microscopy GmbH). 
NanoDrop: NanoDrop 1000 Spectrophotometer with Nanodrop 100 software version 3.8.1 
(ThermoScientific). 
Lightcycler: Lightcycler 480 with Lightcycler 480 software version 1.5.1.62 (Roche 
Diagnostics). 
Thermocycler: TC-512 gradient thermal cycler (Techne, Bibby Scientific Ltd). 
Nuclear magnetic resonance (NMR) spectrometers: 1D and 2D 1H and 13C NMR spectra 
were recorded using an automated Bruker advance NMR spectrometer operating at 500 MHz 
and 125 MHz, respectively. Results were analysed using MetReNova software (version 6.2, 





Mass spectrometers (MS): Low resolution analysis(LRMS): recorded using an Agilent 1100 
series LC/MSD quadropole mass spectrometer under both positive and negative electrospray 
ionisation (ESI) conditions. Spectra were analysed using LC/MS Chem Station Rev 
B.04.03.SPI. High resolution analysis (HRMS): ESI recorded using Thermo Finnigan Sector 
(LCQ) mass spectrometer or ThermoElectron MAT 900; EI recorded using ThermoElectron 
MAT 900 by the School of Chemistry Mass Spectroscopy department. Matrix assisted laser 
desorption ionisation – time of flight (MALDI TOF) MS: Samples were analysed on an 
Ultraflex Extreme MALDI TOF MS (Bruker) and analysed using Data Analysis Viewer 
software (version 4.1, Bruker). 
Infra-red (IR) spectrometer: IR spectra were run using a Bruker Tenzor 27 and analysed 
using OPUS software (SS-Build 5.5.66 [317], 1997-2005). 
High performance liquid chromatography (HPLC) systems: Analytical: Reverse phase 
HPLC was performed on an Agilent 1100 HPLC system equipped with an ultraviolet detector 
connected to a Polymer lab 100 ES evaporative light scattering detector (ELSD). Columns: 
reverse phase Supelco Discovery C18, 5 µm, 50 × 4.6 mm column (FRET probes) or Kinetix 
XB-C18 (100A) 5 µm, 50 × 4.6 mm column (HS1-22 synthesis). Solvents: HPLC grade, 
Acetonitrile (ACN, 0.1 % formic acid (FA)) and water (0.1% FA). Analysis software: 
ChemStation for LC systems, Agilent technologies 2001-2007 Rev: B.13.01. 
Semi-preparative HPLC: the compound was dissolved in HPLC grade ACN/ H2O solution and 
placed in an HPLC vial. Reverse phase HPLC was performed on an Agilent 1260 HPLC 
system equipped with a UV absorption detector and connected to a fraction collector. Column: 
C18 reverse phase column, Agilent Eclipse XB-C18 9.4 × 250 mm, 5 µm. Solvents: HPLC 
grade, ACN (0.1% FA) and water (0.1% FA). Analysis: ChemStation for LC systems, Agilent 





Preparative HPLC Reverse HPLC was performed on an Agilent 1100/1200 HPLC system 
equipped with an ultraviolet absorption detector and connected to a fraction collector. Column: 
C18 reverse phase column, Kinetix XB-C18 21.2 × 150 mm C18 column. Solvents: HPLC 
grade, ACN (0.1% formic acid) and water (0.1% formic acid). Analysis: ChemStation edition 
for LC systems, Agilent technologies 2001-2007 Rev: B.03.01.SR1 [317]. 
 
2.4.2 General compound analytical procedures 
NMR spectroscopy: Compound (5 mg) was dissolved in 1 mL of deuterated solvent. 
Mass spectrometry (MS): Low/ High MS: compound (0.25 mg) was dissolved in 1 mL of 
HPLC grade methanol or ACN. MALDI-TOF MS: A solution of the compound (1 µL, serially 
diluted to 0.01M,) was mixed with a sinapinic acid solution (1 µL) on the MALDI plate and 
allowed to dry at room temperature for 10 min prior to analysis.  
HPLC: Analytical HPLC: Compound (0.5 mg) was dissolved in 1 mL of HPLC grade 
methanol or ACN. Method: GE15ACN was used unless otherwise stated (GE15ACN: ACN 
in water with (0.1% FA) on a gradient 5 to 95% (8 min); Isocratic (4 min); gradient 95% to 
5% (5 sec) then isocratic (3 min) at a flow rate of 1 mL/ min). Semi-preparative HPLC: the 
compound was dissolved in HPLC grade ACN/ H2O solution for purification on the HPLC 
semi-preparative system. Method: see compound experimental (Section 2.5.5 and 2.6). 
Collected fractions were analysed by analytical HPLC. Those with pure product were 
combined and the solvent removed under reduced pressure. Preparative HPLC: the compound 
was dissolved in HPLC grade MeOH or ACN and placed in an HPLC vial for purification on 
the HPLC preparative system. Method: the solvent gradient used for purification depended on 
the compound, see the compound experimental. Collected fractions were analysed by 






2.5 General procedures for solid phase synthesis of 
FRET probes  
2.5.1 Materials 
Reagents for the free amine assays were prepared as described in Section 2.1. Fmoc-Lys 
(Dde)-OH was synthesised in-house using a published method and prepared by Andrew Nolan 
(Chhabra et al., 1998). All other reagents were commercially available and used without 
further purification.  
 
2.5.2 Free amine assays  
Kaiser test 
Mini reactions, on solid phase, were conducted to test for the presence of free primary amines 
as follows: Reagent A (3 drops) and reagent B (1 drop) were added to a small sample of resin 
(< 0.5 mg) in a small test tube. The mixture was heated to 100 °C for 2 min and the sample 
inspected. The intensity of the blue colour of the solution gives a qualitative indication of the 
presence of the free primary amine groups; a negative test is yellow. 
 
Chloranil Test 
Mini reactions, on solid phase, were conducted to test for the presence of free secondary 
amines as follows: Reagents A and B (3 drops of each) were added to a sample of resin (< 0.5 
mg) in a small test tube. After brief mixing, the mixture was left at room temperature for 10 
min and the beads inspected. The intensity of the colour change from yellow to blue gives a 







2.5.3 General methods 
Peptide synthesis 
Reactions were conducted in a polypropylene syringe fitted with a polyethylene porous frit. 
Heating was assisted by microwave radiation in a SP Wave (Biotage). Lysine(Dde) 
deprotection and coupling of dyes (and quencher) was achieved without microwave heating.  
 
Resin  
Peptides were prepared using standard Fmoc synthesis on H-Gly-Trityl-ChemMatrix resin 
(Sigma Aldrich, loading = 1.1 mmol/g) (Amblard et al., 2006). Note: 3 equivalents (eq) of 
reagents were used for coupling reactions (3.3 mmol of reagent/g of resin used). 
Resin wash: On a vacuum manifold, the resin was isolated by filtration and washed with DMF 
(3 × 2v/v), dichloromethane (DCM, 3 × 2v/v) and MeOH (3 × 2v/v).  
Swelling: The beads were swollen in (DCM, 10 min), the resin should not fill > 1/3 of the 
vessel. 
Resin-peptide storage: After completed coupling and a standard resin wash, an additional 
wash with ether (2 v/v) shrank the resin. This was then stored at -20 °C 
 
2.5.4 Deprotection reactions 
Fmoc deprotection 
In the SP Wave the pre-swollen resin was treated with 20% piperidine in DMF (v/v) and 
vortexed (3 min) then washed with DMF (v/v). The resin was then treated again with 20% 
piperidine in DMF (v/v) and vortexed (10 min). After a resin wash, the presence of free amines 






Lysine Dde deprotection 
Immediately before use the stock Dde deprotection solution was dissolved in DCM (1:5 DCM 
stock), added to the pre-swollen resin (2 v/v) and gently shaken (3 × 1 h) (Díaz-Mochón et al., 
2004). 
 
Deprotection of side chains and cleavage from the resin 
Beads were stirred with a cleavage cocktail (TFA: DCM: TIS, 95: 2.5: 2.5) for 45 min (v/v), 
and the filtrate collected in a 25 mL falcon tube; the solvent was then evaporated under N2 gas. 
Cold ether (10 mL) was then added to the remaining mixture to precipitate out the peptide; 
this solution was centrifuged 4500 rpm (2 min) to form a pellet. The supernatant was discarded 
and the solid washed a further 2 times with ether; the remaining solid was then purified by 
HPLC. 
 
Amino acid (aa) and spacer coupling 
To a solution of 8-(Fmoc-amino)-3,6-dioxaoctanoic acid (peg2) or Fmoc-aa-OH (3 eq) in 
DMF, oxyma (3 eq) was added and stirred for 5 min. N,N'-Diisopropylcarbodiimide (DIC, 3 
eq) was added to the mixture and stirred for a further 10 min. This solution was then added to 
the pre-swollen resin beads and the mixture heated and vortexed (75 °C, 5 min) in the SP wave 
microwave. After a resin wash, the completion of the couplings was confirmed by an 







Fluorophore Coupling  
Three equivalents of 5(6)-carboxyfluorescein (FAM) or 5(6)-carboxyrhodamine B (RhodB) 
or methyl red (MR) were dissolved in DMF (2v/v); coumarin 343 was dissolved in 1:1:3 
dimethyl sulfoxide (DMSO): N-Methyl-2-pyrrolidone (NMP): DMF. To a fluorophore 
solution, oxyma (3 eq) was added and stirred for 5 min at room temperature. DIC (3 eq) was 
then added and the mixture and the solution stirred for 10 min. This solution was then added 
to the pre-swollen resin beads and the mixture stirred for 50 min at RT. Excess fluorophore 
was then washed off the resin as follows: 5(6)-carboxyfluorescein: 20% piperidine in DMF (× 
10) followed by an appropriate number of resin washes until the filtrate was colourless. 
Coumarin 343 and MR: resin wash (× 4) or until the filtrate was colourless. 5(6)-
carboxyrhodamine B: resin wash (× 4) followed by hexane wash (× 10), this was repeated 
until the filtrate was clear. Coupling was then confirmed using a Kaiser test.  
 
2.5.5 FRET probe purification and characterisation 
FRET probes were synthesised using standard solid phase Fmoc chemistry, purified by HPLC 
(ACN in water with (0.1% FA with a flow rate of 2 mL/ min. Compounds were characterised 
by MS and analytical HPLC (spectra/ traces in Appendix 2 and 3, respectively). 
 
HS1-58 (12): (Coumarin343)-peg2-PLGLEEA- peg2-K(RhodB)G-OH 
Semi-preparative HPLC. Gradient: 5 to 80% (20 min); Isocratic (1 min); gradient 80% to 5% 
(1 min). Collection at 254 nm. MALDI-TOF MS: calculated for C97H133N15O27+ [M]+ 1940.2, 






HS1-59 (13): (FAM)- peg2-PLGLEEA- peg2-K(RohdB)G-OH 
Semi-preparative HPLC. Gradient: 5 to 95% (30 min); Isocratic (5 min); gradient 95% to 5% 
(5 sec) then isocratic (1 min). Collection at 495 nm, this allowed the isolation of the rhodamine 
2 isomers. MALDI-TOF MS: calculated for C102H129N14O30+ [M]+ 2031.22 found 2031.68. 
Analytical HPLC (GE15ACN): 5.62 min. Yield of a single isomer: 0.38 mg, 188 nmol, 4%. 
 
HS1-65 (14): (MR)-peg2-PLGLEEA- peg2-K(FAM)-G-OH 
Semi-preparative HPLC. Gradient: 5 to 95% (25 min); Isocratic (5 min); gradient 95% to 5% 
(5 sec) then isocratic (1 min). Collection at 495 nm. MALDI -TOF MS: calculated for 
C88H113N15O27Na [M+Na]+ 1835.95 found 1835.6. Analytical HPLC (GE15CN): 7.45 min. 
Yield: 0.85mg, 468 nmol, 8%. 
 
2.5.6 Absorption spectroscopy yield determination 
Linear equations were derived from a plot of dye absorbance (Y) vs concentration ((X) µM) 
of probe. RhodB was used to quantify HS1-58 and HS1-59 due to the minimal absorbance of 
Coumarin 343 and 5(6)-carboxyfluorescein (FAM) at 546 nm, See Appendix 4. 
 
Table 2.1 Experimentally-derived linear equations for FRET probe yield quantification.  
Dye Abs (nm) Equation R2 
Used to Quantify 
yields of: 
RhodB 546 Y = 0.0054X+0.0821 1.00 HS1-58, HS1-59 











Experimental method was adapted from published by Keumi and colleagues (1991).  
Dibenzofuran (5.00 g, 30.0 mmol) dissolved in TFA (200 mL) was cooled to -20 ˚C. Fuming 
nitric acid (>90% HNO3, 1.7 g (1.3 mL), 27.0 mmol) in TFA (4 mL) was added dropwise into 
the dibenzofuran solution. After 1 h the reaction mixture was warmed to 0˚C and stirred for a 
further 3 h. Upon completion, the solution was warmed to room temperature and ice water (40 
mL) added, and the resulting precipitate was collected by vacuum filtration. The solid was 
dissolved in DCM (30 mL), dried (MgSO4), and the solvent removed under reduced pressure 
to give 15 as a yellow solid (5.2 g, 91% yield). 
1H NMR (500 MHz, d6-DMSO) δ: 8.62 (d, J = 1.9 Hz, 1H, 4), 8.42 (d, J = 8.5 Hz, 1H, 1), 8.34 
(dd, J = 8.4, 1.2, 0.7 Hz, 1H, 9), 8.32 (dd, J = 8.5, 1.9 Hz, 1H, 2), 7.83 (dt, J = 8.4, 0.7, 0.7 Hz, 
1H, 6), 7.69 (ddd, J = 8.4, 7.3, 1.2 Hz, 1H, 7), 7.53 (ddd, J = 8.4, 7.3, 0.7 Hz, 1H, 8). 13C NMR 
(125 MHz, DMSO) δ: 157.8 (C, 4a), 154.5 (C, 5a), 146.6 (C, 3), 130.2 (CH, 7), 129.9 (C, 9b), 
124.3 (CH, 8), 122.8 (CH, 2), 122.1 (C, 9a), 121.9 (CH, 1), 118.8 (CH, 9), 112.3 (CH, 6) 108.0 
(CH, 4). IR (neat), cm-1: 3101 (aromatic C–H stretch), 1629 (aromatic C=C stretches), 1522 
(N–O asymmetric stretch), 1359 (N–O symmetric stretch), 1198 (C–O aryl stretch). HRMS: 
(EI+) calculated for C12H7NO3 213.0420 [M]+ found 213.0425 (δ 2.0 ppm). HPLC retention 






7-Nitrodibenzo[b,d]furan-2-sulfonic acid (16) 
 
 
To a solution of 15 (0.50 g, 2.4 mmol) in DCM (15 mL), cooled to 0 ˚C, chlorosulfonic acid 
(0.20 mL, 300 mmol) was added dropwise. After 30 min, the reaction mixture was warmed to 
room temperature and stirred for 4 h. Upon completion the reaction mixture was cooled to 0 
˚C and the precipitate collected by filtration. This was dissolved in DCM:MeOH (1:5), dried 
(MgSO4), and the solvent removed under reduced pressure to give a quantitative yield of 16. 
1H NMR (500 MHz, d6-DMSO, ppm) δ: 8.61 (d, J = 2.0 Hz, 1H, 9), 8.57 (d, J = 1.8 Hz, 1H, 
4), 8.52 (d, J = 8.5 Hz, 1H, 6), 8.29 (dd, J = 8.5, 2.0 Hz, 1H, 7), 7.93 (dd, J = 8.6, 1.8 Hz, 1H, 
2), 7.77 (d, J = 8.6 Hz, 1H, 1). 13C NMR (125 MHz, DMSO, ppm) δ: 157.5 (C, 8), 155.0 (C, 
3), 146.6 (C 4a), 144.8 (C, 5a), 129.9 (C, 9b), 128.0 (CH, 7), 122.2 (CH, 1), 121.4 (C, 9a), 
120.0 (CH, 9), 118.8 (CH, 2), 111.4 (CH, 6), 108.0 (CH, 4).  
IR (neat), cm-1: 3093 (aromatic C−H stretch), 2901 (SO−H broad stretch), 1631 (aromatic C=C 
stretches), 1546 (N−O asymmetric stretch), 1419 (S=O stretch), 1344 (N−O symmetric 
stretch), 1141 (C−O stretch). HRMS: (EI+) calculated for C12H8NO6S [M+H]+ 294.0067 found 






Tert-butyl D-valinate (17) 
 
The synthesis was adapted from that published by (Chen and colleagues (2005), compound 
analysis data agree with literature values.  
To a solution of D-valine (1.0 g, 8.5 mmol) in tert-butyl acetate (20 mL) at 0 ˚C, perchloric 
acid (1.2 mL, 13 mmol) was added dropwise. The reaction mixture was warmed to room 
temperature and stirred for 18 h. Upon completion the solution was washed with water (10 
mL) and 1M HCl (10 mL). The aqueous fractions were combined and adjusted to pH 9 using 
K2CO3 (0.1 M). The basic solution was extracted with DCM (5 × 10 mL). The organic fractions 
were combined, dried over MgSO4 and the solvent removed under reduced pressure to yield a 
clear oil of D-valine tert-butyl ester 17 (0.50 g, 40%).  
1H NMR (500 MHz, CDCl3) δ: 3.22 (d, J = 4.8 Hz, 1H, 2), 2.04 (qqd, J = 6.9, 6.9, 4.8 Hz, 1H, 
3), 1.53 (s, 9H, 8), 1.02 (d, J = 6.9 Hz, 3H, 4), 0.98 (d, J = 6.9 Hz, 3H, 4a).13C NMR (125 
MHz, CDCl3) δ: 175.1 (C, 5) 82.4 (C, 7), 61.2 (CH, 2), 33.4 (CH, 3), 28.3 (3(CH3), 8), 19.2 
(CH3, 4), 17.9 (CH3, 4a). HRMS: (ESI+) calculated for C9H2oNO2 [M+H]+ 174.1489 found 







dimethylethyl ester (18) 
 
To a suspension of 16 1.6 g, 5.0 mmol) in SOCl2 (20 mL), DMF (10 drops) was added. The 
reaction mixture was refluxed at 80 ˚C for 1 h under N2 atmosphere, then cooled to RT and 
stirred for a further 16 h. Excess SOCl2 was removed from the filtrate under reduced pressure 
to give a green solid. To a solution of the green solid (1.7 g, 5.0 mmol) in dry DCM (20 mL), 
17 (0.95 g, 5.0 mmol) was added and the reaction mixture stirred and cooled to 0 ˚C. This was 
followed by the slow addition of DIPEA (3.8 mL, 22 mmol), the reaction mixture was then 
warmed to RT stirred for 4 h. Upon completion the solvent removed under reduced pressure 
and the crude compound was purified by silica gel chromatography (20 – 30% EtOAc/ Hex) 
to yield a yellow solid 18 (1.9 g, 71%). 
1H NMR (500 MHz, CDCl3, ppm) δ: 8.57 (d, J = 1.9 Hz, 1H, 9), 8.50 (d, J = 1.5 Hz, 1H, 4), 
8.36 (dd, J = 8.5, 2.0 Hz, 1H, 2), 8.13 (d, J = 8.5 Hz, 1H, 1), 8.08 (dd, J = 8.7, 1.9 Hz, 1H, 7), 
7.75 (d, J = 8.7 Hz, 1H, 6), 5.27 (d, J = 9.9 Hz, 1H, 11), 3.72 (dd, J = 9.9, 4.5 Hz, 1H, 12), 
2.12 – 2.04 (m, 1H, 13), 1.10 (s, 9H, 18), 1.02 (d, J = 6.8 Hz, 3H 14), 0.86 (d, J = 6.8 Hz, 3H 
14a). 13C NMR (125 MHz, CDCl3, ppm) δ: 170.4 (C, 15), 160.1 (C, 8), 156.0 (C, 3), 147.8 (C, 
4a), 136.1 (C, 5a), 129.1 (CH, 9b), 128.7 (CH, 7), 123.2 (C, 9a), 122.3 (CH, 9), 121.5 (CH, 
1), 119.5 (CH, 2), 113.1 (CH, 6), 108.6 (CH, 4), 82.6 (C, 17), 61.6 (CH, 12), 31.8 (CH, 13), 
27.7 (3(CH3), 18), 19.3 (14), 17.2 (14a). IR (neat), cm-1: 3269 (N−H secondary amine) 3099 
(C−H aromatic stretch), 1721 (C=O ester), 1571 and 1340 (N−O asymmetric and symmetric 
stretch), 1159 (S=O stretch). HRMS:(ESI+) calculated for C21H21N2O7NaS [M+Na]+ 471.1196 





D-valine, N-[(7-amino-2-dibenzofuranyl)sulfonyl]-, 1,1-dimethylethyl 
ester (19) 
 
To a solution of nitro-aryl compound 18 (0.29 g, 0.12 mmol) in DCM (3 mL), zinc dust (0.2 
g) was added with acetic acid (1.0 mL). The reaction was stirred for 1 h (30 °C); upon 
completion the reaction mixture was filtered through celtite and the solvent (and acetic acid) 
removed under reduced pressure. The crude material was purified by silica gel 
chromatography (50 % EtOAc/Hex) to afford a yellow solid 19 (0.23 g, 86%). 
1H NMR (500 MHz, CDCl3) δ: 8.25 (d, J = 1.9 Hz, 1H, 9), 7.79 (dd, J = 8.6, 1.9 Hz, 1H, 7), 
7.69 (d, J = 8.3 Hz, 1H, 1), 7.50 (d, J = 8.6 Hz, 1H, 6), 6.83 (d, J = 1.9 Hz, 1H, 4), 6.71 (dd, J 
= 8.3, 1.9 Hz, 1H, 2), 5.19 (d, J = 9.7 Hz, 1H, 11), 4.04 (s, 2H, 19), 3.68 (dd, J = 9.7, 4.5 Hz, 
1H, 12), 2.10 – 1.98 (m, 1H, 13), 1.08 (s, 9H, 18), 1.00 (d, J = 6.8 Hz, 3H, 14), 0.85 (d, J = 
6.8 Hz, 3H, 14a). 13C NMR (125 MHz, CDCl3) δ: 170.5 (C, 15), 159.0 (C, 8), 158.1 (C, 3), 
148.1 (C, 4a), 134.2 (C, 5a), 125.7 (C, 9a), 124.6 (CH, 7), 121.9 (CH, 1), 119.3 (CH, 9), 114.3 
(C, 9b), 112.2 (CH, 2), 111.6 (CH, 6), 97.4 (CH, 4), 82.4 (C, 17), 61.5 (CH, 12), 31.9 (CH, 
13), 27.7 (3(CH3), 18), 19.2 (CH3, 14) 17.3 (CH3, 14a). IR (neat), cm-1: 3467 and 3378 (N−H 
primary amine stretch); 3269 (N−H secondary amine stretch), 2966 and 2932 (C−H aromatic 
stretch), 1722 (C=O ester stretch) 1634 and 1603 (aromatic C=C stretches), 1132 (S=O 
stretch). HRMS: (ESI+) calculated for C21H27N2O5S [M+H]+ 419.1635 found 419.1628 (δ 1.71 









The aryl amine 19 (50 mg, 0.12 mmol) and ethyl chloroformate (13 μL, 0.13 mmol) were 
dissolved in 1.0 mL DCM followed by the addition DMAP (17 mg, 0.14 mmol). The solution 
was stirred at RT for 5 h then the reaction mixture as washed with H2O (mildly acidic), dried 
(MgSO4) and the solvent removed under reduced pressure to give 20 (36 mg, 61 %).  
1H NMR (500 MHz, CDCl3) δ: 8.37 (d, J = 1.8 Hz, 1H, 9), 7.89 (dd, J = 8.6, 2.0 Hz, 1H, 2), 
7.87 (d, J = 8.3 Hz, 1H, 6), 7.61 (d, J = 8.6 Hz, 1H, 1), 7.19 (dd, J = 8.3, 1.8 Hz, 1H, 7), 6.82 
(d, J = 2.0 Hz, 1H, 4), 5.15 (d, J = 9.8 Hz, 1H, 11), 4.28 (q, J = 7.1 Hz, 2H, 22), 3.69 (dd, J = 
9.8, 4.6 Hz, 1H, 12), 2.10 – 2.02 (m, 1H, 13), 1.35 (t, J = 7.1 Hz, 3H, 23), 1.08 (s, 9H, 18), 
1.01 (d, J = 6.8 Hz, 3H, 14), 0.86 (d, J = 6.8 Hz, 3H, 14a). 13C NMR (125 MHz, CDCl3) δ 
170.5 (C, 15), 158.7 (C, 8), 158.5 (C, 3), 158.0 (C, 20), 149.0 (C, 4a), 137.3 (CH, 2) 134.6 (C, 
5a), 125.7 (CH, 7), 124.9 (C, 9a), 121.4 (CH, 1), 120.3 (CH, 9), 118.3 (C, 9b), 112.1 (CH, 6), 
108.8 (CH, 4), 82.5 (C, 17) 67.9 (CH2, 22), 61.5 (CH, 12), 31.8 (CH, 13), 27.7 (3(CH3, 18), 
19.2 (CH3, 14), 17.2 (CH3, 14a), 14.1 (CH3, 23). IR (neat), cm-1: 3284 (N−H secondary amine 
stretch); 2968 and 2931(C−H stretch), 1719 (C=O ester stretch), 1602 and 1537 (aromatic C=C 
stretches), 1210 (C−O stretch), 1135 (S=O stretch) HRMS: (ESI+) calculated for C24H31N2O7S 










Compound is named HS1-22 in the subsequent chapters. 
Compound 20 (44 mg, 0.090 mmol) was dissolved in 1.0 mL of DCM followed by the addition 
of TFA (1.0 mL), the resulting solution was stirred at room temperature for 1 h. Upon 
completion toluene (0.5 mL) was added to the mixture and solvent removed under reduced 
pressure. The crude sample was purified by preparative HPLC: 70 − 83% ACN (8 min) then 
70% isocratic (1 min) collection detection at 254 nm. Fractions containing pure compound 
were combined and solvent removed under speed vacuum to give 21 (26 mg, 50%).  
1H NMR (500 MHz, MeOD,) δ: 8.47 (d, J = 1.8 Hz, 1H, 9), 7.99 (d, J = 8.4 Hz, 1H, 1), 7.98 
(d, J = 1.7 Hz, 1H, 4), 7.93 (dd, J = 8.6, 1.8 Hz, 1H, 7), 7.68 (d, J = 8.6 Hz, 1H, 6), 7.37 (dd, 
J = 8.4, 1.7 Hz, 1H, 2), 4.26 (q, J = 7.1 Hz, 2H, 20), 3.66 (d, J = 4.6 Hz, 1H, 12), 2.07 (m, 1H, 
13), 1.36 (t, J = 7.1 Hz, 3H, 21), 1.00 (d, J = 6.8 Hz, 3H, 14), 0.92 (d, J = 6.8 Hz, 3H, 14a). 
13C NMR (125 MHz, MeOD,) δ: 173.1 (C, 15) 159.6 (C, 8), 159.2 (C, 3), 155.9 (C, 18), 141.5 
(C, 4a), 137.0 (C, 5a), 126.8 (C, 9b), 126.0 (CH, 7), 122.4 (C, 9a), 121.0 (CH, 1), 119.2 (CH, 
9), 115.9 (CH, 2), 112.7 (CH, 6), 102.6 (CH, 4), 62.1 (CH, 12) 57.5 (CH2, 20), 32.6 (CH, 13), 
18.1 (CH3, 14), 17.4 (CH3, 14a), 14.9 (CH3, 21). IR (neat), cm-1: 3326 (O−H) 3226 (N−H 
stretch); 3070 and 2964(C−H stretch), 1718 (C=O stretch), 1600 and 1547 (aromatic C=C 
stretches), 1246 (C−O stretch), 1167 (S=O stretch). HRMS: (ESI+) calculated for 






2.7 In vitro Förster resonance energy transfer (FRET) 
probe and inhibitor assays with recombinant 
enzymes 
2.7.1 Materials 
Compounds were tested against a panel of recombinant (r) catalytic (cat) domain MMPs 
(MMPcat-1, 2, 3, 7, 8, 9, 10, 11, 12 and 13, Enzo Life Sciences). Full MMP-12 proteins were 
also purchased (recombinant human (rh) MMP-12 and recombinant murine (rm) MMP-12 
(R&D systems) and activated prior to use. Neutrophil elastase (Elastin Products Company, 
Inc.) was diluted in PBS to the desired concentration. Inhibitors used were: marimastat (Tocris 
bioscience, R&D Systems, low molecular weight broad spectrum MMP inhibitor (Rasmussen 
& McCann 1997)), AZD1236 (donated by AstraZeneca, MMP-9 and 12 inhibitor) and HS1-
22. MMP activation: amino-phenyl mercuric acetate (AMPA) (1 mM) was incubated with 
recombinant proteins (1 µM) in MMP buffer for 18 h (37 °C).  MMP proteins were then diluted 
in MMP buffer to the desired concentration. 
 
2.7.2 FRET probe plate assays 
General protocol: In a 384 well plate 15 µL reactions we set up in triplicate as follows: 
enzyme (5 µL, 30 nM final concentration unless otherwise stated) and MMP buffer (5 µL) or 
inhibitor (various concentrations, 5 µL) were incubated (37 °C). Plates were then cooled to 0 
°C followed by the addition of a FRET probe (made in house, 5 µL, 10 µM final concentration) 
and then immediately transferred to the plate reader. MMP buffer was used to replace 
components of the reaction mix to act as the corresponding controls. The plate reader was 
programmed to detect fluorescence from the probes. Data were exported in Microsoft Excel 
and analysed in PRISM; see figure legends in the results chapters for further details on study 






Enzyme activation of FRET probes 
FRET probes were tested against MMPcat-12 without inhibitors. Spectral fluorescence 
emissions of reactions were monitored after the addition of the probe in a plate reader (37 °C, 
at wavelengths in Table 2.2) until fluorescence intensity reached a plateau. The fold change in 
fluorescence was calculated. 
 
Table 2.2 Wavelengths used for spectral scanning of FRET probes. 
  Excited dye Excitation (nm) Emission detected (nm) 
HS1-58 Coumarin 343 440 460–700 
HS1-59 FAM 460 495–700 
HS1-65 FAM 460 490–700 
 
 
FRET Probe selectivity assay 
The selectivity of FRET compounds was tested against a library of enzymes (MMPcat -1, -2,  
-3, -7, -8, -9, -10, -11, -12, -13 and activated rh-MMP-12, rm-MMP-12, rh-neutrophil elastase). 
Enzymes were incubated with marimastat (200 nM final concentration) for 2 h at 37 ˚C. The 
plate was cooled, probe added and transferred to the plate reader set at 37 ˚C to detect 
fluorescence of the respective FRET probe dyes (Table 2.3). The reaction was allowed to 
procced for 2 h, the fold change in fluorescence was calculated. 
 
Table 2.3 Excitation and emission wavelengths of FRET probes. 
  Excited dye Excitation (nm) Emissions monitored for: 
HS1-58 Coumarin 343 440 coumarin (490 nm) 
HS1-59 FAM 485 FAM (528 nm),  





IC50 assays for MMP inhibitors 
Inhibitors (AZD1236, marimastat or HS1-22, 5 µL, 0.5-500 nM final concentration) and 
MMPcat-12 were incubated in MMP buffer (37 °C, 1 h). The plate was then cooled to 0 °C 
before the addition of an MMP activity sensor probe (FAM-PEG2-G-P-K-G-L-K-G-K(MR)-
NH2). Reactions were monitored in a plate reader (37 °C, ex = 495, em = 525, 1 h). Data were 
processed in PRISM; a scatter plot for each inhibitor was created (as log concentration vs log 
fluorescence) and analysed using a best-fit non-linear regression plot.  
 
Inhibitor selectivity assays 
Enzymes (MMPcat -1, -2, -3, -7, -8, -9, -10, -11, -12 and -13; rh-MMP-12, rm-MMP-12 and 
rh-neutrophil elastase) were incubated with marimastat or HS1-22 (200 nM final 
concentration) for 2 h at 37 ˚C. The plate was cooled before the addition of HS1-65; this was 
then immediately transferred to the plate reader set at 37 ˚C to detect the fluorescence (Table 
2.3). Data were analysed in PRISM by calculating the fold change in fluorescence. 
 
2.7.3 MTT toxicity assay 
The toxicity of compounds was assessed using the colorimetric MTT assay. HEK 293T cells 
were plated in a 96 well plate (approx. 1 × 106/ well) and incubated for 24 h (100 µL, 37 °C, 
5% CO2) in Dulbecco’s modified Eagle medium (DMEM) with added L-Glutamine (4 mM) 
and antibiotics (100 units/ mL of penicillin and 100 units/mL streptomycin) and heat 
inactivated fetal bovine serum (FBS,10%). HS1-22 was dissolved in sterile DMSO to give a 
200 mM stock solution; this was diluted in media (1mM - 1 µM final concentrations). When 
the cells were > 80 % confluent, they were incubated with the drug for 20 h before removing 
the media and briefly washing the cells with PBS (100 µL). MTT ((3-(4, 5-dimethylthiazol-2-





concentration of (0.5 mg/mL) and incubated will cells for 4 h (100 µL, 37 °C, 5% CO2). The 
solubilising solution was added to the wells (100 µL) and the solutions gently mixed by 
pipetting up and down; the plate was then agitated until all of the formazan crystals had 
dissolved. The absorbance of formazan was measured at 570 nm using a plate reader. The “% 
viability” of cells was evaluated using background corrected absorption values; these were 






2.8 Angiogenesis ex vivo: mouse aortic ring assay 
The aortic ring assay is a popular quantitative ex vivo model of angiogenesis in which 
developing microvessels undergo many key features of angiogenesis, it has recently been 
reviewed by Baker et al., 2012. 
 
2.8.1 Materials 
Medium, DMEM and Opti-MEM, was purchased from LONZA and the collagen type 1 (rat 
tail, Millipore) was used to make the gel. Drugs and growth factors were: marimastat (Tocris 
bioscience, R&D Systems) and VEGF (Sigma Aldrich) and HS1-22. 
 
2.8.2 Collection of aortae 
Mice (8 − 10 weeks) were sacrificed by a schedule one method (asphyxiation in CO2) and the 
aorta carefully dissected out and washed in serum free medium (DMEM). At room 
temperature, using fine tools and a microscope, the peri-adventitial tissue was carefully 
removed and the aorta divided into 1 − 2 mm rings which were stored in fresh medium on ice 
until embedding. 
 
2.8.3 Embedding and culture conditions 
Under sterile conditions, gels were prepared using collagen and serum free medium (DMEM) 
to make a 1 mg/mL collagen solution; this was then re-basified with NaOH solution (1 M) and 
stored on ice until use. In 96 well plates, 1 aortic ring was embedded on its side in each well 
in 50 µL of collagen solution. This was then left at room temperature for 15 min before being 
transferred to an incubator (37 ˚C, 1 h) to solidify. Treatments were made in Opti-MEM (1% 





for the rest of the experiment; to this MMP inhibitors were added (HS1-22 or marimastat, 25 
µM)). Treatment was randomised to ensure the observer was blinded to the treatment during 
analysis. Treatments were added to embedded aortic sections (150 µL/ well) in triplicate and 
cultured (37 ˚C, 0.05% CO2) for up to 7 days.  
 
2.8.4 Quantification of angiogenesis 
Images of aortic vessels were captured at × 20 magnification on D 3, 5 and 7 post embedding. 
The images from mice with different genotypes were randomised and angiogenesis was 
quantified by: 
 Counting the number of sprouts and branches from the ring; the average value 
of the replicates was taken for each mouse. 
 Quantifying the maximum vessel length. The length of the three longest vessels 
for each aortic ring was quantified using ImageJ. The freehand line drawing 
tool was used to measure the length of microvessels (in pixels); the average 
value of the replicates was taken for each mouse. 






2.9 Angiogenesis in vivo: subcutaneous sponge 
implantation assay 
Subcutaneous sponge implantation allows the study of the components of the fibrovascular 
tissue that infiltrates the sponge compartment. The model was adapted from Andrade and 
colleagues (1987) and Small and colleagues (2005). 
 
2.9.1 Materials 
Sponges were cut from a larger sheet of polyurethane sponge (grade XE1700V, Caligen foam 
Ltd., UK) into 1 cm3 cubes and sterilised by autoclaving. All surgical instruments and Michel 
Wound clips (7.5 × 1.75mm) (Fine Scientific Tools, UK) were sterilized by autoclaving prior 
to surgery; between animals, instruments were placed in a bead sterilizer for 10 seconds (sec), 
then allowed to cool. For drug studies, marimastat (Tocris Bioscience, R&D Systems) or HS1-
22 were administered using a micro-osmotic pump (model 1004, Alzet) via a polyethylene 
catheter (0.76 mm diameter, Alzet). 
 
Surgical procedure  
Male C57Bl/6J or MMP-12-/- mice aged 8 − 10 weeks were weighed and anaesthetised by 
isoflurane inhalation with suitable analgesic cover (0.05 mg/Kg, Buprenorphine (Vetergesic)) 
by sub-cutaneous injection. The area around the scruff was shaved and disinfected with 
sterilizing iodine solution. A 1 cm incision was made into the skin between the shoulder blades 
and a subcutaneous tunnel made using blunt forceps to lift the skin from the back of the body. 
Two sponges were inserted into flank; one on the left and one on the right of the lower back 
(Figure 2.1). The incision was then closed with 2 − 3 Michel wound clips. The animal was 
allowed to recover and closely monitored for signs of infection for the following week. The 






Figure 2.1 C57Bl/6J mouse post sponge implantation surgery, the dashed circles indicate the 
position of the sponges. 
2.9.2 In vivo Matrix metalloproteinase inhibitor drug study  
Mini pump preparation 
Drugs were administered to mice at 150.6 nmol/mouse/day (marimastat: 2 mg/kg/day, HS1-
22: 2.6 mg/kg/day) for 21 days (25 g mouse) in DMSO: propylene glycol: H2O (1:1:1). Pumps 
were prepared under sterile conditions (see Appendix 1 for method). The pumps were primed 
by incubation in a saline solution (0.9% NaCl, 37 °C, 48 h) prior to surgery. 
 
Surgical procedure 
Immediately prior to surgery, the catheter was cut to approximately 1.5 inches, inserted into 
the centre of a sponge and glued in place with 1 drop of tissue adhesive (Vetbond, 3M). The 
surgical procedure was similar to that previously described for sponge implantation (Section 
2.9.2). Briefly, male mice were anaesthetised and given analgesic cover before a dorsal 
subcutaneous tunnel was made. The sponge and the mini-pump were inserted, the catheter was 
then tucked in under the scruff and the incision closed with Michel wound clips. The mouse 
was allowed to recover and closely monitored for signs of infection or toxicity for the 






2.10 Fluorescence molecular tomography imaging 
2.10.1 Materials 
Imaging probes, MMPSense 750 FAST and Angiosense 680, and tissue mimic solution were 
purchased from PerkinElmer. The alfalfa free diet, Teklad 2914 maintenance diet, was from 
Harlan Teklad Laboratory. Hair was removed using depilitory cream (Veet, Reckitt Benckiser 
Group). 
 
2.10.2 General FMT procedure 
Further explanation of fluorescence molecular tomography (FMT) method and protocols are 
in Appendix 1. Briefly, mice were fed an alfalfa free diet for 10 days prior to imaging (Inoue 
et al., 2008). Imaging agents were reconstituted, under sterile conditions, with PBS (1.2 mL/ 
vial); agents were combined (2.4 mL). With assistance from Gary Borthwick, 24 h prior to 
imaging the mice were warmed (30 °C, 15 min) and briefly anaesthetised and agent 
administered by intravenous tail vein injection (200 µL, containing 2 nmol of each agent or 
PBS as a control).   
 
Imaging in vivo 
Mice were anaesthetised (isoflurane for the duration of the experiment) and hair was removed 
from the chest and abdomen (clippers followed by depilitory cream). The mouse was 
positioned in the imaging cassette so that the tissue of interest was in the centre. The cassette 
was closed and placed in the FMT 2500 machine. The TrueQuant software was used to acquire 
the data (see Appendix 1). The mouse was then removed from the chamber and either allowed 





Imaging ex vivo 
Once mice had been killed, sponges were removed and placed in a dish and covered with tissue 
mimic solution (PerkinElmer). The dish was placed in the imaging cassette and inserted into 
the FMT machine and the data acquired. After scanning, each sponge was gently cleaned in 
PBS, cut in half and either fixed in paraformaldehyde solution (24 h and then stored in 70% 
ethanol) or snap frozen on dry ice and subsequently stored at -80 ˚C. 
 
Data acquisition 
Using TrueQuant software, a database was created with subject (mouse) numbers and selected 
agents. A reflectance image was acquired onto which the scan field was drawn around the ROI 
to have < 50 laser source positions (Figure 2.2). The mouse was then scanned and data 
reconstructed into a 3D image.  
 
 
Figure 2.2 FMT2500 Reflectance image and ROI determination. The scan field (solid line) was 
drawn around the sponges (dashed circles, added here for clarity) with the maximum number of laser 






2.10.3 FMT data analysis 
The fluorescent signal from within the sponges was reconstructed into a 3D image by the 
TrueQuant software.  
 
In vivo imaging data analysis 
Thresholds were set to eliminate the endogenous background signal found in the controls 
(those injected with PBS rather than agent): AngioSense 680 = 51 nM and MMPSense 750 = 
39 nM. A ROI around each sponge was drawn using the cylindrical drawing tool, the X, Y and 
Z axis lengths were relatively well conserved for all in vivo analyses. The software converted 
the fluorescent signals, using a calibrated algorithm, into pmol of each reagent within the ROI. 
For each agent the average number of pmols detected from the two sponges was used to give 
a value for each mouse. These data were analysed as described (Section 2.3). 
 
Ex vivo imaging data analysis 
Thresholds were set to zero for both agents (no signal in controls) and an ROI was made with 
the cuboid drawing tool which captured all the signal detected. The software converted the 
fluorescent signals, using a calibrated algorithm, into moles (pmol) of each reagent within the 
ROI. For each agent the average pmols from the two sponges was used to give a value for each 






2.11 Ex vivo FRET probe assays with tissue lysates 
2.11.1 Quantification of total protein in tissue lysates  
Tissue homogenisation 
One half of the sponge was thoroughly homogenised in 1 mL of cold cell lysis buffer (Cell 
Signalling) or PBS using the ultra turrax homogeniser (IKA T10 Basic). Samples were then 
centrifuged at 13,000 rpm for 2 min and the supernatant transferred to a new Eppendorf tube. 
The sample was then centrifuged (13,000 rpm, 10 min) and the lysate supernatant transferred 
to a new Eppendorf and stored at -80 ˚C. 
 
Total protein quantification 
The total protein in the lysate samples was quantified colourimetrically using a Bradford’s 
assay against bovine serum albumin (Fisher, ThermoScientific). Briefly, protein standards 
were made by serial dilutions (250, 125, 50, 25, 5 µg/mL) of the supplied BSA standard using 
the working reagent (50:1, Reagent A:B).  In triplicate, each standard or unknown sample (25 
µL) was mixed with the working reagent (200 µL) and the plate mixed thoroughly before 
incubation at 37 °C for 30 min. The plate was then cooled to RT and the absorbance measured 
at 562 nm on a plate reader (blank-corrected at 652 nm). A linear standard curve was 
constructed by plotting the average blank-corrected 562 nm measurement for each BSA 
standard vs. its concentration in µg/mL; the fit was deemed satisfactory if R2 < 0.98. This was 
used to determine the protein concentration of each unknown sample. Tissue homogenate 
samples were standardised to 800 µg of protein using PBS.  
 
2.11.2 Quantification of MMP-12 and TIMP-1 protein  
The enzyme-linked immunosorbent assay (ELISA) assay method is explained in more detail 







MMP-12 protein concentrations (zymogen and active forms) in the sponge tissue lysates were 
quantified using an MMP-12 ELISA (CUSABIO) and the reagents and standards were 
prepared according to manufacturer’s instructions. Standards were analysed in duplicate; 
tissue lysates (800 µg/mL) were diluted (1/400) and analysed in triplicate. Briefly, standards 
and samples were added to the appropriate wells and incubated (100 µL, 2 h, 37 °C). The 
liquid was removed and the biotin antibody was added (100 µL, 1 h, 37 °C). Wells were 
washed with wash buffer (3 × 200 µL, 2 min, 37 °C) and the plated inverted and blotted on 
clean paper towels. The horseradish peroxidase (HRP)-avidin antibody was added and 
incubated (100 µL, 1 h, 37 °C) and then the wells washed (5 × 200 µL, 2 h, 37 °C). The 
3,3′,5,5′-tetramethylbenzidine (TMB) substrate was added to each well for (15-30 min, 
protected from light, 90 µL, 37 °C) before addition of the stop solution (50 µL, 2 h, 37 °C). 
The absorbance was measured at 450 nm and 540 nm using a microplate reader. Absorbance 
readings from 450 nm were subtracted from those at 540 nm for each well. A standard curve 
was constructed (x-axis: log concentration, y-axis: absorbance) and deemed acceptable if R2  
> 0.96. The MMP-12 concentrations in the replicate were calculated and the average calculated 
for each sample, the data were then analysed as described (Section 2.3). 
 
TIMP-1 ELISA procedure 
Tissue inhibitors of metalloproteinases (TIMP)-1 protein concentrations (zymogen and active 
forms) in the sponges were quantified using a TIMP-1 ELISA (Quantikine, R&D Systems). 
Standards were analysed in duplicate; tissue lysate samples (800 µg/mL) were diluted (1/50) 
and analysed in triplicate. Briefly the reagents and standards were prepared according to 
manufacturer’s instructions. Assay diluent was added to each well (50 µL); standards and 





removed, the wells washed with wash buffer (5 × 400 µL, 2 min, 37 °C), and the plate inverted 
and blotted on clean paper towels. Mouse TIMP-1 conjugate was added to each well and 
incubated (100 µL, 2 h, 37 °C). The liquid was removed, the wells were washed with wash 
buffer (5 × 400 µL, 2 min, 37 °C), and the plate inverted and blotted on clean paper towels. 
The TMB substrate was added to each well (30 min, protected from light, 100 µL, 37 °C) 
before addition of the stop solution (100 µL, 2 h, 37 °C). The absorbance was measured at 450 
nm and 540 nm using a microplate reader. Absorbance readings from 450 nm were subtracted 
from those at 540 nm for each well. A standard curve was constructed (x-axis: log 
concentration, y-axis: absorbance) and deemed acceptable if R2 > 0.99. The TIMP-1 
concentrations in the samples were calculated and the mean of the reading taken. Data was 




All gels (12% Tris-Glycine gel with 0.05% casein), the colloidal blue stain, a sharp pre-stained 
protein standard, the XCell SureLock Mini-Cell and all buffers were purchased from the 
Novex range (Life Technologies) and used according to manufacturer’s instructions. 
 
Sample preparation and electrophoresis 
12 well precast 12% Zymogram gels were prepared and loaded into the electrophoresis tank, 
which was then filled with Tris-Glycine SDS Running Buffer and cooled (4˚C). Tissue lysate 
samples were standardised to 1 µg/µL protein with 33.3% sample buffer in PBS. The samples 
(15 µL) and protein standard (10 µL) were loaded and electrophoresis started (4 ˚C, 120 min, 






Renaturing and development of gels 
Gels were carefully removed from their casts (a note of the ladder position taken on clear 
plastic) and submerged in Zymogram Renaturing Buffer (1.5 h, 4 ˚C) with gentle agitation. 
The gel was then moved into Zymogram Developing Buffer (30 min, 4˚C, with gentle 
agitation), the buffer was refreshed and the gel allowed to develop (18 h, 37 ˚C).  
 
Staining and imaging 
The digestion of the gel was imaged using a colloidal blue staining kit, and the gel was 
submerged in the stain (4 h), followed by destaining in H2O (17 h). Gels were digitally imaged 
using a scanner to create a TIFF file.  
 
Densitometry image analysis 
The TIFF files images were analysed by densitometry using Image J as described (Hu & 
Beeton 2010). Briefly, TIFF files were opened in Image J and visualised in black and white. 
The rectangular tool was used to select the first band (drawing a rectangle twice the height of 
the width) and selected as the first lane; this process was repeated for the other lanes. The 
software was then used to generate a profile plot of the regions of interests selected. The area 
of each plot was evaluated by drawing a straight line to form an enclosed area under the curve; 
this area is proportional to the extent of gel digestion. The quantitative value for the enclosed 
area was generated (using the wand tool) and was plotted. Gel digestion was directly related 
to MMP activity. 
 
MMP-12 activity inhibition assays 
For MMP inhibition studies, a gel was loaded with duplicated samples, loaded in a mirror 





in each half having the same sample arrangement) and incubated in denaturing buffer (1.5 h, 
4 ̊ C with gentle agitation). One half of the gel was then placed in developing buffer containing 
marimastat (50 µM), the other (control gel) was placed in drug free developing buffer. The 
subsequent protocol was the completed as described above. 
 
2.11.4 FRET probe assays with tissue lysates 
Plate assay with MMP inhibitors 
In a 384 well plate, 15 µL reactions were prepared in triplicate: tissue lysates (D 3 − 35, 5 µL, 
final concentration 1.67 µg/µL) and marimastat (5 µL, final concentration 500nM; MMP 
buffer was used as a control) were incubated together (37 °C, 1 h). The plate was then cooled 
to 0 °C before HS1-65 was added (5 µL, final concentration 10 µM). Reactions were monitored 
in a plate reader (37 °C, ex = 495 nm, em = 525 nm, 2 h). Results were analysed as a fold 
change in the fluorescent signal (compared to HS1-65 with no treatment). The proteins in the 
tissue lysates were denatured (95 °C, 5 min and then cooled to 4 °C in a thermocycler) and 
used as a negative control; MMP cat -12 (5 µL, 30 nM) was used as a positive control.  
 
MS analysis of probe cleavage in tissue lysate 
Tissue lysate reaction mixtures from plate assays were purified and concentrated using pipette 
tips containing C18 resin cartridges for reverse phase purification (Millipore Zip Tip® pipette 
tips, 10 µL). Briefly, tips were prepared by washing with ACN (1 × 5 µL) then H2O with 0.1% 
TFA (2 × 10 µL). Sample was loaded by gently pipetting 10 µL of sample in and out of the 
cartridge 5 times. The cartridge was then washed with H2O with 0.1% TFA (2 × 10 µL). 
Sample was eluted from the cartridge with 80% ACN in H2O, 0.1% TFA (1 × 5 µL) into a 






Plate assay with protease inhibitors 
In a 384 well plate, 15 µL reactions were prepared in triplicate: tissue lysates (D 3 − 35, 5 µL, 
final concentration 1.67 µg/ µL; MMP-12cat (5 µL, 90 nM) was used as a positive control) 
were mixed with protease inhibitors, see Table 2.4 (Sigma Aldrich, 5 µL, MMP buffer was 
used as a control) and then incubated (37 °C, 2 h). The plate was then cooled to 0 °C before 
the addition of HS1-65 (5 µL, final concentration 10 µM). Reactions were monitored in a plate 
reader (37 °C, ex = 495, em = 525, 2 h). Results were analysed as a fold change in the 
fluorescent signal (compared to HS1-65 with no treatment). 
Table 2.4 Protease inhibitors used in the tissue lysate assay with HS1-65 
Drug Final Concentration 
Sivelestat 100 µM 
Antithombin III 400 nM 








2.12 Immunohistochemistry  
Tissue section preparation 
Fixed tissues were embedded in paraffin and cut into 5 µm thin sections using a 
microtome. Tissue sections were floated on a water bath to smooth out creases and attached 
to Apex superior adhesive glass slides (Leica) and allowed to dry in an oven (30 °C, 24 h).  
 
Hydration and dehydration of tissue sections 
Before staining, slides were deparaffinised in xylene (2 × 5 min) and rehydrated though a 
series of ethanol solutions (100% 2 min, 100% 2 min, 95%, 1 min and 80% 1 min) and washed 
in H2O. After non-fluorescent staining, slides were dehydrated through a series of alcohols 
(50% 2 min, 75% 1 min, 95% 1 min and 100% 1 min) and then mounted using DPX solution. 
After fluorescent staining, sections were washed and then mounted using permaflour mountant 
(Thermo Scientific).  
 
2.12.1 Quantification of angiogenesis 
Staining 
Antigen retrieval was achieved by autoclaving rehydrated slides in citrate buffer (pH 6). Slides 
were then loaded onto Sequenza cassettes and washed with 0.5% BSA in PBS. Tissues were 
blocked in 10% donkey serum (1 h, RT) before addition of primary CD31 antibody (1 in 200, 
Rabbit anti mouse, ABCAM AB28364, 18 h, 4 ˚C). The excess primary antibody was washed 
away with 0.5% BSA in PBS followed by incubation with the secondary Alexa 488 conjugated 
antibody (donkey anti-rabbit, 1 in 1000, RT, 1 h, Sigma Aldrich) and alpha smooth muscle 
actin (α-SMA) antibody conjugated to Cy3 (rabbit anti-mouse, 1 in 1000, RT, 1 h). The excess 
antibodies were then washed off and the sections incubated with DAPI (1 in 1000, RT, 5 min) 





Imaging and analysis 
Slides were imaged at ×20 magnification, using the slide scanner, and the image files 
randomised. Files were viewed in Zen software and the total area of the section was measured 
using the line tool.  
The images were analysed as follows: 
1) The mean signal intensity across the whole area of tissue for the three fluorescent 
channels was measured using Zen software. 
2) The area of signal was measured by creating 4 ROI (5000 × 5000 pixels) in vessel hot 
spots, for each channel (Figure 2.3a). Image J was then used to measure the % area 
covered by the signal in each ROI; the mean was taken of the 4 ROI for each signal 
per section. 
3) The number of vessels was counted across the whole section; vessels were identified 
as green (CD31, Alexa 488) tubular structures with a black lumen possibly containing 
erythrocytes. Mature vessels were also counted; these were identified as those positive 
for CD31 and α-SMA (red). This was corrected for the area of the section analysed. 







Figure 2.3. The areas where the ROIs were sampled from each section for image analysis. ROI 
were selected near the edge of the section in an area with no staining artefacts and saved as TIFF files: 







2.12.2 Quantification of macrophage infiltration 
Staining was performed by L. Boswell based at the Shared University Research Facilities 
(SuRF) within The Queen’s Medical Research Institute. 
 
F4/80 Immunohistochemistry 
Staining was achieved using a staining robot (Leica Bond-III, leica Biosystems) and the Leica 
refine detection kit. Slides were rehydrated and treated with trypsin (0.5 mg/mL, 10 min at 37 
˚C) before being bathed in hydrogen peroxide (3 – 4%, 5 mins, RT) and then blocked in rat 
impress blocking serum (30 min, Vector labs). The F4/80 antibody was applied (eBiosciences, 
1:300, 30 min) followed by an incubation with the ImmPRESS™ anti-rat Ig reagent (30 min, 
vector labs) which contains a “micropolymer” of a very active peroxidase coupled to an 
affinity-purified anti-rat IgG (H+L) secondary antibody. A solution of 3,3'-diaminobenzidine 
(DAB) was applied to the tissues (10 min), which were then counterstained with haematoxylin. 
Slides were dehydrated and mounted, as previously described. 
 
Imaging and analysis 
Slides were imaged using the slide scanner and image files randomised. Files were viewed in 
Zen software and images were analysed as follows: 
1. The maximum depth of staining into the tissue was measured using the line tool. 
2. The percentage area stained stain was measured by creating 4 ROI per section (3000 
× 3000 pixel; Figure 2.3a). The percentage area of stain was measured by colour 
thresholding for the brown DAB stain using ImageJ. The percentage stain over the 4 
ROI was averaged for each section.  





2.12.3 Quantification of neutrophil infiltration 
Staining with H&E 
Rehydrated slides were washed with water and stained using Harris haematoxylin solution for 
4 min and washed under running water for 1 min before 15 sec in acidified water and another 
rinse under running tap water. Slides were placed in Scott's tap water for 20 sec before a further 
rinse under tap water. Sections were counter stained in Eosin for 2 min, excess stain was washed 
off using running tap water. Slides were dehydrated and mounted as previously described. 
 
Imaging and analysis 
Slides were imaged at × 20 magnification using the slide scanner and image files randomised 
and viewed in Zen software. For each section, 5 regions of interest were selected (500 × 500 
µm; Figure 2.3b). In each ROI the number of neutrophils was counted; the average number of 
neutrophils in the 5 ROIs was taken for each section, data were unblinded and analysed as 






2.12.4 Quantification of matrix deposition 
Staining was performed by L. Boswell based at the Shared University Research Facilities 
(SuRF) within the The Queen’s Medical Research Institute. All reagents are commercially 
available. 
 
Staining with picro-sirius red 
Rehydrated slides were washed with water and stained in the picro-sirius red solution for 3 h, 
briefly washed with water, dehydrated and mounted as previously described.  
 
Imaging and analysis 
Slides were imaged at ×20 magnification using the slide scanner and image files randomised 
and viewed in Zen software. Samples were analysed in 2 ways: 
1. The maximum depth of staining into the tissue was measured using the line tool (µm). 
2. The % stain was measured by creating 4 ROI per section (5000 × 5000 pixel, near the 
perimeter, Figure 2.3a). The % area of stain was measured by colour thresholding for 
the red stain using ImageJ. The % stain over the 4 ROI was averaged for each section.  







2.13 Gene expression analysis 
2.13.1 Materials 
The RNeasy mini kit, QIAzol Lysis Reagent and the QuantiTect Reverse Transcription kit 
were all purchased from Qiagen. Tissues were homogenised using an ultra turrax homogeniser 
(IKA T10 Basic). UPL probes, Probes mastermix and Lightcycler water were from Roche 
Diagnostics. For quantification by real-time polymerase chain reaction (RT-qPCR) a light 
cycler 480 (Roche Diagnistics) was used.   
 
2.13.2 Isolation of RNA from sponges 
Ribonucleic acid (RNA) extraction from the tissue in the sponges was achieved using the 
RNeasy mini kit. Briefly, under strict RNAse free conditions, one half of a frozen sponge was 
homogenised in 700 µL of QIAzol (2 min) until the mixture was smooth. It was then split into 
2 sterile 2 mL Eppendorfs (500 µL sample in each) and another 350 µL of QIAzol added to 
each. The samples were then homogenised (1 min) and left to rest (5 min, RT). Subsequently 
chloroform (200 µL) was added to each and mixed (not vortex) and left to stand (2 min) at 
RT. Samples were spun (12,000 × g, 4 ˚C, 15 min) and the aqueous fractions from the same 
sample were combined (if there was only a little aqueous phase and a large white colloidal 
phase, QIAzol (200 µL) was added and the sample mixed and spun again), this totalled 
approximately 1 mL/ sponge sample. Ethanol (70%, 1 v/v) was added to the aqueous phase 
and mixed well by pipetting. The sample (700 µL) was loaded on to an RNeasy Mini spin 
column, placed in a 2 mL collection tube, and centrifuged (8000 × g, 15 sec), the flow through 
was then discarded; this was repeated until all the sample was loaded. Buffer RW1 (700 µL) 
was loaded onto the column and centrifuged (15 sec 8000 × g), the flow through was then 
discarded. Buffer RPE (500 µL) was loaded onto the column and centrifuged (15 sec, 8000 × 
g), the flow through was then discarded. Buffer RPE (500 µL) was loaded onto the column 





placed in a new 1.5 mL collection tube and the RNA was eluted out with different volumes of 
RNAse free water depending on the sample collection time (Table 2.5). RNA concentration 
and quality by 260/280 nm ratio was determined using Nanodrop. RNA integrity was 
determined by Gel Red agarose gel electrophoresis for the integrity of the abundant ribosomal 
RNA fragments. RNA was stored at -80 ˚C.  
 
Table 2.5 Volumes of RNase free water required to elute RNA from different time point samples (days, 
D) from the spin column. 
 
2.13.3 Preparation of cDNA 
Complementary deoxyribonucleic acid (cDNA) synthesis was performed using a QuantiTect 
Reverse Transcription Kit and used according to the manufacturer’s instructions. Briefly, 
genomic DNA was removed by incubating the RNA sample (500 ng) with gDNA Wipeout 
buffer (42 °C, 2 min). Then reverse transcription was performed using a reaction master mix. 
Per 500 ng of RNA, master mix consisted of: Quantiscript Reverse Transcriptase (1 µL), 
Quantiscript Reverse Transcription buffer (4 µL) and Quantiscript Reverse Transcription 
primer mix (1 µL) adjusted to a total volume of 20 µL with RNase free water. Negative 
controls for cDNA reactions were also performed: 1) without the addition of the reverse 
transcriptase as a control for DNA contamination; 2) without the addition of RNA as a control 
for transcription kit/ processing contamination. Samples were incubated (42 °C for 15 min, 
then 95 °C for 3 min and cooled to 4 °C) using a thermocycler and then stored at -20 ˚C. The 
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2.13.4 Primers and genes  
Primers were purchased from Invitrogen Life Technologies. Primers (Table 2.6) were 
designed to match intron spanning probes within the Roche Universal Probe Library (UPL). 
PubMed nucleotide gene resources was utilised with the online software, UPL assay design 
centre by Roche. The program assigns primers to give a melting temperature between 59-60 
˚C, intron spanning, a molecular weight between 6100 and 7100 µg/µmol and assigns a 




2.13.5 Real-time quantitative polymerase chain reaction 
The RNA transcript levels of genes were assessed by RT-PCR. A standard curve was 
constructed using pooled cDNA (2 µL of cDNA from every sample excluding the negative 
controls). This was subsequently diluted 1/8 with PCR water, followed by serial half dilutions 
to give 1/16, 1/32, 1/64, 1/128, 1/256, 1/512.  
Reactions (10 µL) were performed in triplicate on a 384 well plate. Each reaction contained:  
6 µL LightCycler® 480 Probes Master; 2.7 µL RNase free water; 0.1 µL of the forward primer; 
0.1 µL reverse primer; 0.1 µL of the UPL probe assigned to the designed gene primers and 2 
µL of the sample cDNA.  
Reactions were incubated in the light cycler using the following programme: 95 ˚C for 5 min 
followed by 50 cycles of 95 ˚C for 10 sec, 60 ˚C for 30 sec. Reactions were then incubated at 
40 ̊ C for 30 sec. Once the programme was complete, sample results were analysed in triplicate 
using the absolute quant/ 2nd derivative max setting on the light cycler. A standard curve was 





efficiency between 1.8 and 2.1 was optimal. Triplicates were deemed acceptable if the standard 
deviation of their Cp was less than or equal to 0.5 cycles. One replicate could be removed per 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.13.6 Reference genes and analysis 
The sponge does not contain any endogenous biological tissue when implanted and the 
subsequent cell populations present within the sponge varied depending on the time point 
investigated. Therefore, it was beneficial to investigate for genes with stable expression despite 
the changing cell population to use as reference genes to normalise against. The housekeeping 
genes investigated in this project were βActin (βAct), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), ribosomal 18s (rRNA18s) and TATA-binding protein (TBP).  RT-
qPCR for these genes was run with the samples from different groups (D 3, 7, 14 and 21). The 
Microsoft Excel plug-in “NormFinder” was used to assess the variation in expression between 
groups (Andersen et al., 2004). The average of TBP and GAPDH had least variation between 
the groups and was used in this study to normalise expression from genes of interest (Table 
2.7). Furthermore, the samples from D 3 had minimal gene expression that could not be 
compared to that of samples collected on D 7, 14 and 21. For each sample the gene of interest 
transcript expression was normalised against the reference genes (TBP and GAPDH); this 
value was analysed as described in Section 2.3 
 




value   Best gene TBP 
βAct 0.483   Stability value 0.254 
rRNA18s 0.551      
TBP 0.254   Best combination of two genes TBP + GAPDH 

































 Chapter 3: Synthesis and In Vitro Testing of 
MMP-12 Targeting Compounds 
3.1 Introduction 
The extracellular matrix (ECM) is the structural connective tissue between cells which helps 
give tissue its structure, it also enables basic cellular behaviour such as cell division (Hynes, 
2009). Structural changes in the ECM are also required for vascular remodelling (Liu et al., 
2006) with matrix metalloproteinases (MMP) required for the breakdown of the ECM. An 
increase in MMP-12 mRNA, protein expression and protease activity has been associated with 
the progression of vascular disease pathology (Longo et al., 2005; Liang et al., 2006). MMP-
12 has also been suggested to be anti-angiogenic (Li et al., 2012). Tools to enable the 
interrogation and real-time assessment of MMP-12 activity could lead to a better 
understanding of its precise role in angiogenesis and disease pathogenesis. Furthermore, 
molecular imaging of MMP-12 could facilitate real-time drug engagement studies, assessment 
of disease progression and in vivo and ex vivo surgical guidance (Figure 1.14).  
In this chapter, two molecules were synthesised to target MMP-12. Firstly, an MMP-12 
selective FRET probe (discussed in detail in Section 1.5.4); secondly an MMP-12 inhibitor 
(MMP-12 selective inhibitors are discussed in Section 1.6.4). These molecules have the 
potential to be used to monitor MMP-12 activity and to test the effects of MMP-12 activity in 






3.2 Hypothesis and aims 
3.2.1 Hypothesis 




1. To synthesise a small molecule MMP-12 inhibitor based on those described by Li and 
colleagues (2009). This molecule will be tested in vitro, for selectivity against a panel 
of MMPs and for potency against MMP-12. 
2. To synthesise a small family of MMP-12 selective FRET imaging probes based on 
those made by Cobos-Correa and colleagues (2009). These will be tested in vitro for 







3.3.1 MMP-12 inhibitor HS1-22 (21) 
Synthesis 
The synthesis of the MMP-12 inhibitor was adapted from compounds MMP408 and LiMMPI-
12 (Section 1.6.4) described by Li and colleagues (2009). The MMP-12 inhibitor, HS1-22, 
differed from LiMMPI-12 by changing a methyl to an ethyl group on the carbamate moiety. 
HS1-22 was built in 6 synthetic steps from commercial reagents. The experimental procedures 
are detailed in Section 2.6. 
 
In vitro assays to test the selectivity, potency and toxicity of HS1-22 
The inhibition selectivity of HS1-22 was tested against a panel of recombinant (r) MMP 
catalytic domains (MMPcat). The IC50 of HS1-22 with MMPcat-12 was tested against 
marimastat and AZD1236 (MMP- 9 and 12 inhibitor). The toxicity of HS1-22 was tested using 
an MTT assay. These assays are described in Section 2.7. 
 
3.3.2 MMP-12 activity FRET probes 
Synthesis 
FRET probes were synthesised using standard solid phase peptide synthesis (SPPS) using the 
Fmoc strategy as described in Section 2.5.  
 
Quantification of FRET probes 
As less than 1 mg of each FRET probe was synthesised, yield determination by weighing the 
masses was challenging. Therefore, standard curves of the associated dyes were created. The 
absorbance of the FRET probes was measured, and then using the standard curve, used to 





Selectivity of FRET probes  
The activation of the FRET probes was tested initially against MMPcat-12 and the fluorescence 
emission monitored over time. The peptide sequence PLGLEEA was tested as a substrate for 
MMP-12 against a panel of recombinant MMP catalytic domains as described in Section 2.7. 
 
3.3.3 Statistics 
Data were analysed, firstly by checking for outliers and then using appropriate statistical tests 






3.4 Results and discussion 
3.4.1 Synthesis of HS1-22 
The synthesis of HS1-22 (21) was completed in 6 steps, starting from commercially available 
dibenzofuran (22) (Scheme 3.1).  
 
Scheme 3.1 Synthetic route for HS1-22. Step i) Nitration: HNO3, TFA, -20 °C, 4 h, 91%; Step ii) 
Sulfonation: SO3HCl, DCM, 0 °C, 4 h, quantitative; Step iii) a) Chlorination: SOCl2, reflux, 18 h, 
quantitative, b) Sulfonamide formation: t-butyl D-valine, DIPEA, DCM, 0°C, b) 4 h, RT, 55%; Step iv) 
Nitro reduction: Zn dust, acetic acid, THF, RT 86%. Step v) Carbamate formation: Ethylchloroformate, 
DIPEA, 5 h, RT, 61%. Step vi) TFA : DCM (1:1), 1 h, RT, 50%. 
 
Step i) Nitration of Dibenzofuran 
The synthesis started with the selective nitration of the dibenzofuran 22 at the 3’ position, this 
was achieved with fuming nitric acid (HNO3, > 90%) in trifluoroacetic acid (TFA) to give 3-






Scheme 3.2 Nitration of the dibenzofuran (22) with the nitronium ion derived from nitric acid. 
The nitronium ion (Equation 3.1) can coordinate to the oxygen on the furan ring, this is stabilised in 
more polar solvents (solvent with a high ɛ). The coordinated ion donates a positive charge into the ring 
system which directs the nitronium attack to the 3’ (15) over the 2’ (23) position. 
 
The dibenzofuran (22) ring system reacts through electrophilic aromatic substitution; the first 
aromatic substitution reaction with nitric acid (to give 15) was exothermic. The resulting 
nitrated tricyclic ring system is deactivated towards a second reaction as electron density is 
withdrawn by the nitro group. Furthermore, reaction conditions were disadvantageous for a 
second reaction due to excess of 22 and the low reaction temperature. Traditionally 
electrophilic aromatic substitution reactions with dibenzofuran are favoured at the 2’ position 
(para to the oxygen) over the 4’ position (ortho to the oxygen) owing to the effect of the furan 
ring (23). Conversely, for nitration reactions the 3’ position is favoured but interestingly, the 
substitution position is solvent dependent: TFA favoured the 3’ position (≥ 93%) whereas 
Ac2O favoured the 2’ position (≥ 39%) (Keumi et al., 1991). The reaction is dependent on the 
nature of HNO3 reacting species in the organic solvents; this is thought to be a nitronium 






Equation 3.1 The ionisation of nitric acid in an organic solvent. 
 
Although the exact mechanism is unclear, it is suggested by Keumi and collegues (1991) that 
preferential formation of the 3’ isomer was less dependent on the pH of the solvent than on its 
dielectric constant (ε); solvents with a higher ε (higher polarity) stabilized the nitronium ion 
(NO2+). The nitronium ion is suggested to coordinate with the oxygen on 22 and then rearrange 
to the 3’ position to give 15. The conversion of 22 was > 90% by NMR and was purified by 
silica gel chromatography. The regioselectivity was confirmed using 2D NMR experiments 
(correlation spectroscopy (COSY, proton-proton), heteronuclear single-quantum correlation 
spectroscopy (HSQC, proton-carbon) and heteronuclear multiple-bond correlation 
spectroscopy (HMBC, long range correlations)) (raw data not presented). 
 
Step ii) Sulfonation of 3-Nitrodibenzofuran  
Traditionally in sulfonation reactions, sulfur trioxide is used as the electrophile, which is 
generated from concentrated sulphuric acid (at > 80 °C). However, chlorosulfonic acid is now 
a more popular choice; chlorine acts as a good leaving group in this reagent, so is reactive in 
milder conditions. Compound 15 was sulfonated by a dropwise addition of chlorosulfonic acid 
in CHCl3 to give compound 16 in quantitative yield. This electrophilic aromatic substitution 
reaction with compound 15 was directed to the 8′ position by the electronic properties of the 
nitro group (Scheme 3.3); i) the nitro deactivates the ring it is bound to and makes the opposite 
ring more attractive to substitution, ii) the oxygen in the furan ring is para directing. Double 
sulfonation of 15 was aided by the nature of the reagents and the experimental set-up.  Firstly, 
the rings are deactivated by the nitro group present and are further deactivated by the sulfonic 





i) conducting the experiment at low temperatures and, ii) using a low ratio of reagents (1:1.3, 
15: chlorosulfonic acid). The regioselectivity and number of substitutions was confirmed using 
2D NMR experiments (COSY (proton-proton), HSQC (proton-carbon), HMBC (long range 
correlations), raw data not presented). This reaction produced a quantitative yield of 3-nitro-
8-sulfonyldibenzofuran 16 which was taken onto the next step without further purification. 
 
 
Scheme 3.3 Mechanism of sulfonation of compound 15 with chlorosulfonic acid to give 16. The 
electrophilic aromatic substitution reaction is directed to the 8’ position by the electronic properties of 
the nitro group and the oxygen; the oxygen is para directing but the nitro group deactivates the ring it 
is bound to and makes the opposite ring more attractive to substitution.    
 
Step iv) t-butyl Protection of D-Valine and Sulfonamide Coupling 
The next stage of the synthesis was to react the aryl sulfonic acid with an amine on the D-
valine to form the sulfonamide. The carboxylic acid on the D-valine 24 needed to be protected 
(made chemically unreactive) in this and subsequent reactions to allow chemoselectivity. It 
was, therefore, protected with a t-butyl group. Many L amino acid (L-aa) enantiomers are 
commercially available with the carboxylic acid (which would form part of the peptide 





equivalents are rarer. Therefore compound 24 was functionality protected with a t-butyl ester 
in-house; 24 was reacted with t-butyl acetate and perchloric acid to give 17, this was purified 
by an acid-base extraction and used without further purification (40%, Scheme 3.4) (Chen et 
al., 2005). Notably, the t-butyl methyl groups were observed as a singlet (9 H) by 1H NMR 
spectroscopy, whereas the aa sidechain methyl groups were observed as two sets of doublet 
peaks (3H) (Figure 3.1).  
 
 
Scheme 3.4 Protection of the acid using a t-butyl group. The D-valine carboxylic acid was protected 
with a t-butyl group by a reaction with t butyl acetate and perchloric acid at room temperature overnight 







Figure 3.1 1H NMR spectrum of t-butyl D-valine (24). The t-butyl methyl groups were observed as a 
singlet δ 1.5 ppm, whereas the D-valine sidechain methyl groups were observed as two sets of doublet 
peaks (3H), δ 1.02 -0.97 ppm. The two sets of doublets were observed, not as a result of a racemic 
mixture, but because of the diastereotopic nature of the methyl groups. The chemical non-equivalence 
of the methyl groups results in the splitting of apparently identical methyl groups in the (1H and 13C) 
NMR spectrum.  
 
The sulfonic acid 16 was converted to the sulfonyl chloride 25 using thionyl chloride and a 
catalytic volume of DMF. Compound 16 was insoluble in thionyl chloride but compound 25 
was soluble, making monitoring of the reaction simple. This conversion was not analysed by 
NMR or MS due to rapid hydrolysis during the analytical process; therefore, solid IR 








Figure 3.2 Superimposed IR spectra confirm chlorination of sulfonic acid group to give 25.  The 
chlorination of 16 with thioyl chloride could be observed by the loss of the S-OH stretch at 2901 cm-1 
(thick black arrow) of 25. 
 
The aryl sulfonyl chloride 25 was reacted with the t-butyl D-valine 17 in the presence of a 
base, DIPEA, to give a 55% yield of 18 (Scheme 3.5).  DIPEA was used as a non-nucleophilic 






Scheme 3.5 Mechanism of the sulfonoamide formation reaction between compound 25 and 17 in 
the presence of DIPEA to give 18. 
 
Step v) Nitro group reduction 
The reduction of the nitro-group, 18, to generate the aryl amine 19, was achieved using two 
methods. Firstly, by stirring 18 with 10 % Pd/C under H2 (24 h): but the reaction resulted in 
numerous by-products (observed by thin layer chromatography (TLC) and NMR 
spectroscopy). These impurities had similar polarities to 19 and, consequently, 
chromatographic purification proved difficult. Secondly, an alternative reaction using zinc 
dust and acetic acid (DCM, 20 °C, 1 h) was employed (Channe Gowda et al., 2001). In this 
reaction the protons are donated by the acetic acid, whereas the electrons are donated by the 
zinc metal (Scheme 3.6). Importantly the acetic acid (pKa = 4.75) was not strong enough to 
remove the t-butyl group from the carboxylic acid so was conserved. Furthermore, zinc dust 
and acetic acid were cheaper (compared to H2 and Pd) and the equipment set up was much 
simpler, making this a favourable approach. This gave a crude product that was easier to purify 






Scheme 3.6 The reduction of the nitro group on 18 to an amine (19). In this reduction reaction, the 
protons were donated by the acetic acid whereas the electrons were donated by the zinc metal (reagents 
were in > 4 fold excess to 18). The nitroso and hydroxyamine intermediates were not isolated.  
 
Step vi and vii) Carbamate formation and t-butyl deprotection 
The carbamate, 20, was synthesised by a reaction between 19 and ethylchloroformate in the 
presence of 4-dimethylaminopyridine (DMAP) to give 20 (61% yield). DMAP is a 
nucleophilic catalyst, sometimes referred to as an acyl transfer reagent, which activates the 
acid and is an improved leaving group compared to chlorine (Scheme 3.7). 
Subsequently, the final compound HS1-22, 21, was made by the deprotection of t-butyl-acid 
of compound 20 under strong acidic conditions (TFA, pKa = 0.5). The loss of the t-butyl 







Scheme 3.7 Step vi and Step vii: carbamate formation and acid deprotection.  The reaction 
mechanism between 19 and ethylchloroformate was catalysed by DMAP to give 20. Step vii: t-butyl 



































3.4.2 HS1-22 is a selective and potent inhibitor of MMP-12 
MMP Selectivity of HS1-22 
In the selectivity assay, commercially available marimastat, a broad spectrum inhibitor, 
appeared to inhibit all the MMPs (200 nM, broad spectrum inhibitor, black bars) however only 
MMP-9, 12 and 13 reached significance (Error! Reference source not found.). HS1-22 was 
shown to be selective against MMPcat-12. Due to the high homology between MMPs it is not 
surprising that there is also minor inhibition of other MMPs in the panel. These data are 
consistent with analogues of HS1-22 which were designed to be selective inhibitors of MMP-



































































Figure 3.4 HS1-22 is relatively selective for MMP-12.  In this selectivity assay, the substrate probe 
(10 µM) was activated by MMPcat- 2, 7, 9, 12 and 13 (30 nM) (white bars). The addition of marimastat 
appeared to inhibit all the MMPs (200 nM, broad spectrum inhibitor, black bars) however only MMP-
9, -12 and 13 reached significance. The addition of HS1-22 (stripped bars) was selective for MMP-12. 
Bar represents mean ± SEM (n = 3), and multiple comparisons where made using a two-way ANOVA 





Potency and toxicity 
The IC50 of HS1-22 for MMPcat-12 was measured against marimastat (Wojtowicz-Praga et al., 
1998) and AZD1236 (an MMP-9/12 inhibitor in Phase I clinical studies (Dahl et al., 2012; 
Magnussen et al., 2011) Figure 3.5). The data suggest that as the selectivity of the MMPI 
compound increased, the potency decreased: HS1-22 had an experimental IC50 value of 68.2 
nM, marimastat of 3.4 nM and AZD1236 of 22.1 nM. The latter two had higher values than 
expected from the literature (AZD1236: data on file, marimastat (Zucker et al., 2001)). This 
may be because the assay was not set up identically to those used in previous studies. For 
example, different substrate probe, machines and equipment were used. Furthermore, this 
experiment has an n of 1 due to limited resources and difficulty in running the assay. Despite 
this, this IC50 experiment showed that HS1-22 is a relatively selective MMP-12 inhibitor at 
nM concentrations; this compound was, therefore, taken forward to toxicity assays. MTT 
assays showed that HS1-22 was not toxic to HEK293 cells in vitro at concentrations below 
100 µM (Figure 3.6). HEK 293 cells are a common immortal cell line and are very easy to 
grow so have been widely used in cell biology research for many years.  From the data 
collected it was decided to take this compound forward to further biological assays as a tool 










Figure 3.5 Inhibitor potency for MMP-12 is dependent on its selectivity over other MMPS. This 
example IC50 graph was generated using MMPcat-12 (30 nM) and a FRET probe (10 µM) and inhibitors 
at various concentrations (500 - 0.5 nM). Inhibitors tested were: marimastat (circles), a broad spectrum 
inhibitor; AZD1236 (squares), advertised as an MMP-9 and MMP-12 selective inhibitor; and HS1-22 
an MMP-12 inhibitor (triangles). The table illustrates the experimentally (in-house) determined IC50 
values compared with those quoted in the literature (HS1-22: estimate WO 2008/057254 A2, AZD1236: 
data on file, marimastat: (Zucker et al., 2001)). Data are plotted as mean ± SEM, experiments were run 

























Figure 3.6 HS1-22 is not toxic at concentrations below 100 µM. An MTT assay was used to test 
toxicity with HEK 293 cells in vitro. Bars represent mean ± SEM (n = 3 − 6) and comparisons were 
made using a one-way ANOVA followed by a Dunnett's multiple comparison post hoc test comparing 








3.4.3 Synthesis of activity FRET probe  
Fmoc-based solid phase peptide synthesis  
The advent of solid phase peptide synthesis (SPPS) was pioneered by Merrifield in the 1960s 
(Merrifield et al., 1966), which won him a Nobel prise in 1984. Unlike natural protein 
synthesis, SPPS proceeds in a C to N terminal fashion. There are two general strategies that 
can be used: the tert-butyloxycarbonyl (Boc) or fluorenylmethyloxycarbonyl (Fmoc) 
protecting group methods (Stawikowski & Fields, 2012). In this study the FRET probes were 
synthesised in-house using the standard solid phase Fmoc method, which generally employs 
reagents which are safer and more easily handled than those used for Boc SPPS chemistry. 
This strategy utilised Fmoc protected N-termini of aa monomers (Fmoc–aa-COOH). The solid 
supported peptide was extended by a single aa by reacting the free carboxylic acid of the 
monomer with the amine on the peptide terminal to form a new peptide bond (Scheme 3.8). 
The Fmoc protected amine of the newly added monomer to the peptide inhibits any further 
reactions but this Fmoc group could be removed under basic conditions to reveal the free amine 
(“deprotection”) so another monomer could then be added; this cycle was continued until the 
peptide was finished. The peptide could then be cleaved from the resin under acidic conditions. 
In this chapter, peptides were constructed with an MMP-12 selective peptide sequence, 
PLGLEEA (Cobos-Correa et al., 2009). The FRET system was constructed with fluorophore–
fluorophore or fluorophore–quencher systems; these moieties were conjugated to the peptide 






Scheme 3.8 General method for Fluorenylmethyloxycarbonyl (Fmoc) based solid phase peptide 
synthesis (SPPS). SPPS was started with a commercially available resin (sphere) conjugated to an acid 
labile trityl linker (X) coupled to glycine. The amino acid (aa) were commercially available with the 
amine protected with an Fmoc group (hexagon) and any reactive side chains protected with a suitable 
protecting group (pentagon). The acid on the Fmoc-aa-OH was activated (star) with oxyma and N,N'-
dicyclohexylcarbodiimide (DIC) before the addition to the NH-aan-X-resin. Fmoc deprotection was 
achieved by incubation with 20% piperidine in dimethylformamide (DMF). Couplings and deprotection 





removal of all protecting groups on the aa side chains and cleavage of the peptide from the resin was 
achieved in a single step by incubating the resin beads in a solution of trifluoroacetic acid (TFA), 
dichloromethane (DCM) and triisopropylsilane (TIS). The solution (containing the peptide) is then 
isolated from the resin and the solvent evaporated; the peptide was the precipitated out from the 
remaining mixture with ether and then purified by HPLC.  
 
Resin and linker 
Within the Bradley group, aminomethyl functionalised polystyrene (PS) resin is frequently 
used as the polymer support scaffold for the synthesis of peptides. A linker, normally 2-
chlorotrityl (trityl), is coupled to the amine handle on the scaffold. This trityl moiety is an acid 
labile functional group which facilitates cleavage of the peptide from the PS scaffold at the 
end of the synthesis; its bulk also prevents the diketopiperazide formation with the first 2 
coupled amino acids. In this project commercially available trityl-PS resin (1.6 mmol/g, 100-
300 mesh) was activated and then the first amino acid was loaded (Scheme 3.9) followed by 
standard Fmoc-mediated peptide synthesis. Unfortunately, this method resulted in low loading 
and the crude peptide had many impurities; disappointingly this ultimately resulted in very 
low yields post purification (< 1%). An alternative resin, ChemMatrix (made predominantly 
with polyethylene glycol (PEG)) was utilised instead; it had greater stability (thermal and 
chemical) and swelling properties (almost double in volume) compared to PS which enabled 
higher loading. Moreover, the preloaded resin (1.1 mmol/g, 75-150 μm) was commercially 







Scheme 3.9 The activation of 2-chlorotrityl-resin. The reaction between thionyl chloride and the 
linker alcohol gave 2-chlorotrityl chloride; this was then coupled to an Fmoc-aa-OH in the presence 
DIPEA.  
 
Amino acid coupling reactions  
The peptide was built using SPPS procedures in a C to N terminal fashion. The free amine on 
the first aa (H2N-G-trityl-ChemMatrix) was reacted with the next amino acid (Fmoc-aa-OH) 
in the sequence. The free acid on the HO-aa-Fmoc was activated with N,N’-
diisopropylcarbodiimide (DIC, 26) using Oxyma Pure (Oxyma, ethyl 2-cyano-2-
(hydroxyamino)acetate, 27) as an additive prior to the addition to the free amine on the peptide 
chain terminus (Subirós-Funosas et al., 2009; Scheme 3.10). Carbodiimides are used in peptide 
synthesis to activate the carboxylate as an O-acylisourea, which is a good leaving group; thus 
improving the reaction speed. However, this complex is also prone to undesirable reactions 
such as aa racemisation and the formation of stable N-acylisoureas. To solve the problem of 
racemisation, triazoles (HOBt and HOAt and their derivatives) are introduced which react with 
the O-acylisourea to form an active ester; this is slightly less reactive and consequently at a 
reduced risk of racemisation reactions. Unfortunately, these triazoles are relatively expensive 
and potentially explosive. Conveniently a safer alternative, 27, has been developed (which has 
similar reactivity profiles to the triazols without their major disadvantages) and has 
unsurprisingly become a popular choice for SPPS chemistry. The coupling additives and the 





the amine which maximised yields. Additionally, the reactive groups on the aa side chains 
(amines, thiols and acids) were also protected (t-butyl, Boc or Dde (1-(4,4-Dimethyl-2,6-
dioxocyclohex-1-ylidene)-3-ethyl) to prevent unwanted reactions, these are discussed further 
below (Deprotection reactions; Figure 3.7).  
 
 
Scheme 3.10 Peptide coupling reaction with Oxyma (27) and DIC (26) additives. First the 
electrophilicity of the carboxylate is improved by “activating” the negatively charged oxygen 
by a reaction with 27 to create a highly reactive O-acylisourea, this is then reacted with 27 to 
form an activated ester (N-acylisourea). This active ester is then introduced to the peptide 
terminus free amine which react to form a new peptide bond and regenerates 27. R = aa-Fmoc, 







Figure 3.7 Common protecting groups for reactive species used in SPPS. Orthogonal protecting 
groups are functional groups which can be removed under different chemical conditions. For example, 
Dde is removed using a reducing solution, Fmoc is removed by in basic conditions and t-butyl in the 
presence of a strong acid. These groups could all be removed selectively from the peptide with minimal 
impact on the stability of the others. 
 
The rate of peptide synthesis can be increased, not just chemically but by heating the reaction 
between the amine and the activated acid. Traditionally this reaction is completed with 
conventional thermal conductive heating but, more recently, microwave irradiation has been 
employed (Murray et al., 2011). In this study, aa coupling reactions at RT took 40 min whereas 
reactions using microwave energy were complete, in some cases, in just 5 min (75 °C). 
Additionally, this method of heating has been shown to increase the purity of the synthesised 





reactions by interacting directly with the solvent (and some reagent) molecules with a high 
dielectric constant (ε) (de la Hoz et al., 2005). Molecules with a high ε have bond dipoles or 
ions which align with the alternating electromagnetic field (microwave). This energy is then 
converted to heat energy by dielectric loss (inherent dissipation of electromagnetic energy 
(heat)). Put simply, these molecules can absorb energy from the microwaves which is then 
dissipated as heat. This method allows for more rapid and even heating compared to traditional 
convention methods. Solvent can also undergo superheating (liquid temperatures above the 
boiling point), which is suggested to also contribute towards increased reaction rates (Klán et 
al., 2001). Microwave irradiation has been suggested to catalyse peptide synthesis not only 
through heating, but by preventing peptide aggregation on the surface of the resin  (Palasek et 
al., 2007). Aggregation is caused by intramolecular hydrogen bonding in the peptide which 
can obstruct the agents from accessing the peptide end. The alternating microwave 
electromagnetic radiation is suggested to cause the polar backbone of the polypeptide to 
continuously align with the radiation, preventing any aggregation. This is difficult to prove 
experimentally but Basca and colleagues (2008) showed little or no changes between 
conventional heating and microware irradiation for yields or purity for their peptide synthesis. 
The improved yields may be primarily down to loss of any aggregation due to disrupted 
hydrogen bonding at warmer temperatures (75 °C) rather than the direct interaction with the 
peptide backbone and the microwaves. Therefore, microwave irradiation may simply be a 
means for convenient, rapid, even heating of the reaction mixture. 
 
Deprotection reactions 
Unwanted reactions with chemically reactive moieties can be stopped by masking their 
behaviour with a “protecting group” (Isidro-Llobet et al., 2009). Protecting groups are 
moieties that are easily attached to reactive species, which renders them inert but can be 





available with the amine on the backbone protected with Fmoc and any reactive side chain 
moieties (amines, thiols and acids) also protected (predominantly with t-butyl or Boc). In this 
study SPPS with the Fmoc method was utilised to make the FRET probes. The Fmoc 
deprotection was achieved in basic conditions allowing the prolongation of the backbone; 
therefore, the aa sidechains are orthogonally protected using acid labile groups (e.g. t-butyl or 
Boc). To incorporate other moieties into the peptide molecule (such as fluorophores or lipids) 
a lysine protected with the side chain amine protected with Dde (Fmoc-Lys(Dde)-OH) was 
integrated into the peptide; Dde is commonly used and enables orthogonal amine deprotection 
with no interference with Fmoc, Boc or t-butyl groups (Díaz-Mochón et al., 2004). This 
enables the selective incorporation of functional moieties on to the side chains (Dde 
deprotection). 
 
PEG and Fluorophore coupling  
To minimise the steric hindrance between the MMP active site and the peptide sequence, PEG 
((2-[2-(Fmoc-amino)ethoxy]ethoxy}acetic acid) spacers were added to either end of the 
peptide sequence to distance the bulky fluorophores. The integration of PEG also improved 
the solubility of these compounds in aqueous solutions. Free amines can be functionalised with 
a reporter with a carboxylate handle, or by conversion of the amine to another functional 
species: for example, an azide (diazo transfer) for CuI click reactions with alkyne species. 
Normally, fluorophores are conjugated to the molecule once the peptide backbone (with 
spacers) is complete.  In this project, fluorophores were conjugated at the N-terminus and via 
a lysine residue near the C terminus with simple amide bonds. Interestingly, microwave 
radiation worked well for aa couplings but caused decomposition during fluorophore coupling; 
these reactions were therefore completed at room temperature. Fluorophores used were 
coumarin 343, 5(6)-carboxyfluorescein (FAM), 5(6)-carboxyrhodamine B (RhodB) and the 





Simultaneous cleavage from the resin and side chain deprotection 
Once the sequence was complete the peptide was cleaved from the ChemMatrix resin via the 
trityl linker. This was achieved using weakly acidic conditions (1% TFA/DCM) if the aa side 
chains still required their acid labile protecting group, or using a stronger conditions (TFA : 
DCM (1:1) with 5% triisopropylsilane (TIS)) if not. TIS acts as a scavenger for the carbo-
cations and the TFA anion formed in the deprotection reaction. The crude compound was 
purified using semi-preparative HPLC as detailed in Section 2.5.5. 
 
Probe purification and characterisation 
Probes were purified by semi-preparative HPLC and then characterised by analytical 
HPLC and MALDI mass spectroscopy. 
 
Probes synthesised  
To enable MMP-12 selective imaging three FRET probes, HS1-58 (12), HS1-59 (13) and HS1-
65 (14), were synthesised with the previously published MMP-12 specific sequence 
(PLGLEEA) (Table 3.1). The structures differed by the conjugated FRET pairing (the 
structures and mass (found by MALDI) are shown in Figure 3.8 (HS1-58 HS1-59) and Figure 
3.9 (HS-65). The fluorophore FRET combinations were tested with MMP-12 to establish the 
best indicator of MMP-12 activity. 
 
Table 3.1 FRET probe sequences and yields 
[Fluorophore1]-PEG2-PLGLEEA-PEG2-K[Fluorophore 2]-G-OH 




12 HS1-58 coumarin 343 RhodB 10% 
13 HS1-59 (single isomer) FAM RhodB 4% 







Figure 3.8 Structures of HS1-58 and HS1-59 are their corresponding mass found by 






Figure 3.9 Structure of HS1-65 and corresponding mass found by MALDI mass 
spectroscopy. 
 
3.4.4 Probes undergo FRET and are cleaved by MMP-12  
The emission of the donor fluorophore of the activity probes was monitored over time in the 
presence of the catalytic domain of MMP-12 (Figure 3.10). The emissions from the donor 
fluorophore did increase over time, as expected, for all three probes. Interestingly the 
emissions from the acceptor fluorophore, in compounds HS1-58 and HS1-59, RhodB (λ ex = 
440 or 485 respectively, em = 590 – 600 nm), also increased. This was unexpected as the 
acceptor emission was expected to decrease; this would suggest that there is a complex 
interaction between the donor fluorophores (coumarin 343 and FAM) and RodB and is not as 
simple as energy loss by fluorescence (but does agree with published data from Cobos-Correa 
et al., 2009). A possible reason for FAM and Rhod B to exhibit quenched fluorescence in the 
intact probe, but not after cleavage, is that the fluorophores do not undergo just FRET, but also 





fluorophores are close in space as they can stack with the aid of hydrophobic effects and 
hydrogen bonding. The stacked fluorophores can then form a complex which interacts through 
proton coupled electron transfers. This mechanism allows an excited complex to lose energy 
(and return to the ground state) by emitting phonons (heat) instead of the usual fluorophore 
emission of photons (light, e.g. fluorescence). A characteristic of complex formation is a 
change in absorption spectra of the fluorophores when the complex is formed: there is a small 
shift to the right for the absorbance of probe HS1-58 and HS1-59 (Appendix 4). Although 
these complexes had a high fold change in fluorescence post cleavage, there was high 
background signal from the RhodB. To minimise the background and costs, a frequently 
utilised fluorophore–quencher system in the Bradley group FAM (fluorophore) and MR, 







Figure 3.10 Activation of FRET probes in vitro. MMPcat-12 (30 nM) cleaved the FRET probes (10 
µM) and the emission of the donor and actor fluorophores monitored over time. All reactions were 
complete by 90 min. HS1-58 λ ex = 440 nm, HS1-59 and HS1-65 λ ex = 485 nm. Data are plotted as 
mean, reactions were conducted in duplicate and error bars removed for clarity (n = 1).  
 
FRET probes are selective for MMP-13 and MMP-12 in vitro. 
Compound HS1-65 was tested against a panel of proteolytic enzymes and shown to be 
activated by human and murine MMP-12 (Figure 3.11). The addition of marimastat (MMP 
inhibitor) suppressed the fluorescence of HS1-65 in the presence of MMPs; this is consistent 
with activation due to MMP proteolysis. In addition, neutrophil elastase did not activate HS1-





completely unexpected due to the high structural and functional homology in the MMP family. 
Furthermore, other groups have shown that this peptide sequence is not 100% specific for 
MMP-12 (Cobos-Correa et al., 2009; Lim et al., 2014). Nonetheless, this assay confirmed that 
this probe is relatively selective for MMP-12 (murine and human) and, therefore, it was taken 
forward for further investigation.  
 
Figure 3.11 HS1-65 is selective for MMP-7, 12 and 13. The emission of fluorescein from 
HS1-65, in the presence of MMPs, monitored over time (120 min). HS1-65 was activated by 
MMP-1, -2, -3, -7, -9, -10, -12 (catalytic and full activated murine and human MMP-12) and 
-13 (no inhibitor, white bars), but the signal from MMP-1, -2, -3, -9 and -10 reactions were 
small and not significant. marimastat treated reactions (black bars) did not exhibit an increase 
in fluorescence from HS1-65. Neutrophil elastase was also shown to not activate HS1-65. Bar 
represents mean ± SEM (n = 3) and multiple comparisons where made using a two-way 
ANOVA followed by Bonferroni post hoc tests comparing groups to buffer alone (** P < 0.01, 







Figure 3.12 Flourescence of HS1-65 in the presence of MMPs over a 2 h period MMP- 7, 12 and 
13 (30nM) were incubated with HS1-65 (10 µM) and the emission monitored over 2 h (λ ex = 485 nm, 
em = 528 nm). MMP -13 (blue) cleaved the probe fastest followed by MMP-12 (catalytic domain (red)> 
murine (purple)> human (yellow) then MMP-7 (green). Data are plotted as mean ± SEM; reactions were 
conducted in triplicate; this graph is one of three experiments.  
3.5 Summary 
In this chapter, a small molecule MMP-12 inhibitor, HS1-22, was synthesised in 6 steps and a 
small library of FRET probes with an MMP-12 targeting sequence was made using SPPS. In 
vitro assays have shown both of these compounds to have selectivity for MMP-12. HS1-22 is 
a relatively selective inhibitor for MMP-12 (IC50 68 nM) that is not toxic in concentrations 
below 100 µM. HS1-65 is an activity probe which is predominantly activated by MMP-12 and 
13. Both compounds were taken forward to the next phase of the study; to be used in ex vivo 





























 Chapter 4: Development of a Bioassay for 
MMP-12 
4.1 Introduction 
The extracellular matrix (ECM) is the connective tissue between cells which helps give tissue 
its structure, it can also facilitate basic cellular behaviour such as cell division. (Hynes 2009). 
The ECM scaffold is constructed from collagens, elastin, glycoproteins and fibronectin; 
structural changes in the ECM, such as during would repair or growth, require a collection of 
enzymes to break down and rebuild the complex network. (Frantz et al., 2010) Matrix 
metalloproteinases comprise a large family (24+) of zinc dependent proteases, each capable of 
degrading one or many components of the ECM (Nagase  et al., 2006). The MMP family is 
essential for physiological processes, including: embryonic development, bone formation and 
wound healing (Vu & Werb, 2000). Conversely, unregulated MMP activity is associated with 
the progression of pathology of diseases such as: inflammatory bowel disease (O’Sullivan et 
al., 2015), rheumatoid arthritis (Burrage et al., 2006) , cardiovascular diseases (Liu et al., 
2006) and tumour development (Overall & Kleifeld 2006). This dual sided nature of tissue 
remodelling by MMPs requires their catalytic domain to be tightly regulated.  Due to their 
powerful capabilities, these proteases are under tight regulation: from translational and 
transcriptional control, to activation of the excreted zymogen and, later, inhibition by 
endogenous tissue inhibitors of metalloproteinases (TIMPs) (Löffek et al., 2011). 
MMP-12 is considered one of the most important enzymes in the degradation of elastin but 
also breaks down fibronectin and collagen IV (Shipley et al., 1996). Interestingly, MMP-12 
activity has protective properties such as: anti-tumour (Houghton et al., 2006), anti-
inflammatory (Dean et al., 2008), antibacterial (Houghton et al., 2009), and antiviral 
(Marchant et al., 2014). But its presence is also associated with several cardiovascular diseases 





al,1998; Longo et al., 2005). MMP-12 is also suggested to inhibit angiogenesis (Li et al., 
2012).  
Tools that enable inhibition and visualisation of MMP-12 activity could contribute towards a 
better understanding of its role during vascular remodelling and other diseases (Lim et al., 
2014; Hensley et al., 2012). This project aims to develop MMP-12-targeting inhibitors and 
imaging probes to do this. Assessment of these compounds required the development of a 
robust in vivo model of vascular remodelling with characterised MMP-12 activity profiles. 
Animal models are useful for improving and developing tools to enhance our understanding 
of the regulation of vascular remodelling (Nakashima et al., 1994; Small et al., 2005).  
Pilot studies were undertaken to establish a murine model of vascular remodelling with MMP 
activity detectable by fluorescent molecular tomography (FMT) using commercial imaging 
agents activated by active MMPs. Greater detail on the commercial probes and FMT is 
provided in Appendix 1 and Section 1.4. Three models of vascular remodelling were 
investigated: 
 Atherosclerosis: ApoE-/- mice fed on a western diet (up to 30 weeks) (Nakashima et 
al., 1994). 
 Neointimal hyperplasia: hyperplasia in the femoral artery following wire injury (Sata 
et al., 2000). 
 Angiogenesis: stimulated by subcutaneous implantation of a sponge (Small et al., 
2005). 
The strongest and most consistent MMPSense signal was detected in the angiogenic 
remodelling model (sponge implantation, data not shown). This is a murine model of 





sponges, usually for 20 days. Spontaneous angiogenesis in the sponge implants is facilitated 
by the porous framework accompanied by the cytokines and chemokines secreted in the local 
environment during the inflammatory response (Leibovich et al., 1987; Barcelos et al., 2005). 
In this model, there is a steady increase in deposition of fibrovascular tissue and growing 
vessels are present at different stages of maturation (Xavier et al., 2010). Angiogenesis is a 
complicated process; during the sprouting phase the surrounding connective network is broken 
down by proteases, such as MMPs, and endothelial cells lead the formation of new vessels 
(Heissig et al., 2003). These vessels then mature by the recruitment of other cells such as 
smooth muscle and pericytes (Jain 2003). MMP-12 has been suggested to be anti-angiogenic 
in other angiogenic models but has not been investigated in this model. For this reason, we 
proposed to examine if and when MMP-12 was present in this model, and its relationship 






4.1.1 Hypothesis  
Angiogenesis in subcutaneous implanted sponges is accompanied by MMP-12 activity. 
 
4.1.2 Aims 
1. To characterise angiogenesis in sponges implanted beneath the skin for 3 −  35 days.  
2. To characterise MMP expression and activity in these sponges. 
3. To use commercial probes and FMT to image angiogenesis and MMP activity in 







4.2.1 Study design  
Two studies were set up to investigate angiogenesis, inflammation and MMP profiles in this 
model (Figure 4.1). The first study aimed to investigate the early stages of angiogenesis in this 
model; days (D) 3, 7, 14 and 21. The second looked at the later stages of this model: D 21, 28, 
and 35. FMT imaging for angiogenesis and MMP activity was achieved using commercial 
probes, AngioSense 680 (AngioSense) and MMPSense 750 F.A.S.T. (MMPSense), 




Figure 4.1 Study design for time course study. The number inside the arrow indicates the time-point 
(days) and the number above/ below relates to the number (n) of mice used at the stage of the 
experiment. Black arrows indicate when mice were killed and the sponge tissue collected for molecular 








Male C57BL6/J (age 8 − 10 weeks) were obtained from Harlan (UK). All mice were housed 
for at least 1 week, with constant access to food and water and a 12 h light/dark cycle, before 
use in experiments. 
 
4.2.3 In vivo imaging of MMP activity and angiogenesis in the 
murine sponge model of angiogenesis by FMT. 
Surgery 
Each mouse was placed under general anaesthesia and two sponges were implanted 
subcutaneously, the mouse was then allowed to recover. This procedure is described in greater 
detail in section 2.9. 
 
FMT imaging and analysis 
Briefly, mice were placed on an alfalfa free diet to reduce autofluorescence and injected with 
MMPSense and AngioSense 24 h prior to FMT imaging. Sponges were imaged in vivo and ex 
vivo by FMT, the data was analysed using the Truequant® software to determine the 
concentration of probe within the sponges. The mean value of probe concentration over the 2 
sponges was taken for each mouse, this was then tested for statistical significance. See Section 
2.10 and Appendix 1 for the imaging procedures and data analysis; Section 1.4 and Appendix 
1 contain more information on FMT and the commercial agents used. 
 
Tissue collection 
The sponges were collected after ex vivo imaging, gently washed in PBS to remove tissue 
mimic solution, cut in half and either snap frozen on dry ice before storage at -80 °C or fixed 






4.2.4 Characterisation of angiogenesis, inflammation and 
MMP profiles over time in the murine sponge model 
Surgery 
Each mouse was placed under general anaesthesia and two sponges were implanted 
subcutaneously, the mouse was then allowed to recover. This procedure is described in greater 
detail in section 2.9. 
 
Tissue collection and histology 
The sponges were collected and cut in half then either snap frozen on dry ice before storage at 
-80 °C or fixed in 4% PFA (12 h) before storage in 70% ethanol. Fixed tissues were prepared 
for histology by embedding in paraffin wax and 5 µm sections cut from the centre of each 
sponge for staining and immunohistochemistry. One section for each mouse was used for: 
1. Staining with haematoxylin and eosin (H&E) to image different cell types and tissue 
structures. 
2. Immunostaining for F4.80 to identify macrophages.  
3. Immunostaining for CD31 and α-SMA to visualise vessel structures. 
Staining and immunohistochemistry procedures are described in section 2.12. Whole sections 
were imaged using a slide scanner and the images appropriately analysed (described in section 
2.12). 
 
Molecular analysis of gene expression 
RNA was isolated from frozen sponges from the two experiments. From this, cDNA was 





MMP-2, 7, 9, 10, 12, 13, CD31, PDGFR, VEGF, and TNFα (gene transcripts were normalised 
against the mean of TBP and GAPDH). The protocols are described in Section 2.13. Due to 
difficulties in acquiring genes able to normalise between the earlier and later time points, the 
data from D 7 − 21 are presented in this chapter. Data from D 21 − 35 are presented in 
Appendix 5. Data from D 3 were excluded as they could not be normalised with the 
housekeeping genes. 
 
Quantification of total MMP-12 and TIMP-1 protein 
Quantification of MMP-12 (zymogen and active forms) and TIMP-1 protein concentrations in 
the sponges over D 3 − 35 was achieved using ELISAs (protocols in Section 2.11). 
 
Zymography 
MMP-12 activity was assessed by zymography using tissue homogenates made from sponges 
collected on D 3 – 35 (protocols in Section 2.11). 
 
4.2.5 Statistics 
Data were checked for outliers and presented as mean ± SEM. Comparisons were made using 







4.3.1  Sponge implantation stimulated an angiogenic 
response 
Angiogenesis in the sponges was observable ex vivo  
In this model, upon dissection of the sponges there was an observable increase in the 
encapsulation and vascularisation over D 3 − 35 (Figure 4.2a).  Tissue lysates collected from 
the sponges had increased in redness, this suggested that haemoglobin content, and therefore 
vascularisation, within the implanted sponges increased over time (Figure 4.2b).   
 
Implantation of sponges results in cell infiltration and tissue deposition 
Microscopy analysis of sections of sponge from D 3 − 35 stained with H&E showed an 
increase in cell infiltration and development of large tubular structures (Figure 4.3). On D 3 
there is no tissue structure but purple nuclei could be discerned and isolated cells could be 
identified throughout the sponges. There was gradual increase in deposition of tissue and 
matrix within the sponge over the duration of the study which was associated with vessel 








Figure 4.2. Ex vivo observations of angiogenesis in the subcutaneous implanted sponges. 
 a) Representative images of sponges during dissections on D 3 −  35. There was no vascular ingrowth 
on D 3 (i) but the sponges were full of fluid. By D 7 (ii) vessels were observed growing into the sponges. 
The number and size of vessels entering the sponges steadily appeared to increase over D 14 (iii) and D 
21 (iv), connective tissue gradually encapsulated the sponges which was generally complete by D 21. 
Sponges appeared to be further incorporated (v) and gradually compressed over the remaining time 
course to D 35 (vi). b)  Representative images of sponge homogenates from samples collected on D 3 
− 21. There is a progressively darker red colour suggesting increasing haemoglobin content in the 






Figure 4.3. Representative haematoxylin and eosin-stained sections, images taken from the edge 
towards the centre of the sponges collected on D 3 − 35. Sponge plastic can be clearly identified as 
triangular or rectangular structures with concave edges. On D 3 (i) there was no tissue structure but 
isolated cells could be identified, individual cells were observable within the sponges on D 3 and 7 (ii). 
By D 14 (iii) the sponges had tissue and observable small vessels around the edge but the centre of 
sponge had relatively little cell content. As the experiment progressed, the depth of tissue infiltration 
and the number of observable vessels increased over D 21 (iv) and D 28 (v). Large tubular structures 
containing red blood cells were clearly identified by D 35 (vi). Images acquired from the edge of a 





RT-qPCR detected gene transcripts of angiogenic markers and growth 
factors 
Over D 7 – D 21, CD31 (a marker of endothelial cells) appeared to increase from D 7 − 21 but 
this did not achieve significance (Figure 4.4a). In contrast, PDGFR(β) (a marker of smooth 
muscle cells, fibroblasts and pericytes) expression did increase significantly (Figure 4.4b). In 













































































































































Figure 4.4. Transcript expression of markers of angiogenesis changed over D 7 − D 21. Analysis 
of gene transcripts of (a) CD31, which does not significantly increase suggesting the quantity of CD31 
in the sponges does not change over this time. (b) PDGFR, transcript numbers significantly increased 
from D 7 to 14 and 21 this receptor is associated with vessel maturation and, therefore, an indication 
that angiogenesis is ongoing. (c) VEGF (an angiogenic promoter) transcript numbers decreased from D 
7 to D 21. Bars represent mean ± SEM (n = 4 – 6) and comparisons where made using a one-way 






Microscopic analysis of vessels in sponges stained with CD31 and αSMA 
Immunostaining for CD31 and α-SMA confirmed the presence of vessels within the sponge 
(Figure 4.5). Images were analysed in 3 ways: Firstly, the mean fluorescence intensity for the 
3 fluorescent channels was calculated (Figure 4.6). CD31 and α-SMA signal intensity both 
increased from D 3 reaching significance on D 14 and remaining steady thereafter; the DAPI 
signal for the number of nucleated cells increased steadily over the experiment. These results 
suggest that vessel growth increased to D 14 and then stabilised, despite increasing cell 
infiltration. The second method measured the area covered by CD31 and α-SMA signal 
(Figure 4.7). This suggested the area of vessel incorporation peaked on D 21 then decreased 
again. The final method required counting all the vessels across the whole section (Figure 4.8). 
Results suggested that vessel growth actually increased to D 28 then decreases on D 35. This 








Figure 4.5 Sponges contain an abundance of cells and vessels expressing CD31 and α-SMA. 
Representative image of sponge tissue collected on D 35: a) composite of images; b) nuclei; c) α-SMA 
and d) CD31. Dashed arrows: pieces of sponge which have a high auto-fluorescence in the 488 channel; 
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Figure 4.6. The mean fluorescent signal intensity from DAPI, CD31 and α-SMA on sections of 
sponges collected on D 3 – 35. The fluorescence intensity was measured across the slide under identical 
conditions in the slide scanner and quantified using the Zen software). a) The measured fluorescence 
intensity of DAPI stain suggests that the number of nucleated cells steadily increased, reaching 
significance on D 21 and a maximum on D 28. b) The intensity of stain for CD31 (b) and α-SMA (c) 
reached a maximum on D 14 and remained steady. Bar represents mean ± SEM (n = 6); (a) comparisons 
were made using Kruskal-Wallis test followed by a followed by Dunn’s multiple comparison; (b) and 
(c) comparisons were made using a one-way ANOVA followed by a Dunnett’s Multiple Comparison 
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Figure 4.7. The mean area covered by CD31 (a) and α-SMA (b) signal over sections of sponges 
collected on D 3 – 35. For both signals the area covered increased from D 3 to 21 and then gradually 
dropped to D 35. Bars represent mean ± SEM (n = 3 – 6) and comparisons were made using a one-way 
ANOVA followed by Dunnett’s multiple comparison tests comparing all data sets to D 3 (* P < 0.05, 
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Figure 4.8. The mean number of CD31, or CD31 and α-SMA positive vessels. Profiles for the 
number of CD31(a) or CD31 with α-SMA (b) positive vessels had similar trends. No vessels were 
observed on D 3 but they could be observed by D 7, the number increased to reach significance on D 
21 and reached a maximum on D 28 followed by a reduction on D 35 (approx. 50%). The total number 
of vessels was then corrected for the area of tissue section to give (c) and (d) respectively; the pattern 
was very similar except a relative increase in the number of vessels on D 35, but still resulted in a drop 
in number compared to D 28. Bars represent mean ± SEM (n = 6) and comparisons where made using 
a one-way ANOVA followed by Dunnett’s multiple comparison tests comparing all data sets to D 3 (* 







4.3.2 Sponge implantation results in an immune response 
Inflammatory cytokine present  
Gene transcripts for TNFα were present and remained stable over D 7- 21 (Figure 4.9a). In 
sections stained with H&E, cells with different morphology could be identified at different stages 
of the angiogenic response. Neutrophil granulocytes (small polymorphonuclear cells, see Figure 
4.9b, empty arrow)Figure 4.9. An inflammatory response was observed in the implanted sponges. 
a) Gene transcripts for TNFα were present and remained stable over D 7- 21. b) Inflammatory cells 
were present during angiogenesis in this model. Representative H&E stained section from a sponge 
collected on D 7. Macrophages (solid arrow) and neutrophils (empty arrow) could be identified, image 
acquired at × 40 magnification, scale bar = 10 µm. Bars represent mean ± SEM (n = 4 – 6) and 
comparisons were made using a one-way ANOVA followed by Bonferroni Post-hoc tests comparing 
all data sets (P > 0.05). 
 
  and macrophages (larger mononuclear cells more cytoplasm, see Figure 4.9b, solid arrow) 








Figure 4.9. An inflammatory response was observed in the implanted sponges. a) Gene transcripts 
for TNFα were present and remained stable over D 7- 21. b) Inflammatory cells were present during 
angiogenesis in this model. Representative H&E stained section from a sponge collected on D 7. 
Macrophages (solid arrow) and neutrophils (empty arrow) could be identified, image acquired at × 40 
magnification, scale bar = 10 µm. Bars represent mean ± SEM (n = 4 – 6) and comparisons were made 
using a one-way ANOVA followed by Bonferroni Post-hoc tests comparing all data sets (P > 0.05). 
 
 Neutrophil Infiltration peaked on D 3 
Neutrophils were easily stained using H&E and identified as polymorphonucleated cells; the 














































Figure 4.10. Neutrophil number in sponges diminished over time. The number of neutrophils was 
highest on D 3 and had diminished by D 21. Bars represent mean ± SEM (n = 6) and comparisons were 
made using a one-way ANOVA followed by Dunnett's multiple comparison test post-hoc comparing all 
data sets to D 3 (* P < 0.05, *** P < 0.001). 
 
Macrophage Infiltration peaked on D 28 
Sponges were stained for F4/80, a marker for murine macrophages, revealing a large 
infiltration of these cells (Figure 4.11). The number of macrophages around the edge of the 
sponge increased to D 14 and then remained steady (Figure 4.12a). However, the depth of 







Figure 4.11. Representative images of F4/80 stained sections showing macrophage infiltration into 
the sponge between D 3 (a) and D 35 (f). There is an increase in F4/80 marker (macrophage 
infiltration) from the edge (right) towards the centre (left) of the sponge. The mean percentage area of 
stained was measured from ROI collected near the perimeter of the sponge (solid arrow, i). The depth 
of macrophage infiltration was measured from the sponge edge, towards the centre, to where the F4/80 
stain diminished (dashed arrow, ii). Images were acquired at × 20 magnification and representative 
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Figure 4.12 Macrophage infiltration increased from D 3 − 28. a) The mean percentage area of F4/80 
stain around the sponge edge increased to D 14 whereas infiltration (b) increased steadily to a maximum 
depth on D 28. Bars represent mean ± SEM (n = 6) and comparisons were made using a one-way 
ANOVA followed by Dunnett's multiple comparison test post-hoc comparing all data sets to D 3 (** P 







Angiogenesis was detected in vivo by FMT imaging. 
AngioSense signal was detected in vivo by FMT in the sponge model over D 7, 14 and 21 
(Figure 4.13a). The mean concentration detected in the sponges was highest on D 7 compared 
to D 14 and 21 (Figure 4.13b). Sponges were removed and the AngioSense signal was analysed 
ex vivo (Figure 4.14a). However, quantification of the signal showed no changes between 







Figure 4.13. AngioSense was detected in vivo by FMT imaging on D 7, 14 and 21. a) Representative 
images from in vivo imaging, the “Area Scanned” shows the total signal detected in the scanned area; 
the “Left ROI” and “Right ROI” show the volume of signal used for quantification. b) The signal was 
highest on D 7 and then reduced at D 14. Bars represent mean ± SEM (n = 6 − 9) and comparisons were 
made using a one-way ANOVA followed by Dunn's multiple comparison test comparing data sets to D 






Figure 4.14. AngioSense was detected by FMT in sponges ex vivo collected on D 7, 14 and 21. a) 
Representative images of the total signal detected from a single sponge. This was used to quantify the 
signal within the sponges. b) The mean concentration of AngioSense 680 detected by FMT imaging in 
the dissected sponges ex vivo did not change significantly over the experiment. Bars represent mean ± 





4.3.3 Sponge implantation results in the presence of MMPs  
MMP gene expression was detected in the sponges 
RT-qPCR analysis of gene transcripts showed that MMP- 2, -9, -10, -12 and -13 were present 
over the experiment (Figure 4.15). MMP-2 and -13 remained fairly constant whereas MMP-
10 was highest on D 14. MMP-9 expression decreased over time whereas, strikingly, MMP-
12 increased overtime.  
 
MMP-12 and TIMP-1 protein were present  
Interestingly the MMP-12 total protein (zymogen and active) expression was highest in 
samples collected on D 3 post implantation and steadily decreased to D 21, then appeared to 
increase again to D 35 (Figure 4.16). The endogenous inhibitor, TIMP-1, was highest on D 3 
and diminished by D 7 (Figure 4.17). 
 
MMP-12 activity was highest in sponges collected on D 7 
Casein zymography of cell lysates resulted in digested regions (clear/ white) of protease 
activity at 29 kDa (Figure 4.18a) (Raza et al.,2000). Analysis of the gels by densitometry gave 
quantitative results of the casein digestion by the 29 kDa protein (Figure 4.18b). When the 
casein gel was treated with marimastat (an MMP inhibitor) the protease action was inhibited 
by approximately 45% (Figure 4.18c). This technique proved to be challenging and due to 







Figure 4.15. MMP-2, -9, -10, -12 and -13 gene transcripts were all present in sponges but had 
differing profiles over D 7 − 21. RT-qPCR analysis showed that gene transcripts for MMP-2 (a) and 
13 (d) remained steady, MMP- 9 (b) and 10 (c) decreased to D 21 whereas MMP-12 (e) expression 
increased from D 7 − 21. Bars represent mean ± SEM (n = 5 − 6) and comparisons were made using a 

















































Figure 4.16. MMP-12 protein was present in sponges. MMP-12 protein concentration was highest in 
sponge tissue lysates from n D 3 which decreased to D 21. Bars represent mean ± SEM (n = 3 − 6) and 
comparisons were made using a one-way ANOVA followed by Dunnett’s multiple comparison tests 
comparing all data sets to D 3 (* P < 0.05, ** P < 0.01, *** P < 0.001).  
TIMP-1 Protien






































Figure 4.17. TIMP-1 protein was present in sponges. TIMP-1 protein had had the highest 
concentration in sponges at D 3, this significantly reduced by D 7. Bars represent mean ± SEM (n = 3 
− 6) and comparisons were made using a one-way ANOVA followed by Dunnett’s multiple comparison 






Figure 4.18. MMP-12 activity peaks on D 7. a) A representative image of tissue homogenates from 
sponges run on a casein gel (lanes 1 − 6 = D 3, 7, 14, 21, 21, 28, 35). White bands of regions of protease 
digestion of the casein substrate were observed (black arrow). b) Quantification of gel digestion was 
achieved by densitometry analysis of the 29 kDa band n = 1 − 2. c) Addition of marimastat (50 µM) to 
the development buffer (24h, 37 °C) appeared to inhibit MMP-12 activity. The Figure shows 






MMP activity was detected in sponges in vivo. 
MMPSense signal was detected in vivo by FMT in sponges on D 7, 14 and 21 (Figure 4.19a) 
but there were no significant changes in the quantified signal (Figure 4.19b). Sponges were 
then removed and the MMPSense imaged ex vivo (Figure 4.20a); quantification of the signal 









Figure 4.19. MMPSense can be imaged in vivo on D 7, 14 and 21. a) Representative images of in 
vivo FMT imaging; “area scanned” shows the total signal detected in the scanned area, the “Right ROI” 
and “Left ROI” identifies the sponge locations and therefore the signal used for quantification of MMP 
activity. b) There were no significant changes in the mean concentration of MMPSense detected in vivo 
by FMT imaging of the subcutaneous implanted sponges. Bars represent mean ± SEM (n = 6 − 9) and 






Figure 4.20 . MMPSense can be imaged by FMT in ex vivo sponges collected on D 7, 14 and 21. a) 
Representative ex vivo FMT images of MMPSense in sponges on D 7, 14 and 21. b) The total signal 
detected was used to quantify the MMP activity within the sponges, there were no significant changes 
detected. Bars represent mean ± SEM (n = 5 − 6) and comparisons were made using a one-way ANOVA 







In this chapter, a preclinical in vivo murine model of angiogenesis was established to determine 
whether MMP activity (particularly MMP-12) is present and can be imaged during 
angiogenesis. Histological techniques confirmed that this murine model exhibited both a time-
dependant inflammatory repose and generation of new vessels. Angiogenesis could be imaged 
by FMT within the sponges in vivo and ex vivo using a commercial probe (AngioSense); but 
this method did not provide precise quantification of angiogenesis consistent with that gained 
by histology. Secondly, the angiogenic and inflammatory responses in these sponges are 
accompanied by expression of MMPS, including MMP-12. MMP-12 was present and active 
during angiogenesis but mRNA expression, protein expression and the protease activity had 
different temporal profiles over D 7, 14 and 21: peaking on: D 21 for mRNA transcript number, 
D 3 for protein expression, and D 7 for protease activity. Other MMPs were investigated 
(MMP- 2, 9, 10, and 13) by analysing mRNA expression; all exhibited transcript expression 
for D 7 − 35 but had varying profiles. Additionally, in this model MMP activity could be 
imaged using FMT in the sponges in vivo and ex vivo with a commercial probe. The data in 
this chapter support the suitability of this mouse model as a tool for: i) testing MMP-12 
targeting inhibitors and imaging compounds and, ii) an investigation into the role of MMP-12 
during angiogenesis. 
The first model of spontaneous angiogenesis by subcutaneous implantation of a (polyester) 
sponge was reported in rats in 1987 (Andrade et al.,1987), but has since been modified for 
mice (Hague et al., 2002; Illanes et al., 2002). This model is attractive as it is very reproducible 
and the number of vessels can be easily quantified using histological techniques. There have 
been several successful adaptations of this model to utilise different scaffold materials such as 
metal meshes, (Schilling et al., 1959) other synthetic polymers (polyvinal alcohol, poly 
urethane) and hydrogels (Kleinman et al., 1986; Phelps et al., 2010). Furthermore, agents can 





releasing sponge coatings, osmotic minipumps, silastic elastomers or injection into the sponge. 
For the experiments in this chapter, inexpensive polyurethane sponges were utilised and 
implanted using a method already established in my supervisor’s laboratory (Small et al., 
2005). 
Spontaneous angiogenesis in the subcutaneous sponge implants is facilitated by the porous 
framework and the host inflammatory response. Post implantation, the infiltration of 
leukocytes results in the secretion of a cocktail of cytokines and chemokines, producing a 
proangiogenic response (Leibovich et al., 1987; Barcelos et al., 2005). The appearance of 
sponges examined ex vivo over D 3 − 35 showed a gradual increase in vessel infiltration, tissue 
deposition and encapsulation accompanied by compression of the sponge. Consistent with the 
literature, histological analysis of the sponges showed a steady increase in deposition of 
fibrovascular tissue containing cells and vessels at different stages of maturation (Xavier et 
al., 2010). 
Angiogenesis is a complicated process; during the sprouting phase the surrounding connective 
tissue and vascular network are broken down and endothelial cells lead the formation of new 
vessels (Van Hinsbergh & Koolwijk 2008; Rundhaug 2005). These vessels then mature 
through the recruitment of other cells such as smooth muscle and pericytes (Ribatti et al., 
2011). These different cell types can be differentiated by fluorescent immunostaining: CD31 
(cluster of differentiation 31 but also known as platelet endothelial adhesion molecule-1, 
PECAM-1) for endothelial cells (Newman 1997); α-SMA (alpha smooth muscle actin) for 
smooth muscle and pericytes (Skalli et al., 1989). CD31 is a 130 kDa type I transmembrane 
glycoprotein that is expressed at high levels on early and mature endothelial cells at the cell-
cell junctions. (Wong et al., 2000) It is also expressed to a lesser extent by leukocyte 
subpopulations (where it facilitates endothelial cell transmigration (Muller, 1995; O’Brien et 





formation (Falati et al., 2006; Rosenblum et al., 1996). The protein α-SMA is a component of 
the cell machinery which enables cell contraction in smooth muscle and pericytes; it is also 
expressed by fibroblasts which are the main producer of fibrous tissue in this model 
(Goodpaster et al., 2008; Hughes & Chan-Ling 2004). DAPI (4',6-diamidino-2-phenylindole) 
was used as a counter-stain for cell nuclei in these experiments.  
The stained sections were analysed in 3 ways. Firstly, the mean intensity of the fluorescence 
was measured for each channel across each section. Secondly, the percentage area covered by 
the signal was measured. Finally, the number of vessels was assessed by counting the total 
number of CD31 and CD31 & α-SMA positive vessels (positively stained structures with a 
lumen). All three methods gave slightly different profiles for vessel infiltration into the sponge. 
The variation in the “vessel number” implied by measurements of CD31 and α-SMA staining 
using these 3 methods could be because: 1) other non-vascular cell types can also be positive 
for CD31 and α-SMA antigens. 2) The sponges were autofluorescent, resulting in a higher 
signal intensity and area measured (especially on the green channel/ CD31). 3) Areas of intense 
staining could be subject to self-quenching (dye-dye energy transfers) resulting in a false lower 
mean fluorescence intensity signal measured. 4) The counting method was limited to larger 
vessels as the smaller capillaries or fragments of vessels were much harder to differentiate 
from artefacts. For the purposes of this study it was decided that the final method provided the 
most reliable measurement of vessel numbers. This method analysed the whole tissue section 
and allowed for assessment of actual vessel numbers as opposed to the number of cells 
expressing the markers. CD31 and α-SMA antibodies have cross reactivity with cell types 
other than vascular cells. This has also been the preferred method within my supervisor’s 
group. Thus these results were interpreted as showing that vessel numbers increased from D 3 





Angiogenesis can also be detected by changes to the expression profiles of cell markers, 
growth factors and mitogens.  The number of mRNA transcripts of VEGF peaked on D 7 and 
diminished by D 21 as the initiation phase of angiogenesis ended (vessel numbers began to 
stabilise from D 21). VEGF-induced activation of endothelial cells results in disassembly of 
VE-cadherin, one of the principal signalling and structural proteins associated with the VE 
cell-cell adheren junctions (Petzelbauer et al., 2000). Disassembly of these junctions increases 
vascular leakiness and enables the migration of the endothelial cells. These then divide to form 
the new vessels (Bates 2010). CD31 is highly expressed by endothelial cells and its expression 
in sponges increased from D 7 – 14 then plateaued despite the actual number of vessels 
increasing up until D 28. CD31 is not exclusively expressed by this cell type and, therefore, 
perhaps this is not a true representation of the number of endothelial cells present. 
Furthermore, a limitation of RT-qPCR is that changes in transcript number may not necessarily 
mean a change in the number cells expressing it, rather a change in expression from cells 
already present. 
PDGF gene transcription increased from D 7 – 21. Although pro-angiogenic, PDGF is of little 
importance in the initiation of new blood vessel formation (unlike VEGF) but is more 
important in the maturation process (Levanon et al., 2006).  These results support evidence for 
vascular growth and maturation within the implanted sponges, but RT-qPCR cannot be used 
as an accurate measurement of angiogenesis in this model. 
During the early stages of angiogenesis, VEGF causes an increase in vascular permeability 
which then returns to basal levels as the new vessel grows and matures (Bates 2010). Basal 
vascular permeability is essential for the health of normal tissues as it allows the exchange of 
small molecules, nutrients or waste products. Increased vascular permeability is a key feature 
of physiological and pathological angiogenesis and is dramatically increased in acute and 





and diminished by D 21, this would suggest that vascular permeability during tissue 
remodelling in this model should be highest on D 7. Vascular leakiness can result in a large 
efflux of water, macromolecules and inflammatory cells from the vasculature to the 
interstitium, often leading to in oedema. Sponges collected in this experiment, even as early 
as D 3, were filled with liquid.  
Angiogenesis has previously been measured in vivo by monitoring the clearance of a 
radioactive (Mahadevan et al., 1989) or fluorogenic (Lage & Andrade 2000) substance post 
injection into the sponges (which then diffused into vessels and cleared). This methodology 
provided useful representation of vascular density in live animals; but needed either radiation 
or repeated blood sampling and relatively lengthy processing of samples to attain the results. 
Vascular permeability was quantified in this study using FMT imaging by ascertaining the 
gain in concentration of the AngioSense probe in the sponges 24 h after iv administration. 
Vascular permeability was expected to be highest on D 7 during angiogenic spouting and the 
initial inflammatory response, followed by a reduction as vessels matured and inflammation 
reduced as the wound healed. The results in this chapter were consistent with this hypothesis 
as the concentration of this probe measured in vivo within the sponges was calculated to be 
highest on D 7 compared to D 14 and 21. Interestingly, there were no significant changes in 
the AngioSense signal quantified from ex vivo imaging (D 7, 14 and 21). This suggests that 
this technique was not sufficiently sensitive to detect any changes occurring in (number or 
functionality of) the vascular network over the experimental period. Furthermore, the 
increased probe accumulation detected in vivo on D 7 is likely to be predominantly in the tissue 
closely surrounding the sponge (subcutaneous skin and the abdominal muscle). These tissues 
are undergoing the early stages of angiogenesis and inflammatory remodelling as a result of 





Inflammation plays a key role in the initiation and/or progression of cardiovascular diseases 
(Stamenkovic 2003). A chronic inflammatory state post sponge implantation helps to stimulate 
angiogenesis via the production of proangiogenic growth factors (Costa et al., 2007). TNFα is 
a cytokine released systemically during acute inflammation. In the work described in this 
chapter, TNFα transcript expression remained stable over D 7 − 21 signifying an ongoing 
inflammatory response. TNFα is also a potent inducer of new blood vessel growth and is also 
a regulator of wound repair (Leibovich et al., 1987). Although its mechanism of action is still 
unclear, TNFα is also suggested to prime endothelial cells for sprouting once the initial 
inflammatory response has passed (Sainson et al., 2008). This suggests that chronic expression 
of TNFα in this model primes endothelial cell to undergo angiogenesis. 
In early inflammation, resident macrophages recognise foreign or damaged material and 
secrete pro-inflammatory mediators that recruit polymorphonuclear neutrophils. In this 
chapter, neutrophils were stained using H&E and identified as small polymorphonuclear cells. 
As expected, the population of polymorphonuclear cells was highest in sponges collected on 
D 3 and had diminished by D 14. During inflammation the neutrophil population is replaced 
by monocytes which differentiate into macrophages. These secrete proteases and phagocytose 
cell debris. The influx of neutrophils is partially halted through chemokine inactivation by 
macrophage derived MMP-12 (Dean et al., 2008). The marker F4/80 was chosen to stain 
macrophages because it has limited cross reactivity with other cells present, including 
fibroblasts (Inoue et al., 2005). The density of macrophages close to the edge of the sponge 
increased from D 3 − 14 and remained steady but, strikingly, the total depth of macrophage 
infiltration into the sponge increased from D 3 – 28. MMP-12, along with MMP-9, is also 
suggested to facilitate the infiltration of macrophages (Gong et al., 2008; Li et al., 2012); in 
this study MMP-9 transcript levels were high on D 7 as infiltration began, MMP-12 expression 





recruited leukocytes release mediators that attract other cells types such as fibroblasts and 
smooth muscle cells to begin the proliferative phase of wound healing.  
Leukocytes are the predominant producers of MMPs which are capable of destroying one or 
many components of the extracellular matrix. MMPs can also indirectly influence endothelial 
cell behaviour by release of proangiogenic factors, destruction of angiogenesis inhibitors, or 
generation of matrix fragments that inhibit angiogenesis, i.e., angiostatin (Cornelius et al., 
1998; Rundhaug 2005). In this study, MMP activity was detected by FMT in sponges (in vivo 
and ex vivo) at similar levels over the time-points investigated (with similar levels detected at 
D 7, 14 and 21). Persistent signal reflects the ongoing MMP activity during the remodelling 
process of the surrounding skin and growth of vessels and deposition of tissue into the sponges. 
The MMPSense probe is activated by a group of MMPs (MMP- 7, -9, -10, -12, -13) and so 
any changes in the signal detected is unlikely to be in response to a single MMP, particularly 
MMP-12. Nevertheless, these data confirm MMP activity is present throughout the 
inflammatory and angiogenic process. 
Interestingly, MMP-9 can manipulate vessel development by processing VEGF. ECM bound 
VEGF can be released by MMP-9 cleavage, when free it promotes angiogenic sprouting. Free 
VEGF can be truncated by MMP-9 proteolysis which can result in increased vessel diameter 
(Bergers et al., 2000; Lee et al., 2005). In this model, MMP-9 and VEGF mRNA transcript 
levels were high soon after implantation (then decreased from D 7 towards D 21). Soon after 
sponge implantation, MMP-9 may promote angiogenic sprouting by degrading the ECM and 
releasing any bound VEGF, but may also provide negative feedback by processing excess free 
VEGF. The expression of these genes decreased as angiogenesis progressed, consistent with 
free VEGF being involved in the initiation of vessel formation; not maturation which occurs 
at the later experimental time points (Bates 2010). MMP-13 mRNA transcripts remained stable 





and so its presence may contribute to angiogenesis in this model but the exact mechanism is 
unclear (Hattori et al., 2009). MMP-10 gene expression dropped significantly between D 14 
and 21, MMP-10 has been shown to have a dual role in vitro; it can promote endothelial cell 
migration and tube formation (Heo et al., 2010) but has also been identified as part of a 
different pathway which resulted in capillary cell regression and tubular network collapse 
(Saunders et al., 2005). Interestingly, its proangiogenic role was validated in vivo as MMP-10 
siRNA inhibits angiogenesis in the Matrigel plug assay (Heo et al., 2010). Gene transcripts of 
MMP- 2 are present and remain fairly stable in this model. MMP-2 has been shown to be 
proangiogenic (Ohno-Matsui et al., 2003). 
Generally, MMPs are considered to be destructive to the ECM and pro-inflammatory, and their 
presence is usually considered to be pro-angiogenic. The role of MMP-12 in these processes 
is less clear cut and it has been suggested to also have anti-angiogenic and anti-inflammatory 
properties. Consistent with its potential role in regulation of angiogenenesis, the results in this 
chapter show that both MMP-12 mRNA and protein were present during angiogenesis in the 
sponges, but interestingly their profiles were almost opposite. The MMP-12 mRNA transcript 
levels increased from D 7 to 21 whereas protein levels decreased from D 3 to 21. Interestingly 
Raza and colleagues (2000) also identified that the release of MMP-12 protein from 
macrophages was not necessarily associated with an increase in mRNA expression (Raza et 
al., 2000). Therefore, there is clearly complex regulation of MMP-12 processing at the 
transcriptional and translational levels. Currently there is limited literature on the activation 
pathway for MMP-12 transcription in macrophages but in SMC it may be regulated through 
phosphatidylinositol-4, 5-bisphosphate 3-kinase (Wu et al., 2003). Information on MMP-12 
post-transcriptional mRNA regulation is also limited in murine models but in human alveolar 
macrophages miR-452 suppressed MMP-12 protein expression (Graff et al., 2012). Raza and 
colleges (2000) also demonstrated that plasmin(ogen) and thrombin induced a significant 





(protease-activated receptor 1 (PAR-1)) in vitro. Once MMP-12 protein is released from the 
cells it can be activated by proteases (mainly plasmin) in the extracellular space, the active 
protein can then take part in the biological processes and diseases (Longo et al., 2005; 
Houghton et al., 2006). MMPs are released as inactive zymogens into the extracellular space, 
where they can be activated by other proteases and inhibited by TIMPs. To gain an insight into 
the relative MMP activity in the sponge tissues over the experiment, zymography was 
performed (Vandooren et al., 2013). Using this technique, we determined MMP-12 activity 
was present in sponges collected throughout the experiment but it peaked on D 7; unfortunately 
only an n = 1 was achieved due to challenges in the zymography technique and limited sample 
and materials available. Therefore, this data provides only a rough guide as to when MMP-12 
is most active in this model. Active MMP-12 can degrade several components of the ECM 
such as collagen, prothrombin and fibrinogen but it predominantly cleaves elastin to facilitate 
(endothelial, smooth muscle, fibroblasts and monocyte and macrophage) cell migration. 
Elastin is a highly elastic protein present in the connective tissues of vessel walls and skin that 
enables them to resume their shape after stretching. Active MMP-12 can also contribute 
towards the production of angiostatin a potent inhibitor of angiogenesis, from plasminogen 
(Dong et al., 1997); this can inhibit endothelial cell proliferation without affecting that of 
fibroblasts and SMC (O’Reilly et al., 1994). In this study, histological analysis demonstrated 
that the number of endothelial cells continued to increase in the presence of MMP-12 activity. 
Angiogenesis is a complex process and, therefore, the production of angiostatin by MMP-12 
may be overcome by other proangiogenic factors. Furthermore, MMP-12 activity diminished 
within the sponges as angiogenesis stabilised, this is despite the continued presence of 
macrophages in high numbers. However, this study did not distinguish between M1 and M2 
macrophage phenotypes, these could be present in different numbers during the study. 





effects and in this study MMP-12 activity peaked as neutrophil numbers were decreasing and 
macrophage infiltration began (Bellac et al., 2014). 
Active MMP-12, like most MMPs, is inhibited endogenously by TIMP-1 coordinating to the 
active site.  TIMP-1 has been shown to inhibit endothelial cell migration in vitro (Akahane et 
al., 2004). In this study TIMP-1 concentration was highest in sponges collected on D 3 (100 × 
TIMP-1 protein compared with MMP-12) at which time the sponges contained no vessels. 
TIMP-1 may be inhibiting the early stages of angiogenesis by minimising cell proliferation 
and mobility (Reed et al., 2003). 
 
4.4.1 Conclusion 
The data presented in this chapter characterised the sponge implantation model which involves 
angiogenesis, chronic inflammation and the presence of MMPs. Histological and molecular 
biology techniques contributed valuable information about a remodelling process, but 
techniques to monitor the process in vivo non-invasively would be advantageous. The FMT 
imaging with commercial probes in this study did provide information on MMP activity and 
vascular function but had low resolution. Furthermore, the commercial probe provided a 
generalised picture of MMP activity as it detected a broad spectrum of MMPs. MMP-12 was 
present during angiogenesis in this model but it’s exact role still remains unclear; this could 
be better investigated using this model with MMP-12 inhibitors, MMP-12 selective FRET 
































 Chapter 5: MMP-12 Does Not Inhibit 
Angiogenesis 
5.1 Introduction 
5.1.1 MMPs  
The extracellular matrix (ECM) is the structural connective tissue between cells, comprising 
collagens, elastin, glycoproteins and fibronectin. Structural changes to the ECM are required 
for growth and repair (Frantz et al., 2010; Hynes, 2009). MMPs are a large family (24+) of 
zinc dependent proteases, each capable of degrading one or many components of the ECM 
(Nagase et al., 2006).  MMPs are under tight regulation (at translation, transcription, secretion, 
and activation levels), with even the active proteases regulated by endogenous tissue inhibitors 
of metalloproteinases (TIMPs) (Löffek et al., 2011). MMPs are essential for everyday 
physiological processes but dysregulation of MMP activity is associated with the progression 
of pathology of many diseases including cancer, inflammatory bowel disease and 
atherosclerosis (Vu, 2000; O’Sullivan et al., 2015; Liang et al., 2006; Overall & Kleifeld, 
2006).  
 
5.1.2 The role of MMPs in regulating angiogenesis 
Matrix metalloproteinases play a dual role during angiogenesis: they are essential for 
endothelial cell migration and tube formation, but some can also create proteolytic products 
which are inhibitors of angiogenesis (e.g. angiostatin or endostatin) (Nguyen et al., 2001; 
Cornelius et al., 1998; Ferreras et al., 2000).   
MMPs degrade the basement membrane, ECM components and VE-cadherin endothelial cell-
cell adhesions, allowing endothelial cells and pericytes to migrate (Herren et al., 1998). 
Consequently, MMPs overall play a positive role promoting angiogenesis (Bergers et al., 





angiogenesis, this may be because other MMPs can compensate for the loss due to the cross 
substrate recognition. Exceptions to this are MMP-1 and -9: MMP-1 KO mice have significant 
skeletal defects and exhibit a minimal response in in vivo angiogenesis assays (Zhou et al., 
2000); MMP-9 KO mice exhibit abnormal angiogenesis in the skeletal growth plate during 
development but this resolves within 3 weeks post-partum (Zhou et al., 2000; Vu et al., 1998). 
 
5.1.3 MMP-12 inhibits angiogenesis 
MMP-12, also known as macrophage elastase (MME), is predominantly produced by pro-
inflammatory macrophages and is considered one of the most important enzymes in the 
degradation of elastin (but also breaks down fibronectin and collagen IV; Shipley  et al., 1996). 
MMP-12 activity has been shown to be protective against certain diseases. Its activity has been 
shown to be: cancer protective (Houghton et al., 2006), anti-inflammatory (Dean et al., 2008), 
anti-bacterial and anti-viral (Houghton et al., 2009; Marchant et al., 2014). But MMP-12 
activity is also associated with several cardiovascular diseases including atherosclerosis 
(Johnson et al., 2011; Yamada et al., 2008), aneurysms (Curci et al.,1998; Longo et al., 2005), 
and acute and chronic arterial stiffening (Liu et al., 2015). Li and colleagues (2012) showed 
that KO mice exhibited increased angiogenesis of the retina after oxygen-induced retinopathy. 
Furthermore, tumour samples with increased MMP-12 expression also exhibited reduced 
vascular content (Margheri et al., 2009; Yang et al., 2001; Gorrin-Rivas et al., 2001; Shi et 
al., 2006). 
MMP-12 can inhibit angiogenesis in two ways: firstly, by the inhibition of plasmin (which is 
pro-angiogenic) production, and secondly by producing inhibitors of angiogenesis, such as 
angiostatin and endostatin (Figure 1.12). Cornelius and colleagues found that MMP-12 is the 
most efficient member of the MMP family for cleaving plasminogen to produce angiostatin, 





cannot produce angiostatin from plasminogen (Cornelius et al., 1998; Serrat et al., 2006). 
MMPs, including MMP-12, can also produce endostatin, a 20 kDa C-terminal fragment of 
collagen XVIII which also acts as a potent inhibitor of angiogenesis (Ferreras et al., 2000).  
The second mechanism linking MMP-12 activity with inhibition of angiogenesis is through its 
interaction with the uPA/uPAR axis. The uPA/uPAR system has complex functions in 
inflammation, cancer and cell signalling processes (Crippa, 2007). The endothelial cell uPAR 
is bound to the cell surface and binds to extracellular pro-uPA, activating it to uPA. The uPA 
catalyses the production of plasmin from plasminogen in the extracellular space; plasmin 
cleaves various components of the ECM and is able to activate pro-MMPs leading to further 
degradation of the matrix. This leaky matrix facilitates the migration of endothelial cells during 
angiogenesis (Blasi & Carmeliet, 2002). MMP-12 cleaves the full-size endothelial uPAR in 
vitro, generating a truncated form; this may render it unable to sustain its role in promoting 
angiogenesis via the uPA/uPAR complex in vivo (Koolwijk et al., 2001; D’Alessio et al., 2004; 
Serrat et al., 2006). 
Tools to enable interrogation and visualisation of MMP-12 activity in vitro, ex vivo and in vivo 
in real-time would allow for assessment of its molecular activity during tissue remodelling in 
disease and angiogenesis. This project aimed to develop MMP-12 targeting compounds which 
could be used to clarify its role in angiogenesis. In Chapter 3, an MMP-12 selective inhibitor 
(HS1-22) and activity FRET probe (HS1-65) were synthesised. In Chapter 4, the in vivo 
sponge implantation model of angiogenesis was characterised and MMP-12 activity was 
measured to be highest on D 7 in tissue lysates using zymography. 
In this chapter HS1-65 was tested as tool to image MMP-12 activity in tissues, initially using 
well plate assays and tissue lysates, with the aim to use a similar probe to selectively image 
MMP-12 activity in vivo. In addition, HS1-22 was used to inhibit MMP-12 in ex vivo and in 





5.2 Hypothesis and aims 
5.2.1 Hypothesis 
MMP-12 activity inhibits angiogenesis. 
 
5.2.2 Aims 
1. To determine whether the substrate activity probe HS1-65 can detect MMP-12 activity 
in tissue lysates during angiogenesis in a mouse in vivo model of angiogenesis. 
2. To determine whether HS1-22 (MMP-12 selective inhibitor) increases angiogenesis 
in the sponge implantation model and in aortic ring explants. 
3. To determine whether MMP-12 deletion increases angiogenesis in the sponge model 









C57BL6/J mice were purchased from Harlan or Charles River, MMP-12 KO mice (B6.129X-
Mmp12tm1Sds/J (Shipley et al.,1996)) were purchased from The Jackson Laboratories (USA) 
via Charles River (UK). Animals were housed in groups, where appropriate, and maintained 
under controlled conditions of light (lights on 08:00 − 20:00) and temperature (21 − 22 ˚C). 
All mice were housed for at least 1 week, with constant access to food and water before use in 
experiments. 
 
5.3.2 FRET probe detection of MMP-12 activity in tissue 
lysates 
Study design 
The ability to image MMP-12 activity quickly in biological mixtures, tissues and in vivo would 
aid our investigation. Here, the ability to detect MMP-12 activity with HS1-65 (an MMP-12 
activity substrate probe) was assessed in lysates of angiogenic tissue (Figure 5.1). In vitro 
zymography analysis of sponge tissue lysates collected over a time course study suggested 
MMP-12 was most active on D 7 (Figure 4.18) so sponges in C57BL6/J and MMP-12 KO 








Figure 5.1 Study design: Protease detection in tissue lysates from sponges (D 3 − 35) with an 
MMP-12 selective probe (HS1-65). C57Bl/6J mice were anesthetised and two 1 cm3 sponges 
implanted subcutaneously on the left and right flanks. Mice were sacrificed and sponges removed on D 
3, 7, 14, 21, 28, and 35 (n = 6) after implantation. Sponges were homogenised in PBS, the lysate isolated 
by centrifugation and the protein content calculated using a Bradford’s assay. In a 384 well plate, 15 µL 
reactions were set up in triplicate. Tissue lysates (1.67 µg/mL) were incubated (37 °C, 2 h) with protease 
inhibitors (marimastat, sivelestat, anti-thrombin III, a protease cocktail block, or MMP buffer, at 
appropriate concentrations). HS1-65 (10µM) was then added to each well and the proteolysis of HS1-
65 monitored in a plate reader over 2 h. Lysates could then be purified and the protease cleavage of 







Surgery, tissue collection and lysate preparation 
Sponges were implanted subcutaneously as described in Section 2.9. The sponges were 
collected on D 3, 7, 14 and 21, cut in half, then either snap frozen on dry ice before storage at 
−80 °C. One half of the sponge was thoroughly homogenised in 1 mL of PBS. Samples were 
then centrifuged to isolate the plastic sponge and the supernatant transferred to a new 
Eppendorf tube. This was repeated and the resulting supernatant was stored at - 80 ˚C. The 
total protein in the lysate samples was quantified colorimetrically using a Bradford’s assay for 
bovine serum albumin (protocol in Section 2.11). 
 
Plate assay with HS1-65, tissue lysates and MMP inhibitors 
Assays with tissue lysates and HS1-65 are described in Section 2.11. Briefly, in a 384 well 
plate, 15 µL reactions were prepared in triplicate: tissue lysates (D 3 − 35, 5 µL, final 
concentration 1.67 µg/ µL) were incubated (37 °C, 1 h) with marimastat (5 µL, final 
concentration 500 nM) or MMP buffer. Other controls used were: negative control, the 
proteins in the tissue lysate were denatured (95 °C, 5 min); positive control, MMPcat-12 (5 
µL, 30 nM). The plate was then cooled to 0 °C before HS1-65 was added (5 µL, final 
concentration 10 µM). Reactions were monitored in a plate reader (37 °C, ex = 495 nm, em = 
525 nm, 2 h). Results were analysed as a fold change in the fluorescent signal (compared to 
HS1-65 with no treatment). 
 
Plate assay with protease inhibitors 
As above but tissue lysates and controls (MMP-12cat or Buffer) were mixed with protease 
inhibitors (sivelestat (100 µM) or antithrombin III (400 nM) or a protease cocktail block (used 





MS analysis of probe cleavage in tissue lysate 
Reaction mixtures from tissue lysate plate assays were purified and concentrated using pipette 
tips containing C18 resin cartridges (Millipore Zip Tip®) (protocol described in Section 2.11). 
The filtrate was analysed by MALDI-TOF MS as described in Section 1.4.  
 
5.3.3 Pharmacological inhibition or deletion of MMP-12 during 
ex vivo angiogenesis  
Study design 
The aortic ring assay is a popular quantitative ex vivo model of angiogenesis in which 
developing microvessels undergo many key features of angiogenesis, it has recently been 
reviewed by Baker and colleagues (Baker et al., 2012). Here we used this assay to test the 
effects of MMP inhibitors or MMP-12 deletion on angiogenesis (Figure 5.2), the experimental 







Figure 5.2 Study design: embedded aortae were treated with growth factors and MMP inhibitors. 
Treatments were made in Opti-MEM supplemented with 2% Foetal calf serum FCS for the first 3 days 
then VEGF (5 ng/mL) for the rest of the experiment. MMP inhibitors were added to the medium (HS1-
22 or marimastat, 25 µM). Microvessel sprouts were counted on days (D) 3, 5 and 7.  
 
Aortic ring assay 
The aortic ring assay (Figure 5.3) is described in Section 2.8. Briefly, aorta were carefully 
dissected out, cleaned and cut into 1 mm rings; these where each embedded in 50 µL of 
collagen I (rat tail, 1mg/mL in DMEM) in a 96 well plate. Treatments were prepared in Opti-
MEM supplemented with 2% Foetal calf serum (FCS) for the first 3 days then VEGF (5 
ng/mL) for the rest of the experiment; MMP inhibitors (HS1-22 or marimastat, 25 µM) were 
also administered in the culture medium which was added on top of the gel (150 µL per well), 







Figure 5.3 Aortic ring assay method. Under a dissecting microscope a) i, the thorax of an asphyxiated 
mouse is dissected to reveal the aorta; ii-iv, the aorta (white triangles) is exposed and carefully removed. 
b) The aorta is placed in DMEM and carefully cleaned by the removal of any excess fat and blood before 
being cut into 1 mm rings (10- 12 per aorta). c) In a 96 well plate a single ring is embedded in a 1% 
collagen gel, the treatment is then added to the medium above the gel.  Treatments were applied on top 
of the gel and refreshed every 2-3 days (150 µL per well). Figure adapted from (Baker et al., 2012). 
 
Analysis  
Images of aortic vessels were captured at × 20 magnification on D 3, 5 and 7 post embedding. 
The images were randomised and angiogenesis was quantified in two ways (Figure 5.4). 
Firstly, by counting the number of sprouts and branches from the ring; the mean value of the 
replicates was taken for each mouse. Secondly, by quantifying the maximum vessel length. 
The length of the three longest vessels for each aortic ring was quantified using ImageJ; the 






 Figure 5.4 Analysis of vessel numbers and lengths in the aortic ring assay. Counting the number of 
sprouts: each sprout was counted as one, additionally to this, each branch was also counted as one; this 
illustrative ring sprout would be counted as 5. Vessel length: the length of a branch was measured in 
ImageJ from the ring to the tip of the microvessel (red line) using the freehand line drawing tool (pixels); 






5.3.4 Pharmacological inhibition or deletion of MMP-12 during 
in vivo angiogenesis  
Study designs 
The in vivo subcutaneous sponge implantation model of angiogenesis (Small et al.,2005; 
Andrade et al.,1987) was used: firstly, to test pharmacological inhibition of MMP-12 (drug 
study, Figure 5.5), and secondly to test the effects of MMP-12 deletion using an MMP-12 




Figure 5.5 Study design: pharmaceutical intervention to inhibit MMPs in a model of angiogenesis. 
C57Bl6 mice were subcutaneously implanted with a 1 cm3 sponge connected to an osmotic pump via a 
catheter. The osmotic pump was filled with either vehicle, marimastat (broad spectrum inhibitor) or 
HS1-22 (MMP-12 selective inhibitor) (n = 6). Drugs were slowly perfused (0.25 µL/h) into the sponge 
at 150.6 nmol/mouse/day (marimastat: 2 mg/kg/day or HS1-22: 2.6 mg/kg/day in vehicle (DMSO: 
propylene glycol : H2O (1:1:1)). Sponges were removed on D 21, cut in half and samples either fixed 
or frozen. Angiogenesis was quantified by staining vessels for CD31 and α-SMA, stained vessels were 






Figure 5.6 Study design, investigation into the effects of MMP-12 deletion in a murine model of 
angiogenesis. C57Bl6 MMP-12+/+ (n = 6) or MMP-12-/- mice (n = 6) were subcutaneously implanted 
with two 1 cm3 sponges. On D 7 FMT imaging of angiogenesis and MMP activity was achieved using 
commercial probes, AngiosSense 680 (AngioSense) and MMPSense 750 F.A.S.T. (MMPSense), 
respectively. Sponges were removed on D 21, cut in half and samples either fixed or frozen. Aortae 
were harvested for use in the aortic ring assay. Angiogenesis in sponges was quantified by staining 
vessels for CD31 and α-SMA, stained vessels were counted under magnification. Gene expression for 
MMPs and markers of angiogenesis was measured using RT-qPCR.  
 
Pharmacological inhibition of MMP-12 during in vivo angiogenesis.  
To limit the side effects of systemic administration of the drugs, osmotic mini-pumps were 
used. Pumps were prepared under sterile conditions, see Appendix 5 for detailed method 
explanation. Briefly, the catheter and the pump cavity were filled with the desired sterilized 
drug solution. The pumps were closed and primed prior to surgical implantation (n = 6 / 
treatment). Pumps and solutions were designed to administer the drug to the mice at 150.6 
nmol/mouse/day (marimastat: 2 mg/kg/day, HS1-22: 2.6 mg/kg/day) for 21 days (25g mouse) 
in DMSO : propylene : glycol : H2O (1:1:1). This concentration was chosen as it is within the 
limits of solubility of the drugs in the vehicle, and within the range used in other studies (Chow 






Each mouse was placed under general anaesthesia. In the MMP-12 KO study, two sponges 
were subcutaneously implanted in each mouse. In the drug study, the sponge and pump system 
were implanted subcutaneously in the mouse. The mouse was then allowed to recover. The 
procedures are described in Section 2.9 and Appendix 1. 
 
Tissue collection 
Mice were sacrificed on D 21 and the sponges were collected, cut in half and either snap frozen 
on dry ice before storage at -80 °C or fixed in 4% PFA (18 h) before storage in 70% ethanol. 
Organs (heart, liver, lungs, pancreas, and kidneys) were collected and weighed. In the MMP-
12 KO study, aortae were collected in DMEM for immediate use in the aortic ring assay. 
 
Histology 
Fixed tissues were prepared for histology by embedding in paraffin wax and 5 µm sections 
were cut for staining and immunohistochemistry. Sections were cut from the centre of each 
sponge.  
In the drug study, one section for each mouse was used for: 
1. Staining with haematoxylin and eosin (H&E) to image different cell types and tissue 
structures. 
2. Immunostaining for CD31 and α-SMA to visualise vessel structures. 
In the MMP-12 KO study, one section for each mouse was used for: 






2. Immunostaining for F4.80 to image macrophages.  
3. Staining with picrosirius red to image collagen deposition 
4. Immunostaining for CD31 and α-SMA to visualise vessel structures. 
Whole sections were imaged using a slide scanner. The images were randomised before being 
analysed by a blinded observer, as discussed in Section 1.12.  
 
MMP-12 KO study FMT imaging and analysis 
Mice were placed on an alfalfa free diet to reduce autofluorescence 10 days prior to imaging 
and injected with MMPSense and AngioSense (Perkin Elmer, 2 nnol) 24 h prior to FMT 
imaging. Images were acquired and the data were then analysed using the Truequant® 
software (PerkinElmer) which converted the measured fluorescent signal to the concentration 
of probe within the sponges. The mean value of probe concentration over the 2 sponges was 
taken for each mouse, this was then tested for statistical significance. See Section 2.10 and 
Appendix 1 for the imaging procedures and data analysis; Section 1.4 and Appendix 1 contain 
more information on FMT and the commercial agents used. 
 
MMP-12 KO study: molecular analysis of gene expression  
RNA was isolated from frozen sponges from sponges from the KO study, from this cDNA 
was synthesised and RT-qPCR was performed. The following genes were investigated: MMP-
2, -7, -9, -10, -13, -12, CD31, PDGFR, VEGFα, TNFα, HIF1α, VECAD, VWF, TSP-1 (gene 
transcripts were normalised against the mean of TBP and GAPDH). The protocols are 







Data were checked for outliers and presented as mean ± SEM. Comparisons were made using 
Students T-test or ANOVA as appropriate. Some studies are n = 1 or 2 as unpromising leads 







5.4.1 Protease detection in sponge lysates with an MMP-12 
substrate activity probe 
HS1-65 is activated in tissue lysates 
Reactions with HS1-65 and MMP-12 (catalytic domain) resulted in an 8 fold increase in 
fluorescence (Figure 5.7). Reactions with tissue lysate (TL, samples were from sponges 
collected on D 3 − 35) and HS1-65 also resulted in an increase in fluorescence, significantly 
so for TL samples collected from D 28 and 35 sponges. 
HS-65 is cleaved in tissue

















































































Figure 5.7 HS1-65 is cleaved in tissue lysates from sponges. HS1-65 (10µM) was cleaved in reactions 
(2 h, 37°C) with MMP-12 (30 nM) and the tissue lysate (TL, 1.67 µg/mL of protein). The fold increase 
in fluorescence compared to control (probe alone) was calculated. Reactions with MMP-12 and TL from 
sponges collected on D 28 and D 35 resulted in a significant increase in fluorescence. Bars represent 
mean ± SEM (n = 3) and comparisons were made using a one-way ANOVA followed by Dunnett’s 






HS1-65 is cleaved by a protease but not an MMP in tissue lysates 
MMP-12 pre-treated with marimastat or denatured prior to a reaction with HS1-65 resulted in 
complete suppression of fluorescence which was comparable to control levels (probe in buffer) 
(Figure 5.8). Heat denaturation of tissue lysates (TL) prior to the reaction with HS1-65 also 
resulted in complete suppression of fluorescence. However, TL pre-treated with marimastat 
prior to a reaction with HS1-65 only resulted in a small suppression of fluorescence on D 7, 
28 and 35 TL samples. 
















































































Figure 5.8 Measured fluorescence from HS1-65 substrate activity probe after incubation with 
tissue lysates (TL), denatured tissue lysates and MMP-12. In a 384 well plate 15 µL reactions were 
set up in triplicate. The addition of HS1-65 (10µM) to the tissue lysates or MMPcat-12 resulted in an 
increase in fluorescence (white bars). Denaturing the proteins (TL or MMP-12, grey bars) resulted in 
complete suppression of fluorescence from HS1-65 levels comparable to HS1-65 incubated with just 
buffer. The addition of marimastat to the reactions with active TL (black bars) resulted in no large 
change in fluorescence form HS1-65 on TL D 3, 14 and 21. The MMP-12 incubated with marimastat 
resulted in complete suppression in fluorescence confirming the marimastat was active. Results are 
plotted as fold change in fluorescence after 2 h, bar represents mean ± SEM (n = 1 in triplicate), this is 





MALDI-TOF MS analysis of probe fragments  
Tissue lysates (D 3 − 35) (or MMPcat-12) and HS1-65 were incubated for 2 h, the reaction 
mixtures were then purified and analysed by MALDI-TOF MS. Cleavage of HS1-65 (M++Na 
m/z = 1834.9) resulted in a clearly identifiable fragment (M+ m/z = 787.7) after reaction in 
MMPcat-12 (Figure 5.9). Spectra with tissue lysates and HS1-65 did not exhibit this distinctive 







Figure 5.9 Analysis of HS1-65 and corresponding cleavage fragment after MMPcat-12 proteolysis 
using MALDI−TOF MS. HS1-65 was incubated with MMPcat-12 (37 °C, 2h). Samples were purified 
using pipette tips containing C18 resin cartridges, the filtrate was analysed by MALDI TOF MS. HS1-
65 (M++Na m/z = 1835.57) was cleaved with a clearly identifiable fragment (M+ m/z 789.06). Other 

























Figure 5.10 Analysis of HS1-65 and corresponding cleavage fragment within tissue lysates using 
MALDI-TOF MS. HS1-65 was incubated with tissue lysates from D 3 − 35 sponges or with MMPcat-
12 (37 °C, 2h). Samples were then purified using pipette tips containing C18 resin cartridges, the filtrate 
was analysed by MALDI TOF MS. HS1-65 was cleaved in all lysates but not by MMP-12, MS spectra 
confirm that the fragment associated with cleavage by MMP-12 was not present (m/z = 789, region in 
box) confirming proteolysis by another protease. Other peaks in region 650 to 850 m/z are surfactant in 
the MMP buffer.  
 
HS1-65 is not cleaved by a serine protease or neutrophil elastase 
In an attempt to discover the source of HS1-65 probe activation in the tissue lysates, reactions 
were challenged with protease inhibitors: i) a commercial broad spectrum protease block, ii) 
sivelestat (a neutrophil elastase inhibitor), iii) antithrombin III (a serine protease inhibitor). 
When compared to the experiments with no treatment: the commercial protease blocker 
virtually abolished the signal from HS1-65 cleavage for all samples (Figure 5.11). The addition 
of sivelestat or antithrombin III resulted in no change in fluorescence for experiments with 








Figure 5.11 HS1-65 is cleaved by a protease in the tissue lysate which is not an MMP, neutrophil 
or macrophage elastase or a serine protease. In a 384 well plate 15 µL reactions were set up in 
triplicate as follows: tissue lysates (TL) were challenged with sivelestat (neutrophil elastase inhibitor, 
black bar, 100 µM), or anti-thrombin II (serine protease inhibitor, striped bar, 100 nM) or a protease 
inhibitor cocktail (broad spectrum protease inhibitor, grey bars, 0.33 stock) or MMP buffer (white bar), 
all incubated at 37 °C, 2 h. Subsequently, HS1-65 (10 µM) was added and reactions monitored in a plate 
reader (ex = 495 nm, em = 525 nm, 37 °C, 2h). HS1-65 was cleaved in all the TL and by MMP-12cat.  
The addition of sivelestat (black bars) or antithrombin III (stripped bars) to these reactions resulted in 
no change in the cleavage of HS1-65 for reactions with tissue lysates collected on D 3 − 21; however, 
there appeared to be a drop in signal on D 28 and D 35. The addition of the protease cocktail block 
inhibited the cleavage of HS1-65 in all samples, but the fluorescence was quenched over 2 h resulting 
in a lower than expected fluorescence at the 2 h time point. Results are presented as mean fold change 






5.4.2 MMP-12 does not inhibit angiogenesis in the ex vivo 
aortic ring assay 
MMP-12 inhibition did not increase microvessel growth in the ex vivo 
aortic ring assay. 
Vascular sprouts were observed to grow from the embedded aortic rings (Figure 5.12) and 
were present in all groups on D 3, 5 and 7 after embedding (Figure 5.13). On D 3, the addition 
of growth factors to the Opti-MEM control did not alter the number or length of endothelial 
microvessel sprouts; but by D 5 the numbers increased to almost double (P < 0.05 Figure 5.13) 
but the length was still similar. On D 7 microvessels were present in greater numbers (P < 
0.05) which were on average 40% longer (P < 0.05, Figure 5.14). Interestingly, the addition 
of marimastat (with growth factors) did not alter vessel length on D 3 but there was a pattern 
for there to be an increase in vessel numbers compared to microvessels without growth factor 
or with growth factors and HS1-22, both P < 0.05). However by D 7, those aortic rings with 
the marimastat treatment had fewer microvessels (P < 0.01 vs growth factors, Figure 5.13) and 
reduced vessel length (P < 0.001 vs all groups, Figure 5.14). When HS1-22 (an MMP-12 
selective inhibitor) was added to the growth factor treatment there were no statistically 
significant changes in sprout numbers or length on D 3 or 5; but by D 7 microvessels were 



















Figure 5.12 Representative images from the aortic ring assay. Aortic rings from C57BL6/J 
mice were embedded in 1% collagen and treated with growth factors (GF) which stimulated 
the growth of long sprouts. MMP inhibitors (marimastat, a broad spectrum inhibitor or HS1-
22 an MMP-12 selective inhibitor; both 25 µM) where added to aortae for the duration of the 
experiment. Representative images are of rings collected from a single mouse and acquired at 







Figure 5.13 Aortic ring assay with growth factors GF and MMP inhibitors: number of sprouts. 
Vessels were treated with growth factors (solid black) and MMP inhibitors (marimastat or HS1-22, 25 
µM). On D 3, marimastat (horizontal lined) almost doubled the number of microvessels from aortic 
rings compared to those treated with (solid black) or without (white solid) GF treatment. On D 5 the 
number of marimastat treated microvessels was only statistically higher than those treated without any 
GF or inhibitors; the addition of GF led to an increase in microvessel number compared to those 
experiments without GF treatment. By D 7, those aortic vessels treated with just GF had more 
microvessels that those without GF or those treated with marimastat. The addition of HS1-22 (diagonal 
lined) to the aortic rings did not significantly alter the number of microvessels compared to those with 
or without GF. Results are plotted as mean ± SEM, n = 6 in triplicate; statistics: two-way ANOVA 
followed by a Bonferroni post-hoc test comparing all pairs of columns; marimastat vs no treatment (# P 
< 0.05, ## P < 0.01); marimastat vs HS1-22 ($ P < 0.05); GF vs no treatment (& P < 0.05, $$ P < 0.01). 


































Figure 5.14 Aortic ring assay with growth factors and MMP inhibitors: length of microvessels. 
On D 3 the length of the microvessels was similar for all treatment groups. On D 5 the length of 
microvessels was similar for those with (solid black) and without GF (solid white); however, 
microvessels growing in the presence of marimastat (horizontal lined) had reduced length compared to 
microvessels treated with GF or without GF. By D 7, vessels treated with GF were longer than those 
without treatment. Vessels treated with marimastat were shorter than those in all other groups. By D 7, 
the addition of HS1-22 (diagonal lined) reduced the length of microvessels compared to those treated 
with GF alone. Results are plotted as mean ± SEM, (n = 6) in triplicate, comparisons where made using 
two-way ANOVA followed by a Bonferroni post-hoc test comparing all pairs of columns; marimastat 
vs no treatment (### P < 0.001); marimastat vs GF (££ P < 0.01, £££ P < 0.001); marimastat vs HS1-22 
($ P < 0.05); GF vs no treatment (&&& P < 0.001); GF vs HS1-22 (* P < 0.005). 
  

































































MMP-12 gene deletion did not change microvessel growth in the aortic 
ring assay  
Aortic rings were cultured in triplicate from MMP-12 KO and C57BL6/J mice (n = 6 each) in 
the presence of GF and MMP inhibitors over D 3 − 7. For all time-points assessed, microvessel 
out-growth was present for both genotypes and for all treatment groups. The deletion of MMP-
12 did not result in increase in vessel numbers (Figure 5.15) or length (Figure 5.16) in the 
presence of GF or MMP inhibitors. Interestingly treatment with HS1-22, an inhibitor designed 









Figure 5.15 Aortic rings deficient in MMP-12 exhibited no differences in vessel numbers and 
didn’t respond differently to growth factors or MMP inhibitors compared to C57BL6/J control. 
Aortic rings from MMP-12 KO (red line) and C57BL6/J (black line) were treated with (a) and without 
(b) growth factors (GF, 2% FCS for 3 days followed by VEGF (5 ng/mL). The loss of MMP-12 did not 
alter microvessels numbers over D 3 − 7. The addition of HS1-22 (MMP-12 selective inhibitor, c) 
marimastat (broad spectrum MMP inhibitor, d) (both 25 µM) also elicited similar responses for both 
genotypes. For each treatment, the loss of MMP-12 did not result in any large changes to the overall 
patterns observed for microvessel numbers over D 3 − 7.  Results are plotted as mean ± SEM, (n = 6). 
Statistics: data were tested with a two-way ANOVA followed by a Bonferroni post-hoc test comparing 







Figure 5.16 Aortic rings deficient in MMP-12 exhibited no differences in vessel length and didn’t 
respond differently to growth factors or MMP inhibitors compared to C57BL6/J controls. Aortic 
rings from MMP-12 KO (red line) and C57BL6/J (black line) were treated with (a) and without (b) 
growth factors (GF, 2% FCS for 3 days followed by VEGF (5 ng/mL). The loss of MMP-12 did not 
alter microvessels numbers over D 3 − 7. The addition of HS1-22 (MMP-12 selective inhibitor, c) 
marimastat (broad spectrum MMP inhibitor, d) (both 25 µM) also elicited similar responses for both 
genotypes. For each treatment, the loss of MMP-12 did not result in any large changes to the overall 
patterns observed for microvessel numbers over D 3 − 7.  Results are plotted as mean ± SEM, n = 6 in 
triplicate. Statistics: data were tested with a two-way ANOVA followed by a Bonferroni post-hoc test 






5.4.3 MMP-12 Inhibition decreases angiogenesis in vivo 
MMP-12 inhibition did not alter body weight but did reduce lung size and 
increase kidney size 
MMP inhibitors were administered locally to the sponge using an osmotic mini pump. After 
21 days, the administration of marimastat led to an increase in body weight compared to both 
vehicle and HS1-22 drug treatment (Figure 5.17 (a), both P < 0.05). Mice treated with HS1-
22 had slightly heavier kidneys compared to controls (Figure 5.17 (f), P < 0.01). Interestingly 
the lung size was significantly smaller in mice treated with marimastat and HS1-22 (Figure 
5.17, (d), P < 0.01 and P < 0.001, respectively). The size of the heart, spleen and liver were 






Figure 5.17  Effects of MMP inhibitors on mouse body and organ weights. Administration of 
marimastat (broad spectrum inhibitor) resulted in increased body weight (a) compared to vehicle (**) 
and HS1-22 (##, MMP-12 inhibitor). Treatment with marimastat or HS1-22 had no effect on heart (b), 
liver (c) or spleen (d) weights. Treatment with HS1-22 resulted in mice with heavier kidneys (e, p < 





0.001 respectively). Bars or column and error bar represent mean ± SEM (n = 6) and comparisons were 
made using a one-way ANOVA followed by Bonferroni post-hoc test comparing all data sets (** or ## 
P < 0.01, *** P < 0.001). 
 
MMP-12 inhibition decreases angiogenesis 
Treatment with marimastat reduced the total number of vessels (Figure 5.18 (a), P < 0.05) and 
the number of vessels positive for CD31 and α-SMA (Figure 5.18 (c), P < 0.01) in the sponges 
compared to the vehicle treated group. There is a pattern for treatment with HS1-22 to also 
reduce the total number of vessels and the number of vessels positive for CD31 and α-SMA 





Figure 5.18 Pharmacological inhibition of MMP-12 did not increase angiogenesis. a) Compared to 
the vehicle, treatment with marimastat resulted in a reduced number of total vessels and treatment with 
HS1-22 resulted in a pattern for reduced vessel numbers. b) The number of only CD31 positive vessels 
was unchanged by treatments. c) Compared to the vehicle alone, treatment with marimastat resulted in 
a reduction in vessels positive for both CD31 and α-SMA, while treatment with HS1-22 resulted in a 
pattern for reduced CD31 and α-SMA positive vessels. Bars represent mean ± SEM (n = 4 − 6) and 
comparisons were made using either a one-way ANOVA followed by Bonferroni post-hoc test 
comparing all data sets (graph a and c) or a Kruskal-Wallis test followed by a Dunn’s multiple 





5.4.4 MMP-12 deletion did not alter angiogenesis in vivo  
MMP-12 KO mice had reduced MMP-12 expression in sponges. 
Two sponges were subcutaneously implanted in mice for 21 days. Expression of MMP-12 was 
significantly reduced in sponges from MMP-12 KO mice compared to the C57BL6/J 




















































Figure 5.19  MMP-12 expression is significantly reduced in sponges collected from MMP-12 KO 
mice. Sponges were removed on D 21 after implantation and MMP-12 gene expression measured using 
RT-qPCR. Bars represent mean ± SEM (n = 5 − 6), comparisons were made using Students t-test (P = 






Loss of MMP-12 was not detected in vivo using a commercial MMP 
activity probe and FMT 
In vivo FMT imaging of MMPSense in sponges on D 7 resulted in no statistically significant 
changes in signal detected within the sponges of MMP-12 KO mice (Figure 5.20).  
 
Figure 5.20  FMT imaging of MMP activity on D 7 did not detect the loss of MMP-12 activity in 
vivo. Sponges subcutaneously implanted in MMP-12 KO and C57BL6/J mice a) representative images 
of the in vivo florescent signal acquired by FMT imaging of MMPSense. The “Area scanned” is 





the two subcutaneous sponges. b) The quantified signal around the sponges, MMP activity detected by 
this method was not significantly different between the two genotypes. Bars represent mean SEM (n = 
6 − 9) and comparisons were made using a Students t-test (P = 0.1060).  
 
Loss of MMP-12 expression did not alter body weight but did reduce lung 
size 
Mice were sacrificed on D 21, there was no significant difference in body weight between the 
C57BL6/J and MMP-12 KO mice (Figure 5.21a). The weights of the heart (b), liver (c), kidney 
(d), spleen (e) were not different between the genotypes (Figure 5.21). MMP-12 KO mice did 







Figure 5.21 No change in body or organ weights, except for the lungs, between the MMP-12 KO 
and C57BL6/J mice. Mice were sacrificed 21 days after the surgery. There was no significant 
difference in body weight (a, P = 0.4196), heart (b, P = 0.3503), liver (c, P = 0.5113), kidney (d, P = 
0.1465), or spleen (e, P =0.3377) weights between the C57BL6/J and MMP-12 KO mice (P > 0.05). 





Bars represent mean ± SEM (n = 5 − 6) and comparisons were made using a Students t-test (** P < 
0.01). 
MMP-12 deletion does not alter deposition of collagen in sponges 
During dissection it was noted that sponges in MMP-12 KO mice had adhered to each other 
and were more strongly bound to the surrounding tissue compared to sponges from their 
C57Bl6/J counterparts (Figure 5.22). Quantification of picrosirius red staining demonstrated 




Figure 5.22 Representative images of sponges ex vivo after subcutaneous implantation for 21 days 
in C57BL6/J and MMP-12 KO mice. Sponges in MMP-12 KO mice were generally observed to have 
adhered to each other and were more tightly bound to the surrounding tissues compared to sponges in 








Figure 5.23 Quantification of picroscirius red staining in sponges implanted in C57BL6/J and 
MMP-12 KO mice. Sponges were removed on D 21 post implantation. The mean density of staining 
around the edge of the tissue section (a, P = 0.4419) and the mean depth of staining into the sponge (b, 
P = 0.1021) were both unchanged. Bars represent mean ± SEM (n = 6) and comparisons were made 






MMP-12 deletion did not alter the TNFα expression or inflammatory cell 
infiltration 
mRNA was extracted from the sponges and, using RT-qPCR, the relative gene expression of 
TNFα was measured. There were no differences in the expression of TNFα in sponges from 














































Figure 5.24 Gene transcripts of TNFα remained unchanged in C57BL6/J and MMP-12 KO mice. 
Bars represent mean ± SEM (n = 6) and comparisons were made using a Students t-test (P = 0.6105). 
 
MMP-12 deletion did not alter macrophage infiltration 
In the sponges the percentage of F4/80 staining around the edge of the sponge (as previously 
described in Figure 4.11) (Figure 5.25a) and the depth of infiltration into the tissue (Figure 






Figure 5.25 Macrophage infiltration was unchanged between C57BL6/J and MMP-12 KO mice. 
a) The mean percentage area of F4/80 stain around the sponge edge (a, P = 0.7146) and depth of 
infiltration (b, P = 0.6762) were unchanged. Bars represent mean ± SEM (n = 6) and comparisons were 
made using a Students t-test (P > 0.05).  
 
MMP-12 deletion did not change AngioSense probe accumulation  
Imaging of sponges on D 7 post implantation showed that accumulation of the AngioSense 







Figure 5.26 MMP-12 deletion did not change vascular permeability in vivo. Sponges 
subcutaneously implanted in MMP-12 KO and C57BL6/J mice. a) Representative images of the in vivo 
fluorescent signal acquired by FMT imaging of AngioSense. The “Area scanned” is representative of 
the signal measured, the left and right regions of interest (ROI) encompass the signal around the two 
subcutaneous sponges. b) The mean quantified AngioSense signal around the sponges was similar in 
C57BL6/J and MMP-12 KO mice (P = 0.5714). Bars represent mean ± SEM (n = 6 − 9) and comparisons 





MMP-12 deletion did not increase angiogenesis  
Deletion of MMP-12 did not increase the total number of vessels (CD31 or CD31 and α-SMA 
positive) (Figure 5.27, a). The analysis of the signals detected over the whole section area also 
identified that there were no changes in the percentage of tissue area covered by CD31,  
α-SMA or DAPI signals (Figure 5.27, b).  
 
 
Figure 5.27 Deletion of MMP-12 did not increase angiogenesis in vivo in the sponge implantation 
model. a) Deletion of MMP-12 did not alter the total number of vessels within sponges after 21 days of 
implantation (P = 0.7600). b) It also did not alter the area stained positive for CD31 (PECAM-1) or α-
SMA, suggesting the number of the cells positive for these markers is unchanged. Columns represent 





MMP-12 deletion did not change gene expression of vascular and 
angiogenic markers. 
The expression of hypoxia-inducible factor 1-alpha (HIF-1-α), vascular endothelial growth 
factor (VEGF) and thrombospondin 1(TSP-1) measured by RT-qPCR was similar in MMP-12 
KO and C57BL6/J mice (Figure 5.27Figure 5.28). Expression of CD31 (also known as platelet 
endothelial cell factor, PECAM-1), vascular cell adhesion molecule (VCAM-1), intercellular 
cell adhesion molecule (I-CAM), vascular endothelial cadherin molecule (VE-cadherin) and 
Von Willebrand factor (vWF) were also all unchanged by the deletion of MMP-12 (Figure 
5.29). Furthermore, the expression of PDGFRβ (platelet derived growth factor receptor β), a 
marker of vascular maturation, was also unchanged in the sponge by the loss of MMP-12 









Figure 5.28 Deletion of MMP-12 did not result in a change in mRNA expression of key angiogenic 
factors. Expression of the pro-angiogenic factors a) HIF-1-α (P = 0.6775) or b) VEGF (P = 0.8818) and 
the anti-angiogenic TSP-1 (c, P = 0.8182) was similar in C57Bl/6 and MMP KO mice. Bars represent 







Figure 5.29. Deletion of MMP-12 did not result in a change in mRNA expression of vascular 
markers. There was no difference in expression of endothelial cell markers: CD31 (a, P = 0.0566), 
VCAM-1 (b, P =0.5928), ICAM-1 (c, P = 0.5225), VE-cadherin (d, P = 0.2304) and vWF (e, P =0.6850). 
There was also stable expression of PDGFRβ (f, P = 0.3939) which is associated with vascular 






In this chapter the role of MMP-12 in angiogenesis was investigated using two MMP-12 
targeting compounds (synthesised in Chapter 3, an MMP-12 inhibitor (HS1-22) and an 
activatable FRET probe (HS1-65)) and MMP-12 KO mice. Out hypothesis was tested in in 
vivo (sponge models, descried in Chapter 4) and ex vivo models (lysates from angiogenic 
tissues or the aortic ring assay) of angiogenesis. This preliminary study found that HS1-65 was 
non-specifically activated by MMP-12 in the lysates from tissues undergoing angiogenesis 
(mouse) in an in vivo model of angiogenesis. Selective inhibition of MMP-12 with HS1-22 
did not increase angiogenesis in the ex vivo aortic ring assay (no effect on the numbers of 
microvessels and decreased their length in the aortic ring assay) or in vivo in the sponge assay. 
Secondly, deletion of MMP-12 also did not increase angiogenesis in the ex vivo aortic ring 
assay (unchanged microvessels numbers and length and the response to MMP inhibitors was 
unchanged) or in vivo in the sponge assay (no change in vessel numbers or gene expression of 
angiogenic markers). Furthermore, deletion of MMP-12 did not change vascular permeability 
when measured in vivo by FMT (AngioSense 680) and suggestion of a reduction in MMP 
activity (detected with MMPSense 750) did not reach significance. Overall, these data suggest 
that MMP-12 activity does not inhibit angiogenesis. This is in contrast to other literature which 
has shown MMP-12 activity to be anti-angiogenic in an oxygen-induced retinopathy model of 
angiogenesis (Li et al., 2012), and in cancer (Kerkelä et al., 2000; Houghton et al., 2006) 
 
5.5.1 The FRET probe HS1-65 is activated in tissue lysates but 
not by MMP-12 
A MMP-12 selective FRET probe, HS1-65, with the peptide sequence PLGLEEA (Lim et al., 
2014; Cobos-Correa et al., 2009) was synthesised in-house (Chapter 3). Using in vitro assays, 
this FRET probe was shown to be activated predominantly by MMP-12 and MMP-13 





peptide sequence was selectively activated by lipopolysaccharide (LPS)-stimulated 
macrophages expressing MMP-12 from MMP-12 +/+ but not MMP-12 -/- mice); whereas Lim 
and colleagues (2014) used an MMP-12 selective inhibitor to block HS1-65 activation in a 
preclinical in vivo model of collagen-induced arthritis. 
It was hypothesised that HS1-65 could be used to detect MMP-12 during angiogenesis in the 
sponges in vivo. In this chapter, HS1-65 was tested to see if it was sensitive enough to detect 
MMP-12 activity in tissue lysates generated from sponges implanted beneath the skin of 
control mice for D 3 − 35. HS1-65 was activated in crude tissue lysates but it was shown that 
this was not mediated selectively by MMP-12, or any other MMP (since activation was not 
inhibited by marimastat). MALDI-TOF MS analysis of the fragments within the tissue lysate 
reactions confirmed that the signature fragment detected after MMP-12 cleavage of the probe 
was not present. The cleavage of HS1-65 by a protease was confirmed using a protease cocktail 
and by denaturing the proteins present. To gain insight into the protease responsible, reactions 
were challenged with other protease inhibitors. The probe was not activated by: neutrophil 
elastase (inhibited by sevilestat) or a serine protease (inhibited by antithrombin III) e.g. trypsin, 
plasmin, thrombin and the contact activation pathway (Factor X-XII) and kallikrein. Tissue 
lysates are a complex mixture of cell contents so it will be a challenging process to pursue the 
protease further.  
 
5.5.2 MMP-12 inhibitor did not promote angiogenesis in the ex 
vivo aortic ring or in vivo in the sponge model. 
The aortic ring assay was reported by in 1990, but has since been developed to the protocol 
used in this chapter (Nicosia & Ottinetti 1990; Baker et al., 2012). This assay has many 
attributes that make it a good in vitro model of angiogenesis; firstly, it is quick, relatively 
inexpensive and requires relatively low animal numbers as 10 − 12 rings can be obtained per 





physiologically-relevant timeline. These tube like structures are clearly visible by microscopy 
(× 20 magnification) and can have a lumen and be supported by perivascular cells (Nicosia & 
Ottinetti 1990; Baker et al., 2012; McSweeney et al., 2010). Finally, this assay allows for 
simultaneous analysis of microvessel formation when subject to varying treatments in 
physiologically-relevant, chemically-defined conditions (Nicosia & Ottinetti 1990; Baker et 
al., 2012; McSweeney et al., 2010). 
Endothelial microvessel out growths (number and length) were enhanced in the presence of 
growth factors (Baker et al., 2012). FCS contains a rich variety of proteins and growth factors 
which help maintain cultured cells in an environment in which they can survive, grow, and 
divide. Plasminogen, present in in FCS, can be activated to plasmin. Plasmin can degrade a 
variety of proteins (including fibronectin and collagen which are components of the ECM) and 
can activate MMP-1, -2, -3, -9, -12 and -13 (Davis et al., 2001; Raza et al., 2000; Monea et 
al., 2002; Carmeliet et al., 1997). Therefore, the presence of plasmin would generally be 
considered to be proangiogenic (Lacroix et al., 2007). The second growth factor used was 
VEGF which is a well characterised potent angiogenic promotor; VEGF promotes endothelial 
cell migration and proliferation (Ferrara et al., 2003).  
As predicted, the inhibition of MMP activity (treatment with marimastat) in this study resulted 
in significantly reduced sprout numbers and stunted vessel growth on D 7. Marimastat has 
previously been shown to inhibit sprouting in ring assays in a dose-dependent manner (Zhu et 
al., 2000; Burbridge et al., 2002).  This is consistent with other laboratories which have also 
highlighted the need for MMP expression during angiogenesis (reviewed by Rundhaug, 2005). 
Inhibition of MMP activity slows the breakdown of the ECM, restricting endothelial cell 
migration and the formation of capillaries (Haas et al., 1998; Nguyen et al., 2001). Marimastat 





growth phase in rat aorta ring assays (Zhu et al., 2000). This suggests that MMPs play a dual 
role in promoting vascular growth and the subsequent pruning and remodelling.  
Interestingly, the addition of marimastat unexpectedly increased the number of microvessels 
on D 3. This is not consistent with other similar experiments which showed marimastat to 
inhibit the sprouting phase of angiogenesis (Zhu et al., 2000; Burbridge et al., 2002). 
Marimastat may promote early angiogenesis in this model by inhibiting MMP-dependent 
production of angiogenic inhibitors, such as angiostatin or endostatin. Interestingly, MMP-7, 
9 and 12 can convert plasminogen/plasmin to angiostatin fragments. (Patterson & Sang 1997). 
Angiostatin inhibits angiogenesis in vitro by limiting endothelial cell migration (Cornelius et 
al., 1998; Dong et al., 1997; Redlitz et al., 1999). Marimastat and HS1-22 both inhibit MMP-
12 and so both would be expected to inhibit angiostatin production; however, on D 3 of this 
study, the selective inhibition of MMP-12 (with HS1-22) did not result in the same increase 
of microvessel formation as marimastat. These results indicate that the increased angiogenesis 
with marimastat on D 3 is unlikely to be caused by inhibition of MMP-12. Endostatin can also 
dramatically inhibit microvessel formation in the aortic ring assay (Kruger et al., 2000; Li & 
Olsen 2004). Endostatin is a 20 kDa C-terminal fragment of collagen XIII (found in the 
vascular basement membrane), this fragment is the proteolytic product of elastase, cathepsin 
L and (importantly for this study) by MMP-9, 3, 12 and 13 (Ferreras et al., 2000; Halfter et 
al., 1998). In this assay, the greater angiogenic response observed with MMP inhibition may 
have been due to reduced synthesis of endostatin. The selective inhibition of MMP-12 did not 
elicit the same increase in angiogenesis as total MMP inhibition, suggesting that MMPs-3, 9 
and 13 could be the important active proteases in this pathway.  
Importantly in this study we identified that the selective inhibition of MMP-12 did not affect 
the number of microvessels on D 3 − 7 but this treatment did result in a slight but significant 





increase angiogenesis in this assay; if anything, the reverse was true. These results are in 
contrast to data published by Li and colleagues (2012) that showed loss of MMP-12 gene 
expression was proangiogenic in vivo in a model of oxygen induced retinal ischemia injury. 
Furthermore, they found that administration of an MMP-12 inhibitor (MMP408 by oral 
gavage) also increased angiogenesis in the same model. This group also found that pre-
treatment with an MMP-12 inhibitor (MMP408; 20 nM, 16 h) did not affect the ability of 
primary human retinal endothelial cells to form branches in the Matrigel tube formation assay 
(Li et al., 2012). This suggested that either MMP-12 does not play a role in angiogenesis or 
that MMP-12 activity is not present in this assay. In the work reported in this chapter using 
the ex vivo aortic ring assay, the addition of an MMP-12 selective inhibitor (HS1-22) was not 
proangiogenic.  
In summary, GF simulated microvessel formation in the aortic ring assay but the addition of 
an MMP-12 inhibitor (HS1-22) did not increase angiogenesis as hypothesised. Marimastat 
inhibited vessel numbers and length late in the study as expected but there was an increase in 
sprout numbers in early experiments (D 3) the reason for which is unclear. 
A major limitation of the aortic ring assay, and other in vitro angiogenesis assays, is the lack 
of the inflammatory process associated with angiogenesis in vivo (Baker et al., 2012). As 
MMP-12 is predominantly secreted by macrophages the lack an inflammatory response limits 
the number of macrophages present in the environment and, therefore, potentially limits MMP-
12 activity. However, adventitial macrophages are present in this assay and are important in 
regulating tube-like structure formation so there is potential for MMP-12 to be present (Gelati 
et al., 2008). To test our hypothesis that MMP-12 is an inhibitor of angiogenesis, we next 
moved into the in vivo sponge model (which has MMP-12 activity peaking on D 7 and a time-





model would be a better for testing HS1-22 as it is more representative of the natural 
angiogenic response compared to the aortic ring assay.  
Spontaneous angiogenesis in the subcutaneous sponge implants is facilitated by the porous 
framework and the host inflammatory response. Post implantation, the infiltration of 
leukocytes results in the secretion of cytokines and chemokines, producing a pro-angiogenic 
response (Leibovich et al.,1987; Barcelos et al.,2005). This model is attractive due to its 
reproducibility, it’s MMP-12 activity, and the ease of vessel number quantification using 
histological techniques; other advantages are listed in the discussion of Chapter 4 
There have been several successful adaptations of the sponge model to utilise different scaffold 
materials such as metal meshes (Schilling et al., 1959), other synthetic polymers (polyvinal 
alcohol, poly urethane) and hydrogels (Kleinman et al., 1986; Phelps et al., 2010). Novel 
polymer coatings have been used to promote attachment, differentiation, and expansion of 
endothelial cells (Pernagallo et al., 2012). Furthermore, agents can be administered 
systemically (via food, water, gavage or intravenous injection) or directly via osmotic 
minipumps (Efron et al., 2001), silastic elastomers (Small et al., 2005) or injection into the 
sponge (Hu et al,. 1995). In this chapter, MMP inhibitors drugs were administered to 
polyurethane sponges using osmotic pump attached by a catheter to the sponge. This 
administration method was chosen as it allowed uninterrupted flow of drug over 3 weeks 
directly into the sponges and potentially limited any systemic effects of the MMP inhibitors. 
Sponge implants have previously limited systemic effects of drugs (Small et al., 2005); local 
administration by osmotic pump was intended to have a similar effect in this study and to limit 
any off target systemic effects of drugs (eg. marimastat causes muscoskeletal toxicity) 
(Wojtowicz-Praga et al., 1998; Bramhall et al., 2002; Jacobsen et al., 2010). 
Overall, marimastat and HS1-22 were well tolerated and there was no loss of body weight. 





treatment. This was mirrored by a similar reduction in lung size in MMP-12 KO mice. MMPs 
are essential for lung homeostasis and are upregulated in pathological conditions but there is 
little literature to explain this reduction in lung size observed in this study (Greenlee et 
al.,2007). Mice treated with HS1-22 also exhibited larger kidneys; MMP-12 is present in low 
levels in the murine kidney but this effect was not mirrored in the mice treated with marimastat 
or in MMP-12 KO mice so was likely an off-target effect of HS1-22 (Rao et al., 2006). These 
small but significant changes in organ weights suggests that, despite local administration, there 
was systemic drug action. Furthermore, it demonstrated that active drug was administered to 
the sponge. 
MMP activity is essential for angiogenesis; it facilitates the breakdown of the ECM and cell 
migration (Hinsbergh & Koolwijk 2008). In this study, marimastat (2 mg/kg/day) was well 
tolerated. Histological techniques showed that marimastat inhibited angiogenesis in sponges, 
specifically, causing a reduction in the number of mature vessels. This is consistent with other 
studies which also show marimastat as an inhibitor of angiogenesis (Skipper et al.,2009; 
Kimata et al.,2002). Therefore, results in this study confirm that MMPs are required for in vivo 
angiogenesis. 
Unlike most MMPs, the role of MMP-12 has previously been suggested to be anti-angiogenic 
in vitro and in vivo (Li et al.,2012; Serrat et al.,2006). Results in this chapter revealed that 
selective pharmacological inhibition of MMP-12 (with HS1-22) did not increase angiogenesis 
in vivo after 21 days of administration. In fact, there was a pattern for fewer vessels, which 
were less mature, but these differences did not achieve significance. To confirm that MMP-12 
did not affect angiogenesis in this in vivo sponge model and in the ex vivo aortic ring assay, 






5.5.3 MMP-12 deletion did not promote angiogenesis in the ex 
vivo aortic ring or in vivo in the sponge model. 
MMP-12 null mice are commercially available and the MMP-12 deletion is relatively well 
tolerated. These mice are more prone to viral and bacterial infection and their litter sizes are 
smaller, ~60% of wildtype (Marchant et al.,2014; Houghton et al.,2009).  Studies have shown 
that deletion of MMP-12 is protective against atherosclerosis and aortic aneurysms, and is 
proangiogenic in an oxygen-induced retinopathy/ ischemia model of angiogenesis (Li et 
al.,2012; Johnson et al.,2005; Longo et al.,2005). Macrophages lacking MMP-12 have limited 
ability to invade tissues as they cannot cleave components of the ECM to facilitate migration 
(Li et al., 2012). Results in this chapter showed that deletion of MMP-12 had no effect on ex 
vivo angiogenesis (microvessel numbers, length and response to MMP inhibitor treatments 
remained unchanged in the aortic ring assay) and in vivo angiogenesis (vascular permeability 
(AngioSense and angiogenesis FMT) and total vessel numbers both remained unchanged in 
sponges).  
As discussed above, the inhibition of MMP-12 (treatment with HS1-22) did not statistically 
increase microvessel formation (number and lengths on D 7) in the aortic ring assay. To 
examine this further, we next cultured aortae rings from C57BL6/J and MMP-12 KO mice. 
Compared to their C57BL6/J counterparts, rings lacking MMP-12 did not exhibit any 
significant changes to the formation of microvessels outgrowths (numbers or length) nor did 
they respond very differently to the growth factor and MMP inhibitor treatments. Briefly, 
administration of GF increased angiogenesis and treatment with marimastat, reduced vessel 
number and length by D 7 in both C57BL6/J and MMP-12 KO mice. Selective inhibition of 
MMP-12 (with HS1-22) inhibited vessel numbers and lengths by D 7 in both C57BL6/J and 
MMP-12 KO mice; this suggested that any small changes induced by HS1-22 were off target 





It was hypothesised that the lack of any pro-angiogenic effect by MMP-12 deletion and 
inhibition in the ex vivo assays could be explained by the lack of a host inflammatory response 
(although, as previously discussed, macrophages are present in this assay (Gelati et al. 2008)). 
However, selective inhibition of MMP-12 in the in vivo sponge implantation assay also did 
not increase angiogenesis. To help clarify the role of MMP-12 during in vivo angiogenesis, 
MMP-12 KO mice were utilised in the sponge implantation assay. 
Ex vivo observations showed that sponges implanted in MMP-12 null mice for 21 days were 
more adhered to each other and the surrounding tissue which suggested that there was greater 
ECM deposition. Nevertheless, no significant changes in collagen(s) deposition were found 
by histology. Lack of MMP-12 may lead to greater elastin deposition but this will need to be 
addressed in future studies. 
Sponges in MMP-12 KO mice had significantly diminished MMP-12 expression within the 
fibrovascular tissue. MMP-12 is predominantly expressed by macrophages (Nénan et al., 
2005); C57BL6/J and MMP-12 KO mice exhibited similar levels of macrophage infiltration 
into their sponges. Macrophages are the major producer of TNFα (Parameswaran & Patial, 
2010) and, in this study, TNFα mRNA expression in sponges was unchanged in MMP-12 KO 
mice. TNFα primes endothelial cells for angiogenic sprouting by inducing tip cell phenotype 
once the initial inflammatory wave has passed (Sainson et al., 2008). In sponges treated with 
corticosterone (which is a potent inhibitor of angiogenesis), the angiogenic response was 
independent of inflammatory cell infiltration and the treatment  had a very limited effect on a 
number of transcripts of inflammatory factors) (Gastaldello, 2015). 
The FMT 2500 machine and MMPSense has previously been shown to be sensitive enough to 
detect increased MMP activity in murine models of gastric and skin cancer (Ding et al., 2012; 
Al Rawashdeh et al., 2014). In this study, imaging MMP activity within the sponges on D 7 





activity (lower concentration of probe with smaller variability) but this did not reach 
significance. Firstly, this could be because this study was not powered to detect this difference, 
by using power calculations and this data, it has been estimated that groups of n = 48 for would 
be required to prove this hypothesis (P < 0.05). Secondly, the MMPSense probe, which is 
designed to detect a spectrum of MMP activities (MMP- 2, 7, 9, 12  and 13), was not sensitive 
enough to detect the selective loss of MMP-12 activity within the sponges (Groves  et al., 
2010). Additionally, other MMPs have substrates in common with MMP-12 (Table 1.1) and 
so may have partially compensated for the loss of MMP-12 activity, in which case there is 
possible genetic redundancy in vivo. Compensation by other MMPs has previously been 
observed: global deletion of MMP-9 resulted in increased expression of MMP-3 and 13 in 
myocardial tissue post myocardial infarction (Ducharme et al., 2000); in postpartum uterine 
involution, deletion of MMP-7 resulted in increased expression of MMP-3 and 10, whereas 
the deletion of MMP-3 resulted in an increase in MMP-7 and 10. 
Interestingly in this study, MMP-12 KO mice exhibited no changes to angiogenesis in the in 
vivo sponge implantation assay. No changes in vascular permeability (a characteristic which 
increases in vessels undergoing active angiogenesis) were detected in vivo in sponges in MMP-
12 KO mice (AngioSense with FMT) or in total vessel numbers on D 21 post implantation. 
Consistent with these results, deletion of MMP-12 had no effect on VEGF (an angiogenic 
promotor) or TSP-1 (an angiogenic inhibitor) gene expression in the sponges. VEGF-induced 
activation of endothelial cells results in disassembly of VE-cadherin, one of the principal 
signalling and structural proteins associated with the VE cell-cell adherens junction 
(Petzelbauer et al., 2000). Disassembly of these junctions increases vascular leakiness and 
enables the migration of the endothelial cells, these then divide to form the new vessels (Bates 
2010). Further to this, the expression of TSP-1, an inhibitor of angiogenesis, was also unaltered 





proliferation, survival, and apoptosis and by antagonizing the activity of VEGF (Lawler & 
Lawler, 2012). 
Consistent with the histological analysis of vessels, gene expression for markers of endothelial 
cells (VE-cadherin, CD31, VCAM-1 and ICAM-1) also remained unchanged between sponges 
from MMP-12 KO and C57BL6/J mice. CD31 was the closest to a significant change between 
the two genotypes (P = 0.0566), power calculations estimate that a groups of n = 9 would have 
been sufficient to prove if this was a real change. CD31 is an adhesion molecule expressed by 
endothelial cells is suggested to facilitate the trans-endothelial migration phase of leukocytes 
(Muller, 1995; Wakelin et al., 1996). CD31 is expressed by endothelial cells but also by 
macrophages (McKenney et al., 2001), therefore any change in gene expression of this marker 
cannot be assumed to be solely from a change in endothelial cell numbers. VCAM-1 also 
mediates the adhesion of leukocytes to inflamed endothelium; when in its soluble form 
VCAM-1 is reported to exhibit angiogenic activity in vivo through mediating endothelial cell 
chemotaxis (Koch et al.,1995). VCAM-1 is also suggested to be required for blood vessel 
maturation via the integrin α4β1–VCAM-1–mediated adhesion between endothelial and mural 
cells (Fukushi et al.,2000). Endothelial cells and macrophages both express ICAM-1 which is 
important for stabilising cell−cell interactions and facilitating leukocyte endothelial 
transmigration (Lawson & Wolf 2009). Platelet derived growth factor receptor (PDGFR) is 
also important in the maturation process as it stimulates pericyte and smooth muscle 
recruitment (Levanon et al., 2006), its gene expression also remained unchanged in sponges 
from MMP-12 KO mice. This supports the histological analysis of angiogenesis within the 
sponges implanted in MMP-12 null mice: the loss of MMP-12 during in vivo angiogenesis did 
not alter angiogenesis. Deletion of MMP-12 also did not affect adipose tissue associated 







The inhibition or deletion of MMP-12 did not promote angiogenesis in in vivo or ex vivo 
murine assays. HS1-22 had off target effects making the associated studies into the effect of 
MMP-12 during angiogenesis less reliable. FMT imaging was successfully used to image 
MMP activity (MMPSense) and angiogenesis (AngioSense) but levels detected were 
unchanged between MMP-12 KO and C57BL6/J mice. HS1-65 was found to be cleaved in 
sponge tissue lysates by a protease other than MMP-12. 
To conclude, firstly, commercial molecular imaging probes are useful tools for non-invasively 
gaining information on a tissue micro-environment, but selective imaging of MMP-12 activity 
in sponges is still to be achieved. Secondly, MMP-12 is not an inhibitor of angiogenesis in the 















Chapter 6  
 
 












 Chapter 6: General Conclusions, Limitations 
and Future Directions 
6.1 Introduction 
The vascular network provides nutrients and removes waste from tissues. A healthy network 
of blood vessels supports tissue maintenance, growth and repair but structural and functional 
abnormalities in the network can contribute towards disease. Poor blood supply can cause 
ischemia in tissues, leading to myocardial infarction (Thygesen et al., 2012), or stroke 
(Prabhakaran et al., 2015). Conversely, increased blood supply to tumours is associated with 
increased tumour growth and metastasis, leading to poor prognosis (Folkman, 2007). The 
ability to image the structure of the vessel network and blood flow could contribute towards 
the assessment of a particular disease state. Furthermore, advancements in molecular analysis 
could contribute towards a greater understanding of the molecular environment of diseases. 
For example, changes in enzyme activities and signalling molecules that contribute to altered 
angiogenesis. Pharmacological manipulation to stimulate or inhibit angiogenesis represents an 
attractive therapeutic opportunity in cancer biology, tissue regeneration and even obesity 
(Folkman, 2007; Cao & Langer, 2010; Yoo & Kwon, 2013). 
The activity of matrix metalloproteinases (MMPs) is associated with increased vessel growth 
and the progression of several cardiovascular diseases (CVD) (Van Hinsbergh & Koolwijk 
2008). Interestingly, MMP-12 is suggested to inhibit vessel growth but its precise role is still 
unclear (Li et al., 2012). It has been suggested that MMP-12 inhibits angiogenesis by the 
generation of inhibitory molecules and by the inhibition of plasminogen activation (Figure 
1.12) (Ferreras et al., 2000; Cornelius et al., 1998; D’Alessio et al., 2004; Koolwijk et al., 
2001). The ability to selectively image and/or manipulate MMP-12 activity in vivo could 





diseases in which it is suggested to have an active role such as atherosclerosis (Liang et al., 
2006), arthritis (Liu et al., 2004) and aneurysms (Longo et al., 2005).  
The aim of work presented in the thesis was conducted to gain a greater understanding of the 
precise role of active MMP-12 during angiogenesis. Thus, commercial and in-house 
synthesised MMP inhibitors and FRET probes were used to address the hypothesis that MMP-





6.2 Research summary, limitations and future work 
6.2.1 Overview 
The work described in this thesis was conducted to test the hypothesis: MMP-12 activity 
inhibits angiogenesis. Firstly, an MMP-12 inhibitor was applied to ex vivo and in vivo 
angiogenesis assays. These showed that inhibition of MMP-12 activity did not result in an 
increased angiogenesis. Secondly, MMP-12 knock out (KO) mice were used in ex vivo and in 
vivo angiogenesis assays; once again impaired MMP-12 activity did not increase angiogenesis. 
Tools to image angiogenesis and MMP, in particular MMP-12, activity non-invasively during 
angiogenesis were tested as part of these studies.   
 
6.2.2 MMP-12 inhibition did not promote angiogenesis 
To answer the hypothesis, initially an MMP-12 inhibitor was synthesised and tested for 
potency and selectivity using recombinant in vitro assays and then used in the ex vivo aortic 
ring and in vivo sponge assays of angiogenesis. 
 
A potent, low-toxic, MMP-12 selective inhibitor was synthesised  
The MMP-12 selective inhibitor, HS1-22, was structurally similar to MMP408 (discussed in 
Section 1.6.4) (Li et al., 2009). It was hoped that a small rearrangement of moieties (from 
MMP408 to HS1-22) would allow for future labelling with a fluorophore (for optical 
molecular imaging of MMP-12) without significant loss of potency or selectivity towards 
MMP-12. HS1-22 was synthesised in 6 steps from commercially available reagents. The 
compound was purified by HPLC and analysed using 1D and 2D NMR and MS techniques. 
In vitro recombinant enzyme assays confirmed that HS1-22 was very selective for MMP-12 
(but also slightly inhibited MMP-2) in a panel of selected MMPs. IC50 assays showed that 





Praga et al., 1998)) and AZD1236 (MMP-9 and 12 (Dahl et al., 2012)) were more potent); 
these results also suggested that there was a compromise between potency and selectivity for 
MMP inhibitors. An MTT assay also showed HS1-22 to be non-toxic at concentrations below 
100 µM. Consequently, this compound was taken forward to ex vivo and in vivo angiogenesis 
assays. To summarise, HS1-22 is a potent MMP-12 inhibitor with low toxicity. 
 
Inhibition of MMP-12 did not promote angiogenesis  
The hypothesis that MMP-12 activity contributes to inhibition of angiogenesis was tested 
using HS1-22 in ex vivo and in vivo angiogenesis assays. It was hypothesized that inhibition 
of MMP-12 by HS1-22 would promote vessel growth in these assays. Firstly, HS1-22 was 
tested as an angiogenesis promoter in the ex vivo aortic ring assay (assay reviewed by Baker 
et al., 2012). MMP inhibitors were administered to aortic rings and the number and lengths of 
microvessel outgrowths measured. A broad spectrum inhibitor of MMPs (marimastat) reduced 
micro-vessel numbers and length. This was consistent  with the work of Zhu and colleagues 
(2000). The selective inhibition of MMP-12 (with HS1-22) did not alter the number of vessel 
outgrowths but did decrease the vessel length by D 7. This result was contrary to the hypothesis 
that selective inhibition of MMP-12 would increase angiogenesis. A possible reason for this 
was that the contribution of macrophages, the main source of MMP-12, is limited in this assay 
(number due to the lack of a systemic inflammatory component). It should be noted, however, 
that inflammatory cells present in the adventitia of the aortic rings have been shown to 
contribute to tube formation in this assay (Gelati et al., 2008). A subsequent investigation 
described in this thesis showed that the microvessel outgrowths from MMP-12 KO mice did 
not respond differently to the MMP inhibitor treatments (by D 7, marimastat reduced 
microvessel numbers, and both HS1-22 and marimastat inhibited vessel lengths) compared to 
those from C57BL6/J mice. This confirmed that any effects of HS1-22 in this assay were 





suggest that MMP-12 does not have a role in inhibiting angiogenesis. However, the aortic ring 
assay has its limitations, primarily that angiogenesis occurs in the absence of a systemic 
inflammatory response (and, therefore, potentially lacks MMP-12 secreting macrophages) and 
the tissue is not exposed to blood-borne or tissue-derived factors (Baker et al., 2012). 
Therefore, the next stage was to test the hypothesis in in vivo model of angiogenesis with an 
inflammatory response. 
An in vivo model of angiogenesis with defined expression and activity profiles of MMP-12 
was developed. The subcutaneous sponge implantation model of angiogenesis is well 
established and regularly used in the Hadoke group (Small et al., 2005; Andrade et al., 1987). 
At the beginning of this project, the precise role and activity profile of MMP-12 in this model 
was unknown. The expression and activity of MMPs in the subcutaneous sponge implantation 
model was characterised over a 35 day period. MMP-12 was present in this model: gene 
expression (increased D 7-21), protein expression (decreased D 7 - 21) and activity (peaked 
on D 7) were all measured. Firstly, these data served as a guide to the presence of MMP-12 
activity during angiogenesis in this model, and secondly, it highlighted the complexity of the 
patterns of MMP activation and regulation. 
To test our hypothesis, that MMP-12 is an inhibitor of angiogenesis, HS1-22 and marimastat 
were administered for 21 days directly into the sponge via an osmotic pump. It was intended 
that direct administration to the sponge would minimise systemic effects. Administration of 
marimastat led to a small but significant increase in body weight and a reduction of lung 
weight; mice treated with HS1-22 exhibited larger kidneys and smaller lungs. Therefore, this 
indicated that local administration was not sufficient to prevent systemic effects of these drugs. 
Sponges from mice treated with marimastat showed a significant reduction in both the total 
number of vessels and the number of CD31 and α-SMA positive vessels. This is consistent 





2003). Mice treated with HS1-22 also had a pattern suggesting a reduction in total and mature 
vessels but this did not reach significance. These data do not support the hypothesis that MMP-
12 inhibits angiogenesis. 
To summarise, an MMP-12 selective inhibitor was synthesised in-house but this compound 
did not promote angiogenesis in ex vivo or in vivo assays.  
 
Limitations and future experiments 
Broad spectrum MMP inhibitors (including marimasat) were first developed as anti-cancer 
treatments but failed to provide the breakthrough hoped for; this was in-part due to their 
musculoskeletal toxicity (Cathcart et al., 2015). It was suggested that inhibitors targeting 
specific MMPs would limit these side effects (Cathcart et al., 2015), but this hypothesis is still 
to be definitively proven. In this study, MMP-12 inhibition with HS1-22 was hypothesised to 
inhibit angiogenesis but this was not proven. There are several avenues for future work 
regarding HS1-22 and the assays used: 
Does HS1-22 alter endothelial cell behaviour in vitro? 
An MMP-12 inhibitor (MMP408) was shown to not affect the ability of endothelial cells to 
form branches in the Matrigel tube formation assay (Li et al., 2012). The effects of HS1-22 on 
endothelial cell behaviour could also be tested in a similar manner using the Matrigel tube 
formation assay (Arnaoutova et al., 2009) or the endothelial scratch assay (Liang et al., 2007). 
Does the aortic ring assay have MMP-12 expression and activity? 
In this study HS1-22 was tested as a proangiogenic drug using the aortic ring assay. Although 
macrophages are known to be present in this assay (Gelati et al., 2008), the presence of MMP-
12 in this assay is still unknown. To better understand of the effects of HS1-22 on aortic ring 





12 gene expression in the aortic rings during angiogenesis could be measured using RT-qPCR 
(Baker et al., 2012). Alternatively, MMP-12 activity in the vessel tissues could perhaps be 
measured using zymography (Vandooren et al., 2013). 
Does HS1-22 inhibit angiogenesis in another model of angiogenesis? 
An MMP-12 inhibitor (MMP408) was shown to promote angiogenesis in an oxygen-induced 
retinopathy model of angiogenesis (Li et al., 2012). HS1-22 could be tested in this 
angiogenesis assay. Angiogenesis in tumours, retinopathy and cardiac ischaemia may be 
regulated in different ways, so it is conceivable that MMPs may contribute differently in 
models of these conditions. Other angiogenesis assays in which HS1-22 could be tested in vivo 
include the chick chorioallantoic membrane (CAM) assay or zebra fish. However, they each 
have their own limitations- including not being mammal based (both reviewed by Norrby, 
2006).  
Does MMP408 inhibit angiogenesis in the sponge implantation assay? 
Compound MMP408 was the compound HS1-22 was based on and is also a potent MMP-12 
inhibitor. It was previously used to support that MMP-12 is an inhibitor in the OIR model of 
angiogenesis.  MMP408 could be used in this sponge model to verify the results from HS1-
22. Should it elicit a similar response in sponges, it would confirm that selective MMP-12 
inhibition is not proangiogenic. 
Can HS1-22 be labelled and used to image MMP-12? 
Selective imaging of MMP-12 activity could allow for better understanding of its role during 
angiogenesis and disease. Compound HS1-22 was chosen for this study due to the potential to 
conjugate it to a fluorogenic reporter group without impacting the compounds potency greatly 
(discussed in Section 1.6.4). Although labelling of HS1-22 was not undertaken for this study 






Figure 6.1 Synthetic strategy for the synthesis of a reporter labelled MMP-12 inhibitor. Synthetic 
divergence to make an imaging probe (rather than HS1-22) would occur from compound 19, with the 
amine acting as a handle. HS1-22 could be modified to incorporate a range of reporters for imaging; for 
example, Gd-DOTA for MRI, Cy5.5 or Cy7 for optical imaging, 18F for PET or a microbubble for 
ultrasound.  
 
6.2.3 MMP-12 deletion did not inhibit angiogenesis.  
Inhibition of MMP-12 did not promote angiogenesis in either the ex vivo aortic ring assay or 
in vivo sponge implantation models of angiogenesis. This was not consistent with our 
hypothesis that MMP-12 contributes to inhibition of angiogensis. To clarify these results 






In the ex vivo aortic ring assay, characteristics of microvessel outgrowths (number or length) 
from the aortic rings from MMP-12 KO mice were similar to those from C57BL6/J mice. Also 
the response to MMP inhibitor treatments (marimastat and HS1-22) was not affected by 
genetic deletion of MMP-12. Again, as discussed above, this may be due to a lack of MMP-
12 activity in this assay. Next, the effect of MMP-12 deletion on angiogenesis was assessed in 
the in vivo sponge assay. Results showed that the number of vessels in subcutaneous sponges 
was unchanged between those from C57BL6/J and MMP-12 KO mice. Additionally, the gene 
expression of vascular marker (CD31, VCAM-1, VE-cadherin, PDGFRβ), angiogenesis 
promotors (VEGF, HIF-1-α) and inhibitors (TSP-1) was unchanged by MMP-12 KO. The data 
collected using MMP-12 KO mice suggest that MMP-12 activity does not inhibit angiogenesis 
in this model.  
To summarise, deletion of MMP-12 did not promote angiogenesis in ex vivo or in vivo assays.  
 
Limitations and future experiments 
Does MMP-12 inhibit angiogenesis in another model of angiogenesis? 
Animal models of disease and tissue remodelling, although useful tools, do not always develop 
and behave exactly like the corresponding process in humans. As such, results and conclusions 
drawn from their use should be interpreted with some caution. Deletion of MMP-12 in the 
sponge implantation assay did not affect vessel number or gene expression. However, MMP-
12 deletion has been shown to inhibit angiogenesis after oxygen induced retinopathy (Li et al., 
2012). Angiogenesis in different tissues occurs under different biological conditions (for 
example, tissues have different ECM compositions and specialised cell behaviours). 
Furthermore, there are differences between developmental, physiological and pathological 





cardiac ischaemia may be regulated in different ways. It is also conceivable that MMPs may 
contribute differently in each of these conditions. 
In cancer, angiogenesis is required to support tumour growth when the tumour size exceeds 
1− 2 mm diameter, and later facilitates metastasis. Tumour cells release a host of factors 
including HIFs, FGF and VEGF to stimulate angiogenesis (Chung & Ferrara, 2011). However, 
the resulting tumour vessels are structurally and functionally abnormal, typically the network 
has irregular branching, different vessel diameters and poor perfusion (Jain 2005; Nagy et al., 
2010). The vessel walls are also leaky, which facilitates cancer cell access to the vessel lumen 
(Hashizume et al., 2000). Tumour cells and endothelial cells can line the lumen of the vessels 
(Chang et al., 2000), but unlike the endothelial cells, these tumour endothelial cells can 
transform to a mesenchymal state and migrate to new tissues which can result in metastasis 
(Voulgari & Pintzas, 2009).  
Inflammation has long been associated with cancer development. Macrophages have been 
implicated in cancer pathogenesis and tumours with a high macrophage content have increased 
vascularity and poor prognosis (Pollard, 2009; Chung et al., 2010). MMMP-12 is 
predominantly secreted by macrophages, can degrade components of the ECM and is required 
for macrophage migration across the basement membrane (Shipley et al., 1996; Gronski et al., 
1997). MMP-12 deletion has already been shown to increase tumour growth and metastasis in 
model of lung cancer (Lewis lung metastases) (Houghton et al., 2006). Selective inhibition of 
MMP-12 (with HS1-22) could be tested as an anti-cancer therapy in a similar model of lung 
cancer. Alternatively, a model of proliferating capillary haemangiomas could be used. These 
tumours are clinically treated with glucocorticoids to supress inflammation and angiogenesis 
(Folkman et al., 1983; Logie et al., 2010; Hasan et al., 2000). A model of capillary 
haemangiomas may be a useful assay to test whether MMP-12 inhibition results in greater 





In the sponge model, does the expression and activity of other MMPs in the MMP-
12 KO mice change compared to C57BL6/J mice? 
Many MMPs have the same substrates and, therefore, there is scope for redundancy (Table 
1.1). There is evidence from other single MMP KO models that other MMPs up-regulate to 
compensate for the loss (Ducharme et al., 2000; Rudolph-Owen et al., 1997). It would be 
interesting to determine whether there is an increase in expression and activity of other MMPs 
in the sponges as a result of deletion of MMP-12. 
Why does MMP-12 inhibition and MMP-12 deletion result in mice with lighter 
lungs? 
In both in vivo studies (the pharmacological inhibition and genetic deletion of MMP-12), it 
was noted that loss of MMP-12 activity resulted in mice with smaller lungs; the reason for this 
is unknown. The lungs comprise of highly vascularised tissues rich in elastin, the major 
substrate for MMP-12. It is already known that increased MMP-12 activity can exacerbate 
COPD (Molet et al., 2005). Histological analysis of lungs from MMP-12 KO and HS1-22 
treated mice could reveal key changes in tissue structure on a cellular level, including the 
vasculature. 
To date there is little understanding of the precise role of MMP-12 during embryonic 
development, and although not fatal, MMP-12 deletion does result in reduced litter sizes (60% 
of wild type (The Jackson Laboratory, 2016)). MMP-12 KO mice do not have MMP-12 
activity during embryonic development but still have a functional cardiovascular system, 
therefore the role of MMP-12 is not essential to angiogenesis regulation in the embryo. Further 







6.2.4 Molecular imaging of angiogenesis, total MMP and MMP-
12 activity 
Optical molecular imaging is developing traction in the field of medical imaging (Bu et al., 
2013; Osborn & Jaffer, 2013; Garland et al., 2016). Optical imaging has many advantages 
including using non-ionizing radiation and non-bulky, easily maintained equipment which 
could be used for bedside diagnostics. Currently there is a broad range of commercially-
available reagents for preclinical imaging, as well as novel probes developed by other research 
groups designed to provide insight into the molecular environment of cells and tissues 
(Peterson, 2011; Groves, 2010; Waschkau et al., 2013). In this study, commercially available 
AngioSense and MMPSense agents were used to image angiogenesis and MMP activity, using 
fluorescent molecular tomography (FMT), in subcutaneously implanted sponges in vivo. 
 
Angiogenesis was imaged in sponges with AngioSense and FMT  
Non-invasive imaging of angiogenesis using AngioSense and FMT was used to help address 
our hypothesis: MMP-12 is an inhibitor of angiogenesis. In the time-course study, in vivo 
imaging of sponges detected an increase in vascular permeability, a characteristic of early 
angiogenesis, in sponges on D 7 compared to D 14 and 21. As D 7 would represent an early 
stage of angiogenesis in this model we hypothesised that the increased signal was due to 
increased angiogenesis within the sponges. Interestingly, imaging of the D 7 sponges ex vivo 
did not identify this difference. This discrepancy between the in vivo and ex vivo measurements 
of vascular permeability in sponges on D 7 may be due vascular changes in tissues immediately 
surrounding the sponges in vivo. Interestingly, the peak in angiogenesis (measured in vivo) 
and the peak in MMP-12 activity (measured by zymography) where both on D 7. Therefore, 
it was possible that MMP-12 may be having the greatest effect on angiogenesis at this time 
point. However, in the MMP-12 KO study, angiogenesis in sponges was imaged on D 7 but 





with AngioSense). These data were supported by histological and gene expression analysis 
from the same sponges collected on D 21 which showed that vessel numbers and angiogenic 
markers were unchanged by MMP-12 KO (discussed above).  
AngioSense and FMT can be used to image vascular permeability, a marker of early 
angiogenesis, in sponges. This tool successfully identified those sponges undergoing early 
angiogenesis (in vivo signal was highest in sponges from D 7 compared to D 14 and 21) and 
provided an indirect measurement of early angiogenesis in sponges. This was consistent with 
the observed increase vessel numbers (measured with histology) and changes in gene 
expression of vascular and angiogenesis markers (measured with RT-qPCR); both provided 
evidence for ongoing angiogenesis over D 7 − 21.  
 
MMP activity was imaged in sponges with MMPSense and FMT  
MMPs are understood to be important in regulating cell movement and behaviour. MMP 
activity is generally assumed to be pro-angiogenic. In the sponge implantation model  
MMP-12 activity was measured using zymography, which suggested it was highest in sponges 
on D 7. In this study, MMP activity was imaged in vivo using FMT and MMPSense; 
MMPSense can be used to image the activity of MMP- 7, -9, -10, -12 and -13. 
In the time-course study, in vivo and ex vivo imaging of sponges detected no significant 
changes to MMP activity in sponges on D 7, 14 and 21. However, MMPs have different 
substrates and roles in regulating cell movement and behaviour during angiogenesis (Table 
1.1, Page-McCaw et al., 2007), so the active MMPs on D 3 may be different from those on D 
21. Supporting this, MMP gene expression profiles were shown to vary between D 7 and 21; 
for example, MMP-12 expression increased whereas MMP-9 expression decreased. 
Furthermore, the variability in the probe concentration measured in vivo in the sponges was 





over the time course, but were most apparent on D 7 during the early inflammatory and 
antigenic response. By D 21, as angiogenesis stabilised, the MMP activity signal had the 
lowest variability. Therefore, FMT and MMPSense can be used to image MMP activity in 
sponges in vivo but cannot be used to infer changes in the activities of individual MMPs. 
In the MMP-12 KO study, it was hoped that the loss of MMP-12 activity could be detected in 
subcutaneous sponges in vivo with FMT imaging and MMPSense. MMP activity measured in 
vivo appeared to be lower in sponges from MMP-12 KO mice but this did not reach 
significance. Therefore, MMPSense and FMT is a potential method to detect MMP-12 activity 
in sponges in vivo, but this requires further investigation to confirm. 
MMPSense and FMT imaging were successfully used to make a measurement of MMP 
activity in sponges in vivo but it was unable detect changes in the activity of specific MMPs 
in the sponge model over time.  
 
MMP-12 activity could not be selectively imaged with HS1-65 in tissue 
lysates  
MMPs comprise a large family of enzymes with different functions (Page-McCaw et al., 
2007). The ability to image the activity of a single, specific MMP could allow for better 
understating of its role during tissue remodelling and disease. Currently, optical molecular 
imaging probes to image selective MMPs are not commercially available. In this thesis, it was 
hypothesised that MMP-12 activity was anti-angiogenic, so the ability to selectively detect 
MMP-12 activity non-invasively in vivo during angiogenesis was of interest. 
 
In this study a small family of MMP-12 selective FRET probes was synthesised using solid 
phase peptide synthesis (SPPS) based on those published by Cobos-Correa and colleagues 





(but was also cleaved by MMP-13 and slightly by MMP-10); total selectivity in these probes 
is difficult due to the high homology between MMPs. Next, tissue lysates (TL) were generated 
from subcutaneous sponges implanted form 3 – 35 days. HS1-65 was cleaved in the TL 
samples but this was subsequently shown not to be a result of MMP-12 activity (using 
MALDI-TOF MS analysis). Protease inhibitors were used to show that HS1-65 was cleaved 
by a protease but not by another MMP, neutrophil elastase or a serine protease. The protease 
in the TL which cleaved HS-65 is still unknown. Therefore, due to limited success and limited 
resources this part of the study was not extended. 
To summarise; firstly, commercial imaging agents and FMT can be used to image MMP 
activity and angiogenesis in the sponge model of angiogenesis. Secondly HS1-65 was shown 
to be selective for MMP-12 in recombinant assays but was not selectively activated in TL 
samples.  
 
Limitations and future experiments 
In vivo 3D optical molecular imaging techniques are still relatively new compared to other 3D 
MRI, PET and CT imaging technologies. The imaging resolution of in vivo of optical 
molecular imaging techniques, such as FMT, is poor compared to the latter techniques. 
Possibilities for human translation of optical molecular imaging techniques are also still 
limited for several reasons: firstly, the tissue penetration depth of imaging is still limited to a 
few cm due to light scattering within tissues. Secondly, equipment for molecular imaging is 
still in development and not readily available in hospitals. Finally, there are few commercial 
agents currently available for use in humans, and pathways for clinical agent approval are still 
challenging. For optical molecular imaging to become a routine tool for diagnostics, these 
limitations need to be resolved.  





Can FMT and AngioSense be used to measure vascular density in sponges?  
AngioSense when imaged within an hour of administration has been used as a blood pool agent 
and so can be used to image the vasculature. Imaging at this time-point in sponges could 
provide a non-invasive measurement of the blood pool and, therefore, of vascular density. 
However, this measurement has been identified to be challenging due to the low signal to noise 
ratio in the tissues (Ardeshirpour et al., 2011) . 
Can FMT and MMPSense be used to measure the loss of MMP-12 activity in vivo? 
MMPSense and FMT did detect a pattern for a reduction MMP activity signal in sponges 
implanted in KO mice but this did not reach significance. In this study, the MMP-12 KO mice 
were shipped from the United States of America at great expense, so due to limited resources 
the numbers in this assay could not be increased during this study.  
Can HS1-65 be used to image MMP-12 activity on cells or sponge tissues? 
HS1-65 was tested in TL but was shown to be unselectively cleaved. Assays using TL are 
somewhat crude; TL are complex mixtures which contain both intracellular and extracellular 
components. Assays which are more representative of the in vivo environment use whole live 
cells or tissues. MMP-12 selective probes could be tested on cultured macrophages (Cobos-
Correa et al., 2009) or ex vivo diseased tissues (Jager et al., 2016).  
Can an MMP-12 selective FRET probe be used to image MMP-12 activity selectively in 
vivo? 
An MMP-12 selective FRET probe, similar to HS1-65, has been used in image MMP-12 
activity in vivo in a preclinical model of arthritis (Lim et al., 2014). This FRET probe utilised 
the PLGLEEA substrate sequence and near infra-red dyes which make it suitable for in vivo 
imaging. This FRET probe could be synthesised in-house tested as tool to measure MMP-12 






6.3 Summary of conclusions 
Molecular imaging is an exciting field of research with potential to improve diagnostic 
medicine and facilitate personalised medicine. Research in this thesis used commercial and in-
house synthesised MMP inhibitors and FRET probes to address the hypothesis that MMP-12 
activity is anti-angiogenic. The major findings were:  
 HS1-22 can be synthesised in 6 steps and was shown to be a potent and selective 
inhibitor for MMP-12 using recombinant enzyme assays. Inhibition of MMP-12 with 
HS1-22 did not increase angiogenesis in in vivo or ex vivo angiogenesis assays.  
 Deletion of MMP-12 did not increase angiogenesis in in vivo or ex vivo angiogenesis 
assays. 
 Commercial imaging probes can be used to image angiogenesis and MMP activity in 
sponges in vivo and ex vivo. 
 HS1-65, an activity FRET robe, was synthesised in house using SPPS and shown to 
be selective for MMP-12 using recombinant enzyme assays. But HS1-65 was non-
specifically cleaved in tissue lysates by an unknown protease. 
To conclude, the work described in this thesis revealed that MMP-12 is not an inhibitor of 
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Appendix 1: Methodological Detail 
MTT assay 
The toxicity of compounds was assessed using the colorimetric MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay. The MTT assay assesses cell metabolic 
activity. NAD(P)H-dependent cellular oxidoreductase enzymes may, under defined 
conditions, reflect the number of viable cells present. Compounds of interest are used to treat 
cells (normally incubated for 24 h) before the MTT assay is conducted. When MTT is added, 
and if the cells are viable, there is a colour change from yellow to purple (Figure A1.1). 
Comparisons are made between healthy cells (without treatment) and those cells which 
received treatment prior to the MTT assay. 
 
 
Figure A1.1 The MMT assay assesses the number of viable cells present by making a 
measurement of cell metabolic activity, specifically of NAD(P)H dependant cellular oxidases. 
Mitochondrial reductase enzymes are capable of reducing the tetrazolium dye MTT to insoluble 
formazan. Compounds of interest are incubated with the cells prior to the MTTT assay. Cell metabolism 
(and therefore viability) is reflected in the conversion of MTT and the resulting colour change from 
yellow to purple which can be measured using a plate reader. Comparisons are made between healthy 






Osmotic minipumps and implantation surgery 
Osmotic mini pumps were chosen as the means of MMP inhibitor (marimasat and HS1-22) 
administration as this approach ensured the compound reached the sponge at a steady rate. It 
was also envisaged at this method would minimise any systemic effects of the drugs. The 
vehicle chosen was similar to that used in other studies and the dose selected (150.6 
nmol/mouse/day) was equivalent to or lower than that used in previous studies administering 
MMPIs (Chow et al., 2008; O-Charoenrat et al., 2002; Skipper et al., 2009; Somlyo et al., 
2003). 
 
Mini pump preparation and surgery 
Drugs were administered to mice at 150.6 nmol/mouse/day (Marimastat: 2 mg/kg/day, HS1-
22: 2.6 mg/kg/day) for 21 days (25g mouse) in DMSO:propylene glycol: H2O (1:1:1). Pumps 
were prepared under sterile conditions (Figure). Briefly, a catheter was attached to a flow 
moderator before it and the pump cavity were filled with the desired drug solution (sterilised 
by micro filtration 0.22 µM pore size) using a syringe with a blunt needle. The metal tubing 
of the flow moderator was then inserted into the pump cavity. The pumps were primed prior 






    
Figure A1.2 Preparation and use of the osmotic minipump. a) The flow moderator was isolated from 
the pump; b) the flange was broken off the flow moderator using a scalpel to reveal the metal tubing to 
which the catheter was attached (covered 2 - 3 mm); c) the tubing and pump (held vertically with 
forceps) were slowly filled with the desired solution using a syringe with a blunt needle. d) The metal 
tube (flow moderator) was then carefully inserted back into the pump.  The pumps were then primed 
(incubated in saline, 37 °C, 48 h); f) prior to surgery, the catheter was inserted into the sponge and glued 
in place; g) the mouse was anaesthetised and a subcutaneous pocket was made under their dorsal skin, 
the sponge (long dash) was then inserted followed by the pump (short dash) and then the remaining 
catheter (solid) was tucked in before closing the wound; h) in vivo the osmotic pump slowly absorbs 
fluid which slowly presses on the cavity containing the drug, this forces it out of the pump and up the 







Fluorescence molecular tomography (FMT) is a tomographic near infra-red (NIR) imaging 
modality that is suitable for in vivo imaging of small animals. The FMT™ 2500 system is 
designed for preclinical research and utilises complex algorithms to construct a 3D image of 
detected signal. The process requires trans-illumination of the subject rather than the surface 
illumination used for epifluorescent assessment (Ntziachristos et al., 2003). This 3D imaging 
helps to resolve the ambiguity of depth and size of the detected signal affecting 2D imaging.  
 
The instrument operates on two near-infrared channels (excited at 670 nm and 746 nm, 
emitting at 700 nm and 775 nm respectively), which facilitates the imaging of 2 agents within 
the same mouse to attain more information on the biological molecular processes present. 
Furthermore, the FMT machine is able to determine the concentration of the probe detected 
within a selected region of interest (ROI). There is a wide range of optical imaging agents for 
different targets, most area available for use in both channels and are supplied by Perkin-
Elmer. In this project AngioSense 680 and MMPSense 750 FAST were used to measure 







Mice were fed an alfalfa free diet (Teklad 2914 maintenance diet, Harlan) for at least 10 days 
prior to imaging to eliminate auto-fluorescence in the gut (Inoue et al., 2008). Imaging agents 
were reconstituted, under sterile conditions, with PBS (1.2 mL/ vial); agents were combined 
(2.4 mL) to create a mixture for administration. With assistance from Gary Borthwick, 24 h 
prior to imaging the mice were warmed in an incubator (30 °C, 15 min) and briefly 
anaesthetised (Isoflurane). Imaging agents (200 µL, containing 2 nmol of each agent or PBS 
as a control) were administered by an intravenous tail vein injection and the mouse allowed to 
recover. 
 
Imaging in vivo 
Mice were weighed and anaesthetised using isoflurane (for the duration of the experiment). 
Hair was removed from the chest and abdomen using clippers followed by application of 
depilitory cream (Veet, Reckitt Benckiser Group). After 2-3 min (or when the hair became 
loose) the mouse was thoroughly rinsed using warm water and then dried using paper towels. 
The mouse was temporarily removed from the anaesthetic rig and promptly positioned in the 
cassette so that the tissue of interest was in the centre. The cassette was closed to a setting of 
17 and then placed in the FMT 2500 machine with the ROI facing up. The inner and outer 
doors of the machine were closed and anaesthesia resumed (before the mouse revived). The 
TrueQuant software was used to obtain the data; the acquisition time was 3 − 4 minutes for 
each agent used. The mouse could then be removed from the chamber and either allowed to 






Imaging ex vivo 
Once mice had been killed, sponges were carefully removed from the carcass and placed in a 
cylindrical dish (approx. 3 cm diameter, 2 cm deep) and covered gently with tissue mimic 
solution (PerkinElmer) while taking care not to squeeze the sponge. The dish was placed in 
the cassette and imaged in the FMT machine as described below. The acquisition time was 
approx. 2 min for each agent. After scanning, each sponge was gently cleaned in PBS and then 
cut in half and either fixed in paraformaldehyde solution (24 h and then stored in 70% ethanol) 
or snap frozen on dry ice and subsequently stored at - 80 ˚C. 
 
Data acquisition 
The TrueQuant software was used to acquire data as follows: 
Under the experiment tab: a data base was created for the experiment with the required groups, 
subject (mouse) numbers and the selected agents used in the experiment.  
Under the scan tab: the system required basic information (the depth of cassette, agent to be 
imaged (only one scanned at a time)); then the preliminary reflectance image could be 
acquired. Using the reflectance image, the scan field was drawn around the ROI to have < 50 
laser source positions (Figure 2.2). The “add to reconstruction queue” was checked and the 







An enzyme-linked immunosorbent assay (ELISA) allows the quantification of an antigen in a 
protein mixture by the use of selective antibodies and a colour change to identify a substance. 
In this project, two “sandwich ELISA assays” were utilised to measure MMP-12 and its 
endogenous inhibitor TIMP-1 in the sponges (Figure 4). 
 
 
Figure A1.4 Sandwich ELISA technique. The protein of interest within the sample is attached to the 
plate surface by specific selective antibodies. Then, a second specific antibody is applied over the 
surface so it can also bind to the protein. The second antibody is either directly conjugated to an enzyme 
such as horse radish peroxidase (HRP) or a biotin moiety (and an avidin–HRP antibody is then applied). 
In the final step, an enzyme substrate such as 3,3',5,5'-Tetramethylbenzidin (TMB) is added; the 
subsequent reaction produces a colour change from clear to blue. The rate of colour change is 
proportional to the concentration of the protein of interest in the sample. This reaction can be stopped 
with an acidic solution (colour change from blue to yellow) to allow absorbance measurements in a 












Appendix 2: MALDI-TOF-MS of FRET Probes 
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) was used to 
confirm the mass of the synthesised Förster resonance energy transfer (FRET) probes.  
HS1-58 
















MALDI Mass Spectrometry: calculated for C88H113N15O27Na [M+Na]












Appendix 3: HPLC ELSD Traces 
High performance liquid chromatography (HPLC) was used to separated compounds and 
impurities within samples to check for purity. Compounds were separated along a 
concentration gradient (5% to 95%) of acetonitrile (ACN) in water. Compounds where 
detected using an evaporative light scattering detector (ELSD) and light absorbance at 
selective wavelengths. The HPLC-ELSD traces are presented here, the signal detected after 
14 min is an artefact of the system. HPLC-ELSD traces for the FRET probes are presented in 
Figure A3.1. HPLC-ELSD traces for HS1-22 and synthesis intermediates are presented in 























Appendix 4: Absorbance of Dyes and FRET 
Probes for Yield Determination 
The absorption of fluorophores and FRET probes was measured (as described in section 2.5.6) 
(Figure A4.1). It was determined that the absorption of Rhodamine B or FAM could be used 
to measure the concentration of the probe due to minimal overlap with the second 
corresponding fluorophore of the FRET probe. To create a standard curve, the absorption of 
RhodB or FAM at various concentrations (25 – 200 µM) was measured using a nanodrop. This 
data was potted so that linear best fit lines could be drawn and associated equations determined 
(Figure A4.2). This equation was used to determine the concentration of the FRET probe. The 
FRET probe was diluted (1/10, 1/50/ 1/100) and the absorbance of the solutions was measured. 
Absorbance was measured at the wavelength of the conjugated fluorophore (FAM or 
Rhodamine B, 495 nm or 546 nm respectively). The absorbance measurement between 0 and 
1 was used to calculate the concentration of the probe sample using a standard curve. The 





















Figure A4.2 The absorption of light by RhodB and FAM at concentrations between 25 and 200 
µM. A linear best fit line was drawn for each and the respective equations determined. Data is presented 
as mean (n = 1 in duplicate). 
  
y = 0.0086x + 0.0919
R² = 0.9965


































Appendix 5: RT-qPCR Data For Sponges 
Collected on D 21 – 35 
To investigate the role of MMP-12 during angiogenesis in vivo the sponge model was utilised 
as described in (Section 2.9 and Chapter 4). Gene expression of vascular markers, and 
angiogenesis markers and MMPs were analysed in sponges collected from D 3 – 35. Two 
studies were conducted, firstly sponges where collected during early angiogenesis (D 3 – 21), 
secondly sponges were collected during later angiogenesis (D 21 – 35). The D 3 sponges 
showed little expression of these genes (likely due to the lack of biological tissue), and 
therefore any analysis of the gene expression in relation to the other time points in this study 
was not possible. Four housekeeping genes were assessed for the sponge model of which TBP 
and GAPDH had the lowest mean variation in gene expression between groups D 7 – 21 and 
D 21 – 35(Table 2.7). Data from D 7 – 21 is presented in Chapter 4 and here (labelled as 
“early”), data from D 21- 35 (labelled as “late”) is just presented in this appendix (Figures 
A5.1, A5.2 and A5.3). To check for consistency in gene expression between the two studies, 
sponges from D 21 from both the “early” and “late” studies were also compared.  
 
Figure A5.1 Gene transcripts of MMP-12 in sponge. a) early time course experiments = D 7 – 21, b) 
To check for consistency in gene expression between the two studies, sponges from D 21 from both the 
early and late studies were also compared. c) late time course experiments = D 21 – 35. Bars represent 
mean ± SEM (n = 6) and comparisons for (b) were made using a Students t-test (P > 0.05); comparisons 
for (a) and (c) were made using a one-way ANOVA followed by Bonferroni Post-hoc tests comparing 






Figure 0.1 Gene transcripts of TNF, PECAM-1 and PDGF in sponges. a-c) gene expression of early 
time course experiments (D 7 – 21) for TNFα, PECAM-1 (CD31) and PDGF respectively. d-f) To check 
for consistency in gene expression between the two studies, sponges from D 21 from both the “early” 
and “late” studies were also compared for TNFα, PECAM-1 (CD31) and PDGF gene expression. g-h) 
gene expression in late time course experiments (D 21 – 35) for TNFα, PECAM-1 (CD31) and PDGF 
respectively. Bars represent mean ± SEM (n = 5 − 6) and comparisons for (d-f) were made using a 
Students t-test (P > 0.05); comparisons for (a-c) and (g-i) were made using a one-way ANOVA followed 







Figure A5.3 Gene transcripts of MMP-2, 9, 10 and 13 in sponges. a-d) Gene expression in the early 
time course experiments (D 7 – 21) for MMP-2, -9, -10 and -13 respectively. e-h) To check for 
consistency in gene expression between the two studies, sponges from D 21 from both the “early” and 
“late” studies were also compared for MMP-2, -9, -10 and -13 respectively. i-l) Gene expression in the 
late time course experiments (D 21 – 35) for MMP-2, -9, -10 and -13 respectively. Bars represent mean 
± SEM (n = 5 − 6) and comparisons for (e-h) were made using a Students t-test (P > 0.05); comparisons 
for (a-d) and (i-l) were made using a one-way ANOVA followed by Bonferroni Post-hoc tests 










Appendix 6: Permissions For Use of Figures 
Figures from open access did not need permission to use. Permission for other figures used in 
this thesis are listed here. All figures in this where modified form the original cited figure 
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